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ABSTRACT 
46BR is a cell line derived from a patient suffering from immunodeficiency, 
growth retardation and sunlight sensitivity. DNA replication and repair is affected in 
46BR cells which are sensitive to the alkylating agent ethylmethane sulphonate and 
to 3-aminobenzamide. Aberrant DNA ligase I activity has been demonstrated in 
these cells, and mutations have been identified in both alleles of the DNA ligase I 
gene. The first mutation specifies a change of glutamate 566 to lysine, a charge 
alteration which renders the enzyme completely inactive and which could be lethal 
in a homozygote. The second mutation is a change of arginine 771 to tryptophan 
which leaves the enzyme with some residual activity. The transformed derivative of 
46BR is either hemizygous or homozygous for this second mutation, so cells 
expressing only this mutant form of DNA ligase I are still viable. This mutation is 
therefore a good candidate for introduction into the mouse gene in order to create a 
mouse model for DNA ligase I deficiency. 
Prior to making a mouse model it was necessary to show that the mutations at 
the DNA ligase I locus in 46BR give rise to the aberrant cellular phenotype. To do 
this, wild-type human DNA ligase I cDNA was introduced into 46BR in an 
expression vector. Selection for transformants was provided by a bacterial neomycin 
phosphotransferase gene. Transformants were assayed for survival in ethylmethane 
sulphonate and 3-aminobenzamide, which demonstrated a correlation between the 
presence of wild-type DNA ligase I sequences within the cells and rescue of 
sensitivity to these agents. Wild-type human DNA ligase I cDNA therefore 
complements the defect in 46BR. 
A 3.2kb mouse DNA ligase I cDNA clone was obtained by probing a mouse 
embryonic stem cell cDNA library with full-length human DNA ligase I cDNA. The 
cDNA clone is amost complete, but lacks sequence from the 3' end, including the 
polyadenylation 
I 
 signal. At the amino acid level, homology between human and 
mouse DNA ligse I is extremely high, with most sequence variation in the N-
terminal regulatory domain. In the C-terminal catalytic domain the amino acid 
sequences are virtually the same, with identical amino acids in the same positions at 
which the two mutations were identified in 46BR. 
The mouse cDNA clone was used to analyse the mouse DNA ligase I gene 
structure by hybridisation to mouse genomic DNA. A discrete number of hybridising 
fragments were observed, with their sizes showing that the mouse gene which 
occupies 39-42kb of DNA is smaller than the 53kb human gene. A minimum of 
1 
eleven exons were identified, compared to 28 in the human gene. However no results 
were obtained incompatible with both genes having the same exon structure. 
A 13.5kb EcoRl genomic fragment of the mouse gene containing the last five 
exons was identified as including sequence equivalent to the site of the Arg77 1 to 
Trp mutation in 46BR. This fragment was cloned from a mouse genomic library by 
probing with the mouse eDNA. Primers designed from the ends of human exon 23 
which encodes Arg771 were used to show that the eighth mouse exon contains 
corresponding sequence. The same primers were used to sequence this exon, 
revealing an arginine residue at the same position as Arg77 1 in the human sequence. 
The 13.5kb EcoRl genomic fragment has been used in gene targeting 
experiments to remove the last five ëxons from the mouse DNA ligase I gene in 
mouse embryonic stem cells. The next step is to reintroduce these exons, but with a 
mutation specifying an arginine to tryptophan alteration in the eighth exon at a 
position equivalent to human Arg771, and eventually to use the resulting cells to 
create a mouse model for DNA ligase I deficiency. 
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Our genetic material is under constant assault from the environment and from 
processes occuring within the cells themselves. Damage to DNA may arise during 
DNA replication and recombination, as a result of spontaneous DNA hydrolysis 
under physiological conditions and from exposure to radiation and other DNA 
damaging agents. It is essential that the genetic material be maintained in an 
informationally active form and so cells have evolved a number of mechanisms by 
which to repair DNA damage. DNA repair pathways appear to be conserved between 
bacterial and mammalian cells, therefore the better understood prokaryotic systems 
have provided a model for investigations in mammalian cells. Work is ongoing to 
elucidate the various steps involved in mammalian DNA repair mechanisms and this 
work has been greatly facilitated by the use of cell lines mutant in various aspects of 
DNA repair. Some of these cell lines are derived from humans with hereditary 
diseases arising from specific DNA repair defects. In most cases, different cell lines 
isolated from patients suffering from the same disease fall into a number of 
complementation groups. This genetic heterogeneity reflects the complex nature of 
DNA repair mechanisms and results from the involvement of a number of enzymes 
in each pathway. Eventual identification of the defective loci in the disease cell lines 
should aid understanding of the many steps involved in mammalian DNA repair 
pathways. It would then be possible to correlate the genetic defects with the 
observed clinical and cellular abnormalities of the disease. Once a particular 
mutation at a specific locus has been characterised, it can then be introduced into the 
equivalent mouse gene by gene targeting and used to create a mouse model for the 
disease. This would allow further investigations into the effects of that mutation. 
1.2: DNA Repair 
DNA can become altered in a number of ways which affect the fidelity of 
replication and introduce mutations into genes, as well as affecting normal cellular 
processes of DNA metabolism (Friedberg 1985, and references therein). Figure 1.1 
shows some examples of DNA damage. Base mismatches may be introduced during 
DNA synthesis as a result of DNA polymerase replicative infidelity, or because 
base-pairing properties may have been altered by a number of mechanisms. For 
example, bases very occasionally undergo tautomeric shifts which allow anomalous 
base-pairing, resulting in base misincorporation into the daughter DNA strand during 
DNA synthesis. Abnormal bases may also be incorporated or may arise from 
spontaneous deamination, which most frequently results in the production of uracil 
from cytosine. In addition, bases may be lost completely by direct cleavage of the 
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Figure 1.1: Examples of DNA damage (adapted from Timme and Moses 1988). 
Abasic sites result from depurination and depyrimidination which may occur 
spontaneously or from the action of DNA glycosylases. Pyrimidine dimers, both 
cyclobutane dimers and 6-4 photoproducts, are the major types of damage produced 
by ultraviolet irradiation. Monofunctional agents can react with DNA to produce 
bulky adducts. Cross-links, both intra- and inter-strand, arise from bifunctional 
agents which can also cross-link proteins to DNA (not shown). DNA strand breaks 
may be single or double (not shown). Abnormal or mispaired bases may also be 
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glycosyl bond between the base and the deoxyribose moeity, a process known as 
depurination or depyrimidination. Damage arising from alkylation can affect the 
base-pairing properties of DNA and may also affect DNA metabolism by formation 
of bulky adducts and intra- or inter-strand cross-links, thus blocking the path of 
enzymes and preventing DNA strand separation. Ultra-violet light is another cross-
linking agent, causing the formation of pyrimidine dimers (cyclobutane dimers and 
6-4 photoproducts). Additionally, there are clastogenic factors, such as ionising 
radiation, which produce DNA strand breaks. 
Cells have evolved a number of mechanisms by which such damage to the 
genetic material can be repaired (Grossman 1981, Lindahl 1982, Friedberg 1985, 
Lindahl and Wood 1989, and references therein). These mechanisms are described 
briefly in this chapter. 
1.2.1: Direct Reversal of DNA Damage 
Mechanisms of direct repair involve a single enzyme which catalyses a single 
reaction to return the DNA to its original state. The simplest example of direct 
reversal is ligation of DNA strand breaks which may be caused by agents such as 
ionising radiation. Other examples of direct reversal are photolysis, 
transmethylation, and direct insertion of purines. 
]Irradiation with ultra-violet light at wavelengths close to the absorption 
maximum of DNA causes cross-linking, mainly intrastrand, by formation of 
pyrimidine dimers. Such intrastrand cross-links are repaired by enzymatic 
photoreactivation. The enzyme photolyase binds to pyrimidine dimers and, using 
visible light at wavelengths between 300 and 600nm, breaks the covalent bond 
between bases and thus promotes monomerisation. 
Transmethylation is the removal of alkyl groups transferred to DNA by 
alkylating agents such as methylnitro-nitrosoguanidine (MNNG) and ethylmethane 
sulphonate (EMS). A major reaction product of alkylating agents, 06 
methylguanine, is thought to be highly mutagenic and is removed by 06 
methylguanine methyl transferase. A methyl group is transferred from the DNA to a 
cysteine residue on the enzyme, forming S-methyl cysteine and resulting in 
permanent inactivation of the enzyme. The enzyme therefore catalyses a reaction 
with suicide kinetics. Other alkyl groups such as ethyl, propyl and butyl moeities are 
also removed from DNA by this enzyme. 
Depurination is the loss of purine bases from DNA, resulting in the formation 
of apurinic sites. These sites are repaired by a number of mechanisms, of which one 
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is an example of direct reversal of DNA damage. An enzyme called DNA purine 
insertase catalyses reinsertion of appropriate purine bases into apurinic sites. 
1.2.2: Base Excision Repair 
Base damage is recognised by a DNA glycosylase which hydrolyses the 
glycosylic bond, releasing free modified base and generating an apurinic or 
apyrimidinic (AP) site. DNA glycosylases are highly specific, for example, 3-
methyladenine-DNA glycosylase removes only 3-methyladenine. AP sites are 
recognised by AP endonucleases which hydrolyse the phosphodiester bond 5' of the 
AP site and then remove a short patch of DNA. The gap is subsequently filled in by 
a DNA polymerase and ligated (figure 1.2). 
1.2.3: Nucleotide Excision Repair 
In this case DNA damage is recognised by local perturbation of the DNA 
double helix. An incision is then made on either side of the lesion and the gap is 
filled in by a DNA polymerase and ligated (figure 1.3). This repair pathway can 
correct several types of lesion, including alkylation, cross-links and dimers. 
Mammalian cells show preferential excision repair of transcribed DNA, with damage 
in untranscribed regions being repaired much more slowly. 
1.2.4: Post-Replication Repair 
In culture, cells halt DNA synthesis following exposure to DNA damaging 
agents. This is presumably because, if damage persists into DNA replication, it could 
potentially be highly mutagenic. For example some types of damage which alter the 
base-pairing properties of DNA, would result in base misincorporations. Also, if 
unrepaired, some types of damage can interfere with the process of DNA replication 
itself. Lesions such as pyrimidine dimers and DNA adducts block the path of DNA 
polymerases, thus interfering with DNA synthesis. There are several possible 
methods by which cells can tolerate such damage and allow DNA replication to 
continue. 
In Escherichia coli there is evidence for two types of damage tolerance 
mechanism. In the first case DNA synthesis halts at a lesion and then continues on 
the other side leaving a gap which is then repaired by recombination. Alternatively, 
translesion synthesis may occur, where a randomly selected base is inserted opposite 
the lesion allowing DNA synthesis to continue uninterrupted. There is a 75% 
probability that an incorrect base will be inserted, therefore this type of repair is 
referred to as 'error-prone' and is mutagenic. 
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Figure 11: Base excision repair (adapted from Thompson 1989). A damaged base is 
recognised by a specific DNA glycosylase which hydrolyses the glycosylic bond and 
generates an abasic (AP) site.. The AP site is recognised by an AP endonuclease 
which makes a strand incision-by hydrolysing an adjacent phosphodiester bond. A 
short patch of DNA is then excised and the gap is filled in by a DNA polymerase 
(unscheduled DNA synthesis). Finally, a DNA ligase rejoins the two strands. 
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Figure 1.3: Nucleotide excision repair (adapted from Thompson 1989). DNA 
damage causes distortion of the DNA double helix which is recognised by a complex 
of proteins. The complex makes a strand incision about 22 bases 5' and 5 bases 3' of 
the damage and about 29 bases of DNA are excised. A polymerase then fills in the 
gap as represented by two closed circles (unscheduled DNA synthesis) and a DNA 
ligase rejoins the strand break. 
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Evidence suggests at least three tolerance mechanisms in mammalian cells. 
Damage may temporarily halt DNA synthesis which, when restarted, continues 
across the lesion by an unknown mechanism (Sarasin and Hanawalt 1980). As in 
bacteria, damage may be bypassed by recombination with the sister chromatid 
(Fornace 1983). Finally, a 'copy-choice' model proposes that the second daughter 
strand is used as a template to allow DNA synthesis to continue past the lesion 
(Higgins et al 1976). 
1.3: Human Diseases Arising from Defective DNA Repair 
If DNA repair mechanisms are deficient, cells will accumulate DNA damage. 
This leads to increased chromosome instability with consequent effects on 
development and predisposition to cancer. Defective DNA repair processing 
mechanisms have been implicated in five rare autosomal recessive diseases since 
cells from patients suffering from these diseases display defective repair and/or 
increased chromosome instability. These diseases are; xeroderma pigmentosum, 
ataxia telangiectasia, Cockaynes syndrome, Fanconi anaemia and Blooms syndrome 
(reviewed by Friedberg in 1985, Timme and Moses in 1988 and Cleaver in 1990). 
These diseases are summarised in table 1.1. 
1.3.1: Xeroderma Pigmentosum (XP) 
This autosomal recessive disease is characterised by extreme sensitivity to 
sunlight and a very high rate of skin cancers (2000-fold increased) as well as an 
elevated rate of internal cancers (20-fold increased). Certain patients also suffer from 
neurological disorders (deSanctis-Cacchione syndrome). The incidence of XP varies 
from 1/200,000 in Europe to 1/40,000 in Japan. Classical XP is caused by a defect in 
the excision repair mechanism, as shown by a substantially reduced rate of DNA 
synthesis outside S-phase (unscheduled DNA synthesis) in response to irradiation 
with ultraviolet light (Cleaver 1968). 
There are seven complementation groups designated A to 0, plus variant 
(typical clinical symptoms, while exhibiting normal unscheduled DNA synthesis, but 
an abnormal pattern of DNA replication following ultra-violet irradiation). These 
groups were assigned according to aquisition by cultured cells of the ability to 
perform ultra-violet induced unscheduled DNA synthesis when fused to cells of 
another complementation group. Evidence suggests that in XP groups A to G it is the 
incision step that is defective, while XP variant cells are deficient in post-replication 
repair (Lehmann et a! 1975). The existence of these groups indicates that there are at 
least seven gene products involved in excision repair in humans. Patients from 
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Table 1.1: Human DNA Repair Diseases 
disease defect complementation cloned genes 
groups  
xeroderma defective excision 8 ERCC2 (XP-D) 
pigmentosum repair in classical ERCC3 (XP-B) 
XP, defective post- ERCC5 (XP-G) 
replication repair XPA 
in XP variant  XPC 
Cockaynes defective 3 ERCC6 (CS-B) 
syndrome preferential repair 
of transcribed 
DNA  
ataxia no blockage of 5 
telangiectasia DNA synthesis 
following DNA 
damage?  
Fanconi anaemia unknown 4 FACC 
Blooms syndrome a general defect 1 
affecting several 
enzymes?  
46BR DNA ligase I LJG1 
deficiency 
complementation groups B, D and G may also suffer from Cockaynes syndrome (see 
below). 
A number of artificially produced rodent excision repair mutant cell lines 
exist. These have been used to clone excision repair genes according to their ability 
to complement the repair deficiency of the mutant rodent cell lines. Such genes are 
therefore named excision repair Qross-omplernenting (ERCC). Some of these genes 
have been found to be involved in XP (for review see Bootsma and Hoeij makers 
1994). The genes ERCC2, ERCC3 and ERCC5 are involved in XP-D, XP-B and XP-
G respectively, while the gene ERCC4 may be involved in XP-F (Biggerstaff et al 
1993, van Vuuren et al 1993). Additionally, the genes XPA and XPC, which are 
involved in XP-A and XP-C have also been cloned. 
1.3.2: Cockaynes Syndrome (CS) 
Patients suffering from the autosomal recessive disorder CS characteristically 
show arrested growth and development, while suffering from sun-sensitivity and 
deafness, optic atrophy, mental retardation and several other developmental 
aberrations. There does not appear to be any increased risk of developing tumours. 
CS may be, but is not always, associated with xeroderma pigmentosum. 
In culture, CS cells are extremely sensitive to killing by ultra-violet 
irradiation. Wild-type cells exhibit preferential repair of transcribed regions of the 
genome in response to irradiation with ultra-violet, but this is defective in CS cells 
(Mullenders et al 1988, Venema et a! 1990). In CS cells, unlike wild-type cells, there 
is no selection of the transcribed -DNA strand over the non-transcribed strand of 
active genes, both are repaired at the same rate (van Hoffen et al 1993). Further, 
although-the-rate of repair-of-transcribed DNA -is-higher than that oftranscriptionally 
inactive DNA in CS cells, it is still slower than repair of the nontranscribed strand of 
active genes in wild-type cells (van Hoffen et a! 1993). Inhibition of RNA synthesis 
also follows ultra-violet irradiation of some CS cells (Mayne and Lehmann 1982). 
This is consistent with defective preferential repair of transcribed DNA, since 
pyrimidine dimers would block the path of RNA polymerases. There would only be 
a transient delay in RNA synthesis following ultra-violet irradiation in wild-type 
cells because transcriptionally active DNA is repaired first, thus removing the block 
to the RNA polymerase. 
At least three CS complementation groups, A to C, have been identified on 
the basis of recovery of normal rates of RNA synthesis following ultra-violet 
irradiation (Lehmann 1982). Patients in groups A and B suffer from CS alone, while 
complementation group C is represented by patients who may also be members of 
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xeroderma pigmentosum groups B, D and G. The excision repair gene ERCC6 
(Troelstra et al 1990) complements the ultra-violet sensitivity of CS 
complementation group B cells (Troelstra et al 1992). ERCC6 encodes a protein of 
1493 amino acids with homology to the helicase family of proteins and may 
therefore be involved in searching for, or recognition of, damage on the transcribed 
strand of active genes. 
1.3.3: Ataxia Tetangiectasia (AT) 
AT affects up to 1/40,000 people and in these patients the nervous and 
immune systems are particularly affected. They are exceptionally susceptible to 
infections and to neoplasia of the lymphoreticular system. Cerebellar ataxia results in 
a staggering walk with a severe lack of muscle coordination and progressive mental 
retardation. In addition there is prominent dilation of small blood vessels in the skin 
and eyes (telangiectasia). Like XP and CS, this disease displays an autosomal 
recessive mode of inheritance. 
The first indication of a DNA repair defect came with the observation that X-
rays, which cause DNA strand breaks, are fatal to many AT cancer patients when 
used for radiotherapy. AT cells are sensitive to X-irradiation, which elevates the 
already high number of chromosomal breaks. AT cell lines do not exhibit the 
blockage of DNA synthesis which is seen in normal cells in response to ionising 
radiation. Because of this, it has been suggested that the disease is not due to a DNA 
repair defect per Se, but rather to the lack of inhibition of DNA synthesis allowing 
DNA replication prior to repair (Painter and Young 1980). This property has been 
used to define AT complementation groups, of which there are at least five, 
designated AB, C, D,E and V1 (Jaspers et al 1988). 
Although no AT genes have yet been cloned, linkage analysis using 31 ataxia 
telangiectasia families has localised at least one AT gene to chromosome 1 1q22-23 
(Gatti et al 1988). It remains to be seen whether this region of chromosome 11 
contains a cluster of AT genes, or just one. 
1.3.4: Fanconi Anaemia (FA) 
Pancytopenia (depression of all types of blood cells), skeletal defects, stunted 
growth, bone marrow failure and predisposition to develop acute myeloid leukaemia 
distinguish this autosomal recessive disease. The incidence of this disease may be up 
to 1/40 000. 
FA cells show high levels of spontaneous chromosome aberrations which are 
increased still further by DNA cross-linking agents. The molecular cause of the 
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disease is yet to be identified, but removal of intra-strand cross-links appears to be 
abnormally slow. 
Cell fusion experiments have indicated that there are at least four 
complementation groups, designated A to D (Strathdee et a! 1992a). A cDNA for 
complementation group C (FACC) has been cloned by complementation of the 
sensitivity of FA group C cells to cross-linking agents (Strathdee et a! 1992b). The 
cDNA encodes a protein of 557 amino acids. There is no significant homology with 
any other known protein sequences and the function of the FACC gene product 
remains unidentified. 
1.3.5: Blooms Syndrome (BS) 
This disease, although rare in the general population, is relatively common 
among Ashkenazi Jews and the Japanese. There is some clinical variation in BS, but 
typical symptoms include retarded growth, sunlight sensitivity and sun-sensitive 
facial telangiectasia in a characteristic butterfly pattern. Immunodeficiency results in 
repeated infections during infancy and early childhood. This usually improves with 
age, however patients often then go on to develop severe chronic lung disease, 
probably arising from respiratory tract infections. Slight to moderate mental 
retardation is sometimes present. One of the most notable clinical features is a 
predisposition to develop cancer, of no particular type, at an early age, 24.8 years on 
average (German and Passarge 1989). 
In culture, the most notable feature of BS cells is the elevated level of sister 
chromatid exchanges (SCEs) compared to normal cells (Chaganti et a! 1974), and 
this property has been useful in the diagnosis of BS. Interestingly however, some BS 
patients have two populations of circulating lymphocytes, exhibiting high and low 
SCE levels (German et a! 1977). 
It appears that BS is represented by a single complementation group 
(Weksberg et al 1988). Cell fusion experiments were carried out with BS cell lines 
isolated from patients with dissimilar ethnic backgrounds (Ashkenazi Jewish, 
French-Canadian, Mennonite and Japanese). The cell lines used were all of the high-
SCE type and failed to complement this characteristic in each other. The mutation 
responsible for BS is therefore located within the same gene in all these cell lines, 
despite the fact that BS patients show substantial clinical variation. It may be that 
this reflects allelic differences or variable interaction with other gene products rather 
than several defective loci. 
BS cells exhibit increased rates of spontaneous mutation and somatic 
recombination. The glycophorin A assay has been used to investigate this in vivo 
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(Langlois et al 1989). Glycophorin A is a protein found on the surface of 
erythrocytes which has two codominantly expressed alleles, M and N. Using 
fluorescently labelled monoclonal antibodies where the colour of fluorescence is 
allele-specific, heterozygotes (MN), homozygotes (MM or NN) and hemizygotes 
(Mø or Nø) can be distinguished. Cells from heterozygous BS blood donors were 
analysed by this means. A high level of somatic recombination was indicated by the 
high frequency of homozygous variants, while the high frequency of hemizygous 
variants obtained is consistent with increased genomic instability and chromosome 
breakage. 
Sensitivity to a number of different DNA-damaging agents is another 
characteristic of BS cells. For example, they are hypersensitive to mitomycin C (an 
alkylating agent which produces bulky adducts and interstrand crosslinks) as 
measured by cell killing (Hook et al 1984). They are also sensitive to the alkylating 
agents ethylmethane sulphonate (Arlett and Harcourt 1978) and N-ethyl-N-
nitrosourea (Kurihara et al 1987). Sensitivity to these agents implies that BS cells are 
defective in DNA repair. The high levels of SCEs in these cells are consistent with 
this, since SCEs are thought to occur as a result of unrepaired DNA damage 
persisting into S phase. 
DNA replication is abnormal in BS cells. The rate of DNA chain growth is 
retarded (Hand and German 1975). Furthermore, short-term pulse labelling 
experiments using [ 3H]tritium allowed the detection in BS cells of aberrant 20kb 
DNA replication intermediates which are not seen in normal cells (LOnn et a! 1990) 
indicating a deficiency in DNA ligation. A defect in ligation is further suggested by 
the work of Runger and Kraemer (1989). A linearised, replicating, shuttle vector 
plasmid was passaged through BS cells and used to transform bacteria to give a J 
measure of ligation. The in vivo joining efficiency was found to be three-fold 
reduced in BS cells. In addition, sequencing revealed a number of aberrant joining 
events. Deletions, point mutations, plasmid DNA reverse insertions, non-plasmid 
DNA insertions and filling in of cohesive ends were all observed. 
Consistent with work suggesting that DNA ligation is defective in BS cells, 
reduced DNA ligase I activity has been demonstrated in lymphoid cell lines from BS 
patients (Willis and Lindahi 1987, Chan et a! 1987). Two types of abnormal DNA 
ligase I have since been identified (Willis et al 1987). Five independently derived 
cell lines exhibited a thermolabile enzyme with reduced levels of activity, designated 
type I-i. However in one cell line the enzyme showed normal activity and heat-
stability, but was apparently present in a dimeric form within the cell. This enzyme 
has been designated type 1-2. It has been shown that similar amounts of DNA ligase 
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I protein are present in normal and BS cell lines (Chan and Becker 1988), therefore 
the observed reduction in DNA ligase I activity in type I-i BS cells is due to 
impaired activity rather than abnormally low levels of the enzyme. This was 
confirmed by demonstration that formation of DNA ligase I reaction intermediates is 
affected in the cell lines examined. These results strongly suggested that the primary 
defect in BS is in DNA ligase I, which would explain a number of the abnormalities 
observed in BS cells, such as the elevated rate of sister chromatid exchanges, 
increased somatic recombination rate, delayed maturation of DNA replication 
intermediates and reduced and error-prone ligation of plasmid DNA. Further, the 
presence of two separate alterations in the same enzyme is consistent with a single 
BS complementation group. 
In contrast to these findings, other laboratories have shown, under different 
conditions, that levels of DNA ligase I activity are not reduced. Kenne and Ljunquist 
(1988) demonstrated that DNA ligase I activity is two to three-fold higher than 
normal in the BS line GM1492 which expresses a DNA ligase-stimulatory factor. 
Mezzina et al (1989) found that DNA ligase I activity in BS cells was equal to or 
greater than that in normal cell lines. 
Although BS cells do apparently contain aberrant DNA ligase I, recent work 
has demonstrated that the primary defect is not at this locus. Human DNA ligase I 
cDNA has been cloned and sequenced (Barnes et al 1990) and eDNA sequence 
comparisons have revealed that the amino acid sequence of DNA ligase I from BS 
cells contains no alterations (Petrim et al 1991, Barnes et a! 1992) It has also been 
shown that DNA ligase I cDNAs from BS cell lines encode a functional enzyme, 
since they can complement S.cerevisiae DNA ligase cdc9 mutants (Petrini et al 
1991). In addition, the DNA ligase I gene has been mapped to human chromosome 
19 (Barnes et a! 1990, Barnes et a! 1992a), yet the high sister-chromatid exchange 
phenotype characteristic of BS cells is complemented by human chromosome 15 
(McDaniel and Schultz 1992). The DNA ligase locus itself is therefore not mutated 
since, as well as these observations, it has been shown that expression of the gene is 
normal (Chan and Becker 1988, Petrini et a! 1991). It is possible that some other 
factor is at fault, such as defective post-translational modification or some other 
factor mediating activity of the enzyme. 
Reports have been made concerning a number of other biochemical 
abnormalities in BS cells (for review see German and Passarge 1989). These include 
an increased rate of synthesis of 'a set of proteins' (Mallick et a! 1982), increased 
activity of a DNA recombining protein (Kenne and Ljunquist 1984) and aberrant 
regulation of the DNA repair enzymes uracil-DNA glycosylase (Gupta and Sirover 
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1984) and hypoxanthine-DNA glycosylase (Dehazya and Sirover 1986). Abnormal 
regulation of 06-methylguanine methyltransferase has also been observed (Kim et al 
1986). It has been reported that uracil-DNA glycosylase from BS cells is 
immunologically altered (Seal et al 1988) and has different properties to the enzyme 
from normal cells, including a changed isoeleciric point, Km and Vmax, and 
increased thermolability (Seal et a! 1991) Another study has shown, however, that 
the activity of the enzyme is normal (Vilpo and Vilpo 1989). It has further been 
shown that more DNA breakage occurs in BS cells in response to 5-fluorouracil 
treatment, an effect which depends upon uracil-DNA glycosylase levels (Lönn et al 
1990). 
Elevated levels of the enzyme superoxide dismutase have been detected 
(Nicotera et al 1989) and it has also been shown that BS cells sustain abnormally 
high levels of DNA damage arising from free radicals (Poot et al 1990). This is 
consistent with the significantly raised amount of active oxygen present within the 
cells (Nicotera et a! 1993). It is therefore likely that BS cells are defective in the 
detoxification of oxygen free radicals. 
In normal cells the tumour suppressor gene product p53 accumulates in the 
nuclei following damage to DNA and is thought to play a role in arresting the cell 
cycle in G1, thus allowing DNA repair to take place prior to replication. In BS cells 
there is no p53 build-up (Lu and Lane 1993), and in one BS line (GM1492) p53 is 
undetectable, although cell cycle arrest occurs as normal (van Laar et a! 1994). 
The significance of such a wide range of abnormalities is unclear, but when 
these are considered together with the findings on the DNA ligase I abnormality, it 
may be that there is a general defect in BS cells which affects several enzymes. 
1.3.6: The DNA Ligase I-Deficient Cell Line 46BR 
A fibroblast cell line (4613R) has been derived from a patient, now deceased, 
who exhibited some of the characteristic clinical symptoms of BS - retarded growth, 
sunlight sensitivity and immunodeficiency. She was diagnosed as having a 
malignant lymphoma and died of pneumonia, aged 19 (Webster et a! 1992). 
46BR cells exhibit a deficiency of DNA ligase I. Defective ligation was first 
suggested by initial characterisation of the cell line. Teo et a! (1982, 1983a) found 
that 46BR cells are sensitive to ionising ('y)  radiation, slightly sensitive to the DNA 
cross-linking agent mitomycin C, and sensitive to alkylating agents such as N-
methyl-N-nitrosourea (MNU), MNNG and EMS, but not to N-ethyl-N-nitrosourea 
(ENU). This sensitivity to a wide range of DNA damaging agents indicated a defect 
in a common step of DNA repair, either DNA polymerisation to fill in gaps created 
by damage excision, or ligation. This is consistent with the lack of sensitivity to 
ENU, since its major reaction products, such as 0 6-ethylguanine, are removed 
directly rather than by a repair process involving polymerisation or ligation. 
Dimethyl sulphate reaction products are removed by the excision repair pathway and 
--------------- 	---- 	- 
DNA strand breaks are produced by the first repair step - excision of the damaged 
nucleotides. In 46BR these strand breaks accumulate (Teo et a! 1983b), indicating a 
defect at a later stage of excision repair - DNA polymerisation or ligation. No 
reduction in repair DNA synthesis could be detected therefore the defect was 
identified as being at the ligation step. These workers also demonstrated that 46BR 
cells are hypersensitive to 3-aminobenzamide, which inhibits polyADP-ribose 
polymerase, an enzyme required as well as ligase for efficient ligation, further 
showing that there is a ligation defect in 46BR. A similar study by Squires and 
Johnson (1983) showed that single-strand breaks accumulate in the DNA of 46BR 
cells following ultraviolet irradiation, even in the presence of inhibitors of DNA 
polymerisation. This indicated that, during repair of ultraviolet-induced damage via 
the excision repair pathway, DNA strand breaks were not accumulating following 
the incision step because of defective gap-filling, but due to a defect in the later step 
of DNA ligation. 
Defective ligation in 46BR was demonstrated more directly by measuring 
accumulation of replication intermediates (Henderson et a! 1985). Transient 
accumulation of low molecular weight DNA was observed, indicating abnormally 
slow joining of Okazaki fragments. However doubt has recently been cast over the 
validity of this conclusion. Prigent et a! (1994) measured the rate of Okazaki 
fragment joining and found that the initial rate, at least, was normal. 
When 46BR cell extracts were size-fractionated and assayed for DNA ligase 
I activity it was found that the enzyme present appears to have the type 1-2 defect 
(Lehmann et al 1988). Subsequent to the demonstration that ligation is indeed 
abnormal in 46BR, due to aberrant DNA ligase I activity, mutations were identified 
on each allele of the DNA ligase I gene (Barnes et a! 1992b). One mutation is at the 
active site of the enzyme, and specifies a change of G1u566 to Lys. This Glu residue 
is highly conserved between human DNA ligase I and DNA ligases of E. coli, 
Vaccinia, Ti and the yeasts S. cerevisiae and S. pombe (Tomkinson et a! 199 ib). 
ATE' binds covalently to the active site of the enzyme, forming an enzyme-adenylate 
intermediate (figure 1.4). G1u566 is separated from the site of ATP binding to the 
enzyme by only one amino acid and the charge alteration from acidic to basic 
significantly impairs the enzyme's ability to form a DNA ligase 1-adenylate 
intermediate, and completely removes its ability to complement a temperature 
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Figure 1.4: Reaction mechanism of ATP-dependent DNA ligases (adapted from 
Lehman 1974). A: An enzyme-adenylate complex is generated by formation of a 
phosphoamide bond between AMP and a lysine residue at the active site of the 
enzyme. Pyrophosphate is released in this step of the reaction. B: The enzyme-
adenylate complex reacts with nicked DNA and AMP is transferred from the enzyme 
to the 5' phosphoryl group, creating a covalent DNA-adenylate intermediate. C: 
Enzyme-catalysed nucleophilic attack by the 3' hydroxyl group on the 5' phosphoryl 
group generates a phosphodiester bond, sealing the nick and releasing AMP. 
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sensitive E. coli DNA ligase mutant (Kodama et al 1991). DNA ligase I carrying the 
G1u566 to Lys alteration is therefore probably enzymatically inactive. The second 
mutation, which was maternally inherited, is an alteration of Arg771 to Trp. Again, 
this has occured in a region of the enzyme which is extremely highly conserved. The 
allele carrying this mutation is the only one expressed in the SV40-transformed 
derivative of 46BR, called 46BR.1G1. Extracts from these cells were found to show 
a decreased ability of DNA ligase I to form an enzyme-adenylate intermediate 
(Barnes et al 1992b), indicating that the Arg771 to Trp mutation leaves the enzyme 
with reduced activity. 
The activity of DNA ligase I from 46BR.1G1 is reduced about 20-fold 
(Prigent et al 1994). The enzyme is almost entirely present in an adenylated form in 
vivo indicating that adenylation occurs as normal and the defect is therefore at a later 
stage of the reaction mechanism. This is consistent with earlier reports of a 
decreased ability to form an enzyme-adenylate intermediate since, if most of the 
enzyme is already adenylated, only a low level of a1enylation with labelled ATP will 
be measurable. Following adenylation, the AMP moeity is transferred from enzyme 
to DNA, forming a covalent DNA-adenylate intermediate (figure 1.4). During the 
ligation reaction accumulation of DNA-adenylate intermediates can be detected, 
indicating that formation of this reaction intermediate is normal but that the ability of ! 
the enzyme to perform phosphodiester bond formation is reduced. 
46BR is so far the sole human representative of DNA ligase I deficiency and 
the cell line will be useful in investigating the role of DNA ligase I in cellular 
metabolism. 
1.4: Mammalian DNA Ligases 
Following the demonstration of defective DNA ligase I in Blooms syndrome 
and in the human cell line 46BR, much interest has been focused on mammalian 
DNA ligases, of which three kinds have been identified (table 1.2). 
DNA ligases are essential for replication and recombination of DNA. In 
addition, all mechanisms of DNA repair involving strand breakage and rejoining 
depend ultimately on DNA ligases for success. Mammalian DNA ligases mediate 
joining of single strand breaks in double stranded DNA in the presence of ATP and 
Mg2 ions. 
The reaction mechanism is apparently identical to that elucidated for 
bacterial and bacteriophage enzymes, although bacterial enzymes require NAD+. 
Overall, a phosphodiester bond is formed between a 3'-hydroxyl group and a 5'- 
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Table 1.2: Properties of Mammalian DNA Ligases 
DNA ligase I DNA ligase II DNA ligase III 
ligation of: 
oligo(dT).poly(dA) yes yes yes 
oligo(dT).poly(rA) no yes yes 
oligo(rA).poly(dT) yes no yes 
size estimated by 125-130kDa 67-72kDa lOOkDa 
SDS-PAGE  (plus 46kDa) 
Km for AT? low high low 
recognition by yes no no 
DNA ligase I- 
specific antisera 
apparently yes no no 
involved in DNA 
replication  






phosphoryl group (reviewed by Lehman, 1974). There are three steps involved in 
this reaction (figure 1.4): 
The enzyme reacts with ATP, forming a covalent ligase-adenylate 
intermediate, with release of pyrophosphate. Adenylation occurs by means of a 
phosphoamide bond to a lysine residue on the protein. 
The adenylyl group is transferred from the enzyme to DNA, forming a 
pyrophosphate linkage between AMP and the 5' phosphoryl group. 
A phosphodiester bond forms between the 3'-hydroxyl and the activated 
5'-phosphoryl group with elimination of AMP. 
This reaction mechanism was confirmed for mammalian enzymes by 
isolation of the two reaction intermediates. First, incubation of mammalian DNA 
ligase with [14C]ATP  produced a labelled enzyme. This enzyme could ligate DNA 
single strand breaks in the absence of added ATP in a reaction releasing AMP. Also, 
ATP could be released from the complex by addition of pyrophosphate (Söderhäll 
and Lindahi 1973a). Therefore the adenylated ligase is an intermediate allowing the 
reaction to proceed in either direction. Second, incubation of adenylated ligase with 
nicked DNA at 0°C produced covalently labelled DNA still containing single strand 
breaks (Soderhäll 1975). 
DNA ligases also catalyse the reverse reaction. In the presence of AMP and 
Mg2-'- they act as topoisomerases, mediating the progressive loss of superhelical 
turns from covalently closed double stranded DNA circles. This activity of a human 
DNA ligase is inhibited by pyrophosphate and ATP (Montecucco et al 1988). 
Ligation activity is inhibited by histones, but appears to be stimulated by 
polyADP-ribose (Creissen et a! 1982, Chashi et a! 1983). The enzyme which 
synthesises polyADP-ribose, called polyADP-ribose polymerase, appears to be 
involved in the ligation reaction. This enzyme utilises NAD to produce (ADP-
ribose)n. Its activity increases in response to DNA damage and is specifically 
inhibited by 3-aminobenzamide (Durkacz era! 1980). Inhibition of polyADP-ribose 
polymerase results in the accumulation of dimethyl sulphate-induced DNA strand 
breaks as well as increased cytotoxicity of the alkylating agent MNU and of 'y -
radiation (Durkacz et a! 1980, Nduka et a! 1980), which initially suggested that it is 
involved in DNA repair in some way. A direct link between this enzyme and DNA 
ligases was indicated by the work of Creissen and Shall in 1982. They showed that 
DNA ligase II is induced in response to treatment with dimethyl sulphate and that 
this increase in activity is blocked by 3-aminobenzamide, thus demonstrating that 
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polyADP-ribose polymerase is required for ligation. It is now thought that the 
enzyme binds tightly to DNA strand breaks and is released by automodification with 
polyADP-ribose, which then allows ligation to take place (Satoh and Lindahi 1992). 
If release is inhibited by 3-aminobenzamide, the polyADP-ribose polymerase will 
remain bound and interfere with ligation. The role of polyADP-ribose polymerase in 
ligation remains unknown. 
1.4.1: DNA Ligase I 
Of the three DNA ligases which have been identified in mammalian cells, 
DNA ligase I is thought to be the major activity. The three ligases can be 
distinguished in a number of ways, including their substrate specificities, size and 
immunological reactivity. 
1.4.1.1: Substrate Specificity of DNA Ligase I 
As well as joining single and double strand breaks in DNA, including blunt 
ends, DNA ligase I is also active on the synthetic substrates oligo (dT) bonded to 
poly (dA), and oligo (rA) bonded to poly (dT) (Arrand et al 1986, Tomkinson et al 
1991a). It has a high affinity for ATP during the ligation reaction (Tomkinson et al 
1991 a). 
1.4.1.2: The Human DNA Ligase I Gene 
Human DNA ligase I cDNA has been cloned by two separate methods 
(Barnes a a! 1990). A cDNA library was screened with oligonucleotide probes 
designed from the sequences of tryptic peptides of bovine DNA ligase I, and in 
parallel, a human cDNA library in a yeast expression vector was tested for 
complementation of a temperature sensitive DNA ligase mutation (cdc9) in S. 
cerevisiae. Identical clones were obtained by both methods. The sequence of an 
apparently full-length 3.2kb clone revealed that it encodes a 102kDa protein of 919 
amino acids. The gene encoding human DNA ligase I is present on the long arm of 
chromosome 19 at position 13.2-13.3 (Barnes a a! 1990, Barnes et a! 1992a). It 
occupies 53kb of DNA and consists of 28 exons, ranging in size from 54 bases to 
173 bases, which are transcribed to produce a single 3.2kb mRNA (Noguiez et a! 
1992). Like many other 'housekeeping' genes, the promoter region is highly GC-rich 
and lacks a TATA box. 
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1.4.1.3: DNA Ligase I Structure 
The N-terminus of DNA ligase I is blocked to sequencing (Tomkinson et a! 
1990). The enzyme is highly asymmetric with a Stokes radius of 52-53A (Teraoka & 
Tsukada 1982, Tomkinson et a! 1990) and hydrodynamic measurements suggest a 
molecular weight for the native enzyme of 98kDa (Tomkinson et a! 1990) which is 
close to the value of 102kDa determined by sequencing (Barnes et a! 1990). 
However DNA ligase I has an apparent molecular weight of 130kDa (Teraoka and 
Tsukada 1982) or 125kDa (Tomldnson et al 1990, Lasko et al 1990) as determined 
by SDS-PAGE. Additionally, some workers have detected a 200kDa protein with a 
half-life of just 30 minutes by immunoprecipitation with DNA ligase I-specific 
antibodies (Teraoka & Tsukada 1985), which rapidly breaks down to an active 
130kDa form (Teraoka & Tsukada 1986). The discrepancy between the calculated 
molecular weight and that apparent from SDS-PAGE may be because sequencing 
has revealed that DNA ligase I has an unusually high proline content and as a result 
runs anomalously slowly on polyacrylamide gels. 
Human DNA ligase I cDNA is 40% homologous to the DNA ligases of S. 
cerevisiae and Schizosaccharomyces pombe, with homology being restricted to the 
C-terminal region of the enzymes (Barnes et a! 1990). It has been shown that this 
region contains the catalytic domain, since limited proteolysis of DNA ligase I 
generates a relatively protease-resistant 85kDa fragment from the C-terminus which 
retains catalytic activity (Tomkinson et a! 1990). Additionally, in experiments where 
the human DNA ligase I cDNA was truncated from the 5' end, followed by 
functional expression in a conditional lethal ligase mutant of E. coli to look for 
complementation at the non-permissive temperature, it was shown that an 80kDa C-
terminal fragment is sufficient to provide ligation activity. However loss of only 22 
amino acids from the C-terminus abolished complementation of the mutation 
(Kodama eta! 1991). 
Inhibition of DNA ligase I activity by pyridoxal phosphate indicates the 
presence of a lysine residue at the active site of the enzyme, as would be expected 
(Tomkinson et al 1991b). The position of this lysine residue within the enzyme was 
determined by labelling with [ 3H]ATP, followed by trypsin digestion and 
chromatographic purification of labelled peptides (Tomkinson et a! 1991b). 
Sequencing of adenylated peptides revealed a stretch of amino acids also present in 
the predicted amino acid sequence of human DNA ligase I. Sequences present in 
DNA ligases from S. cerevjsjae, S. pombe, vaccinia virus, E. coli, and 
bacteriophages T3, Ti and T4 also show some homology with the peptide sequence. 
Contained within this sequence is an active site motif, Lys-Tyr/Ala-Asp-Gly-X-Arg, 
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present in all ATP-dependent DNA ligases studied so far. The lysine residue 
(Lys568 in the human enzyme) in this motif is presumed to be the site of adenylation 
and is consistently 332 ± 20 amino acid residues from the C-terminus of the enzyme. 
The functional significance of some of the amino acid residues around the active site 
lysine of human DNA ligase I has been tested by in vitro mutagenesis (Kodama et a! 
1991). Alteration of the lysine residue at position 568 to histidine or arginine 
completely abolished the ability of the active catalytic domain of human DNA ligase 
I to form a covalent enzyme-adenylate intermediate or to complement E. coli 
conditional lethal ligase mutants. Further, alteration of G1u566 to Lys (one of the 
mutations identified in 46BR) had a similar effect, as did alteration of the residues at 
positions 569, 570, 571 and 573, although enzyme-adenylate formation was not 
impaired in every case. 
1.4.1.4: Regulation of DNA Ligase I Activity 
The function of the N-terminal domain of DNA ligase I appears to be 
regulatory. When DNA ligase I purified from calf thymus is dephosphorylated, it is 
also inactivated (Prigent et al 1992). In contrast, the C-terminal catalytic domain 
retains activity despite phosphatase treatment. It therefore appears that the N-
terminus regulates activity via phosphorylation, while the catalytic domain on its 
own is unregulated. When full-length human DNA ligase I cDNA is expressed in E. 
coli, the resulting protein is inactive until phosphorylated in vitro, whereas the C-
terminal catalytic domain, lacking the N-terminus, is active independently of 
phosphorylation (Prigent et a! 1992). This is consistent with other reports that, when 
expressed in E. coil, the C-terminal catalytic domain, but not full-length DNA ligase 
I, is active and can complement ligase-deficient E. coli cells (Kodama et a! 1991). 
When expressed in S. cerevisiae, on the other hand, both full-length human DNA 
ligase I and the catalytic domain complemented ligase deficient cdc9 mutants 
(Barnes et a! 1990). It is possible, therefore, that active DNA ligase I can only be 
expressed by cells which possess the specific kinase necessary for phosphorylation 
and this kinase may only be present in eukaryotic cells. Of the kinases tested, only 
casein kinase II (ubiquitous throughout eukaryotes) appeared able to activate the 
enzyme, by phosphorylation at serine residues. Seven S_ _E motifs, which are 
possible casein kinase II phosphorylation sites (Kemp and Pearson 1990), are present 
in the N-terminal domain of human DNA ligase I. Of these putative phosphorylation 
sites, two are potentially 'strong' substrates for the enzyme, and it was suggested that 
one of these is the site of phosphorylation (Prigent et a! 1992). 
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In contrast to these observations, separate studies where human DNA ligase I 
cDNA was expressed in E. coli, demonstrated that expression of a full-length cDNA 
produced an active protein, even though it was not phosphorylated (Teraoka et al 
1993). The major difference between these experiments is that Kodama et al (1991) 
and Prigent et al (1992) expressed DNA ligase I as a fusion protein with 23 amino 
acids of 13-galactosidase, while Teraoka et al (1993) had altered the protein only by 
addition of a threonine residue immediately after the initiator methionine. 
There have been reports of other factors which affect the activity of DNA 
ligase I. A heat-resistant protein stimulatory factor, which also acts upon DNA ligase 
II, was observed in the Blooms syndrome fibroblast cell line GM1492 (Kenne and 
Ljungquist 1988), while a heat-sensitive DNA ligase I stimulatory factor has been 
isolated from human embryo kidney cells (Fairman et al 1992). An inhibitor of DNA 
ligase I has also been identified (Yang et al 1992, Yang et al 1993). The inhibitor is 
heat-labile, with a molecular weight of 55-75kDa and appears to block ligation 
activity by a reversible physical interaction with the catalytic domain of the enzyme. 
Formation of the enzyme-adenylate intermediate is unaffected, but subsequent 
transfer of the adenylate moeity to DNA cannot take place when DNA ligase I is 
complexed with the inhibitor. 
1.4.1.5: 1[ntiraceilliullair Location and Function of DNA Lgase 11 
Immunocytochemical and indirect immunofluorescence studies on bovine 
kidney cells localised DNA ligase I to the nucleus, but not nucleoli. However, in 
mitotic cells it is present in the cytoplasm following breakdown of the nuclear 
membrane (Lasko et al 1990). 
The observation that DNA ligase I levels increase in rapidly dividing cells 
such as malignant cells or those found in regenerating liver (Söderhäll 1976, Chan 
and Becker 1985) suggests that the major function of this enzyme is in DNA 
replication. Moreover, it has been demonstrated that levels of DNA ligase I mRNA 
increase during proliferation in mouse and human fibroblasts and in human 
lymphocytes (Montecucco et al 1992). Also, the observed pattern of DNA ligase I 
expression in response to proliferation resembles that of DNA polymerase a (Wáhl 
et al 1988), which is involved in DNA replication. Further, when cells are induced to 
differentiate, DNA ligase I mRNA levels fall (Montecucco et a! 1992). Waga et a! 
(1994) have demonstrated that DNA ligase I is an essential component for 
replication of Simian virus 40 replication in vitro. DNA ligase I has also been shown 
to be a component of mammalian DNA replication complexes. A 21S complex 
which can replicate Simian virus 40 DNA in vitro has been isolated from HeLa cells 
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(Malkas et a! 1990). The complex contains DNA polymerase a, DNA primase, a 3'-
5' exonuclease, RNase H, topoisomerase I and DNA ligase I (Li et a! 1993, Li et al 
1994). Wu et al (1994) isolated a 17S complex from a mouse mammary carcinoma 
cell line, capable of replicating polyomavirus DNA in vitro. The components of this 
complex were identified as DNA ploymerases a and , DNA primase, proliferating 
cell nuclear antigen, DNA helicase, DNA topoisomerases I and II, and DNA ligase I. 
These observations support the hypothesis that DNA ligase I is involved in DNA 
replication. 
However, DNA ligase I mRNA levels also increase in response to ultraviolet 
irradiation (Montecucco et al 1992) and the DNA ligase I-deficient human cell line 
46BR is sensitive to a wide range of DNA damaging agents (Teo et a! 1982, 1983a). 
This suggests a role for DNA ligase I in DNA repair. 
1.4.2: DNA Ligase II 
A second DNA ligase was identified when it was discovered that two DNA 
ligase activities from calf thymus are separable by hydroxyapatite chromatography 
and gel filtration (Soderhäll and Lindahl 1973b). Size-fractionation of the enzymes 
by gel filtration, followed by ligation activity assays, revealed a large peak of 
activity due to the high molecular weight DNA ligase I and a minor peak of activity 
resulting from the smaller DNA ligase H. The two ligases are also distinguishable 
immunologically. Antiserum which neutralises the activity of DNA ligase I does not 
affect DNA ligase II (Söderhall and Lindahi 1975). 
SDS-PAGE followed by immunoblotting with an antibody specific for calf 
thymus DNA ligase II indicates that this enzyme consists of a single 68kDa 
polypeptide (Teraoka and Tsukada 1986), while other workers have estimated its 
size as 67kDa (Yang et al 1990) or 72kDa (Tomkinson et a! 1991a). Like DNA 
ligase I, the N-terminus of DNA ligase II is blocked to sequencing (Tomkinson et al 
1991a). Also like DNA ligase I, DNA ligase II is a nuclear enzyme (Söderhäll and 
Lindahi 1975). 
DNA ligases I and II have a number of distinct properties. DNA ligase H is 
more thermolabile than DNA ligase I and has more specific pH requirements for 
activity (Soderhall and Lindahl 1973b). Unlike DNA ligase I, DNA ligase II cannot 
catalyse blunt-end DNA joining or ligation of oligo(rA) molecules bonded to a poly 
(dT) template, while it can join oligo (dT) molecules bonded to a poly (dA) template 
and oligo (dT) molecules bonded to a poly (rA) template (Arrand et a! 1986, 
Tomkinson et a! 1991a). DNA ligase H has a high Km for ATP (a low affinity for 
ATP), while DNA ligase I has a low Km (Tomkinson et a! 1991a). 
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DNA ligases can be labelled at the active site with (X- 32P-ATP since one of 
the ligation reaction intermediates is a covalent enzyme-AMP complex. When DNA 
ligases I and H were labelled in this way, followed by partial proteolysis and SDS-
PAGE, a labelled fragment common to both enzymes was observed (Yang et al 
1990). This indicates that the active sites of both enzymes are closely related. 
However other workers have been unable to identify any proteolytic catalytic 
fragments shared between DNA ligases I and II (Roberts et a! 1994). This is 
consistent with previous reports that an antibody which inhibits the activity of DNA 
ligase I does not affect DNA ligase II (Soderhäll and Lindahi 1975), while, in 
contrast, an antibody which neutralises DNA ligase II activity has no effect on DNA 
ligase I activity (Teraoka et a! 1986). 
DNA ligase II is apparently not induced in response to cell proliferation 
(Söderhäll and Lindahi 1975). Thus there is no elevation of DNA ligase II levels 
present in rapidly dividing cells (mouse ascites tumour cells and calf thymus) over 
other cells (calf liver, calf spleen, human placenta and rabbit spleen). It has also been 
demonstrated that DNA ligase H levels are similar in normal and regenerating rat 
liver (Söderhäl.l 1976, Chan and Becker 1985) while DNA ligase I levels increase 
15-fold during liver regrowth. This suggests that DNA ligase II is not extensively 
involved in DNA replication. 
1.4.3: DNA Ligase Ill 
During purification of DNA ligase II from calf thymus, using for 
identification its ability, unlike DNA ligase I, to ligate an oligo (dT).poly (rA) 
substrate, an additional ligase activity able to act on this substrate was detected 
(Tomkinson a a! 1991a). This ligase activity has different purification properties to 
both DNA ligases I and H and is detectable as a polypeptide of lOOkDa in size as 
estimated by SDS-PAGE. It is apparently associated with a second polypeptide of 
46kDa. It has different substrate specificities to both DNA ligases I and II since it 
can ligate the oligo (dT).poly(rA) substrate and also oligo (dT).poly(dA) and oligo 
(rA).poly (dT) substrates. DNA ligase I can ligate only the latter two substrates, 
while DNA ligase H can only ligate the first two. The newly discovered ligase 
activity has a similar low Km for ATP, and a similarly sized catalytic domain 
(87kDa, compared to 85kDa), to DNA ligase I, but is immunologically distinct from 
it. This ligase activity therefore represents a separate enzyme from DNA ligases I 
and II and has been designated DNA ligase ifi. It is possible that other workers had 
already isolated DNA ligase ffi, although if so, it was erroneously identified as DNA 
ligase H. A ligase activity sharing characteristics of DNA ligase ifi, most notably a 
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size of lOOkDa, a low Km for ATP and the ability to ligate an oligo(dT).poly (rA) 
substrate, was isolated from rat liver (Elder and Rossignol 1990). 
Peptide fingerprinting of DNA ligases has revealed several small fragments 
indistinguishable between DNA ligases H and ifi, indicating that their active site 
regions around the ATP binding sites are very closely related (Roberts et al 1994). 
DNA ligase Ill has a Stokes radius of 58A (Tomkinson et al 1991a) and 
comigrates with DNA ligase I (which has a Stokes radius of 52-53A, Teraoka and 
Tsukada 1982, Tomkinson et a! 1990) during gel filtration, resulting in a single peak 
of high molecular weight ligase activity (Tomkinson et a! 1993). In SV40-
transformed human fibroblasts the major ligation activity in this peak is due to DNA 
ligase Ill. However, in calf thymus DNA ligase ifi contributes only 5-10% of DNA 
ligation activity. 
DNA ligase ifi is not induced in proliferating rat liver (Elder and Rossignol 
1990) which suggests that it may not be heavily involved in the replication of DNA. 
It may therefore have a role in DNA repair, a possibility which is supported by the 
isolation of a protein complex that repairs double stranded breaks and deletions by 
recombination (Jessberger et a! 1993). The complex, called RC-1, contains at least 
five proteins and so far a DNA polymerase (C), a 5'-3' exonuclease and a DNA ligase 
have been identified. The ligase activity is probably DNA ligase ifi since it can act 
on an oligo(dT).poly (rA) substrate and is about lOOkDa in size. This implicates 
DNA ligase III in DNA repair and recombination. It has further been shown that 
DNA ligase ifi interacts with the DNA repair protein XRCC1 (Caldecott et a! 1994) 
since it copurifies with XRCC1 during affinity chromatography. This raises the 
interesting possibility that XRCC1 is another component of RC-1. 
1.5: Gene Targeting and the Creation of Mouse Models for Human Genetic 
Disease 
Gene targeting permits the precise alteration of specific genes in cultured 
cells which can then be used to generate animals in which every cell carries the 
desired alteration (reviewed by Capecchi in 1989 and Melton in 1990). As well as 
complete gene inactivation, examples of alterations which can be made include 
domain removal, active site mutations, point mutations and elimination of protein-
protein recognition sites. This ability to modify genes at will means that gene 
targeting is an excellent technique for investigating the role of gene products, both at 
the cellular and multicellular levels. It is also potentially of great use in gene therapy 
and the study of human genetic diseases. In this respect, creation of a mouse model 
for a human disease by introduction of mutations associated with that disease, looks 
37 
promising for studies into disease progression and even evaluation of possible 
treatments. 
Some of the work presented in this thesis involves gene targeting, therefore it 
seems appropriate to briefly describe the main aspects of this technique. The 
procedure is to design a targeting vector which will cause the desired alteration in 
mouse embryonic stem (ES) cells. The vector should contain DNA sequence 
homologous to the gene of interest, but carrying the modification. When introduced 
into the cells, homologous recombination between vector DNA and the endogenous 
gene introduces the desired alteration at the chosen locus. There are two classes of 
targeting vector, called insertion or replacement, according to whether the whole 
vector is inserted or part of the genome is replaced with exogenous DNA containing 
the alteration (figure 1.5). Insertion vectors, by their very nature, are extremely 
disruptive, while replacement vectors have the advantage that they can be used to 
make more subtle alterations. 
When DNA is introduced into the ES cells most becomes randomly 
integrated into the genome by joining of the exogenous DNA ends with the 
chromosomal DNA (Folger et al 1982). Targeting events occur much more rarely 
and all targeting strategies therefore include one or more methods of enrichment. 
Due to the extreme' rarity of targeting events, the success or failure of a targeting 
experiment may rely on the method of enrichment used. The simplest example of 
enrichment is to target a directly selectable gene, such as HPRT. HPRT is involved 
in the purine salvage pathway and it is possible to select for, or against, cells 
expressing the wild type gene. Cells in which the enzyme is active can grow in HAT 
medium which contains hypoxanthine, aminopterin (an inhibitor of de novo 
synthesis of purines and pyrimidines) and thymidine. Cells ban bypass the metabolic 
block resulting from the presence of aminopterin in the medium by utilising 
hypoxanthine and thymidine in the purine salvage pathway, unless HPRT is mutated. 
Selection against active HPRT is achieved using the cytotoxic analogue 6-
thioguanine. In addition, because it is present on the X chromosome, only one copy 
of the HPRT gene needs to be altered in male ES cells for the cellular phenotype to 
reflect the change. Because of these useful properties, HPRT has been extensively 
used in gene targeting experiments. However, unlike HPRT, most other genes are 
not directly selectable so alternative methods of selecting for targeting events have 
been developed. One such method is known as positive-negative selection, so-called 
because cells which have integrated input DNA are selected for integration of a 
marker (positive selection), while negative selection is used against cells in which 
DNA has integrated randomly (figure 1.6). This can be achieved using the Herpes 
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Figure 1.5: Insertion and replacement targeting vectors. Targeting of the HPRT gene 
is illustrated. The cells being targeted have a wild-type HPRT gene, consisting of 9 
exons (indicated by the filled-in boxes), and can therefore be selected against in 6-
thioguanine. The targeting vector contains a genomic fragment extending from exon 
6 to exon 9, but with exon 8 replaced by a neomycin phosphotransferase gene (neo, 
hatched box). A: Insertion - The vector is linearised within the region of homology, 
i.e. between exons 6 and 7. Recombination between the vector and the target gene 
therefore results in the insertion of the whole vector, with consequent duplication of 
the region of homology. Thus the gene ends up with two copies of the region 
spanning exons 6 to 9. However, in the first copy, exon 8 has been replaced with a 
neomycin phosphotransferase gene, conferring resistance to the synthetic antibiotic 
0418. The genotype of the targeted cells is therefore now hprr G418r and they will 
grow in medium supplemented with 6-thioguanine and 0418. B: Replacement - The 
vector is linearised outwith the region of homology so that recombination results in 
replacement of the region between exons 6 and 9 with the equivalent region from the 
vector. In this case there is no duplication of genomic sequences, but exon 8 has 










Figure 1.6: Positive-negative selection. Targeting of the HPRT gene is illustrated. 
The cells being targeted have a wild-type HPRT gene, consisting of 9 exons 
(indicated by the filled-in boxes), and can therefore be selected against in 6-
thioguanine. The targeting vector contains a genomic fragment extending from exon 
6 to exon 9, but with exon 8 replaced by a neomycin phosphotransferase gene (neo, 
hatched box). A viral thymidine kinase gene has been placed adjacent to exon 9 (tIc, 
shaded box). A: Targeting - Homologous recombination occurs between the two 
regions of homology flanking the neomycin phosphotransferase gene, which then 
integrates into the gene, replacing exon 8. No other part of the vector inserts into the 
gene, therefore the thymidine kinase gene is lost. Targeted cells can therefore be 
selected for growth in 6-thioguanine and gancyclovir. B: Random Integration - The 
linearised vector inserts into the genome via its ends. The whole plasmid, including 
the thymidine kinase gene, integrates at a random position. The HPRT gene is 








simplex virus thymidine kinase gene (HSV-tk). Cells expressing HSV-tk can be 
selectively killed using the nucleoside analogue gancyclovir, which is specific for 
the viral enzyme. Overall, the effect is selection for cells in which a targeting event 
has occured. A replacement vector is used, which contains homologous DNA 
sequences with the positive marker gene inserted, and the HSV-tk gene adjacent to 
the region of homology. This design makes it probable that homologous 
recombination will result in loss of the HSV-tk gene thus rendering cells resistant to 
gancyclovir, while also becoming selectable for the inserted marker and mutated in 
the targeted gene. However, should random integration occur, the HSV-tk gene will 
be retained since most random integrations of linear DNA molecules occur via the 
ends and therefore the cells can be selectively killed. Other methods of enrichment, 
such as insertional activation of marker genes, have also been used. 
Following selection, cells are screened for targeted alterations by procedures 
such as Southern blotting or PCR, where one primer is specific for the alteration and 
the other for the target locus. A PCR product will therefore only be seen if the gene 
has been correctly modified. 
Once the alteration has been made, targeted ES cells are injected into a 
recipient blastocyst which is surgically implanted into a foster mother (figure 1.7). 
ES cells are isolated from the inner cell mass of a blastocyst and are capable of 
differentiating to form all different cell types. Thus, in the resulting animal targeted 
ES cells, because they are pluripotent, should have contributed to all the body 
tissues. The mouse is therefore called a chimaera since its tissues are composed of 
donor and recipient cells. If the injected cells have also contributed to the germ line 
some gametes will carry the altered gene and it is possible, by breeding, to obtain an 
animal homozygous for the targeted alteration. 
1.6: Project Aim 
At the start of this project it was thought that the human disease Blooms 
syndrome results from a defect at the DNA ligase I locus and initially the aim was to 
generate a mouse model for Blooms syndrome by introducing a mutation into the 
mouse DNA ligase I gene. It soon became evident that the DNA ligase I gene itself 
is not mutated in BS cells and therefore the aim of the project shifted from 
generating a mouse model for Blooms syndrome, to generating a model for DNA 
ligase I deficiency. 
The initial purpose of the project is to provide information enabling the 
introduction of a mutation into the mouse DNA ligase I gene in embryonic stem 
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Figure 1.7: Generation of mice homozygous for a targeted alteration. Once a gene 
has been targeted in embryonic stem cells, targeted cells are injected into mouse 
embryos. These are then surgically implanted into a pseudopregnant foster mother. 
The reulting offspring should be chimaeras since embryonic stem cells are 
pluripotent and can therefore potentially contribute to all tissues in the body. In this 
example the quality of the chimaeras is assessed by coat colour, using embryonic 
stem cells derived from mice with a dark coat, and recipient embryos which will 
develop a light coat. A chimaera is therefore recognizable by patches of light and 
dark coat colour. Chimaeras are then bred and, if the donor ES cells have contributed 
to the germ line of the chimaera, the targeted alteration should be inherited by some 
of the offspring, which will have a dark coat. 
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cells, by gene targeting, which will partially impair the activity of the enzyme. The 
eventual intention is to use the targeted ES cells to create a mouse model for DNA 
ligase I deficiency. 
Mutations have been identified in both alleles of the DNA ligase I gene of a 
human fibroblast cell line (46BR) displaying a number of abnormalities. Prior to the 
introduction of one of these mutations into the mouse gene in order to generate DNA 
ligase I-deficient mice, the aim is to demonstrate that the observed abnormalities of 
this cell line arise directly from the mutated DNA ligase I. Following this, the 
structure of the mouse DNA ligase I gene will be investigated in order to identify 
parts of the gene which will be of use in gene targeting experiments and such 
experiments will be then be carried out. 
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CHAPTER 2 
MATERIALS AND METHODS 
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2A Materials 
2A.1 Suppliers of Laboratory Reagents 
2A.1.1 Restriction Endonucleases and other DNA/RNA Modifying Enzymes 
Boehringer Mannheim plc. 
GIBCO BRL Life Technologies 
New England Biolabs inc. 
Pharmacia LKB Biotechnology 




GIBCO BRL Life Technologies 
ICN Flow Ltd. 
Sigma Chemical Co. 
2A.1.3 Bacterial Media Reagents 
Becton-Dickinson UK Ltd. 
Difco Laboratories 
Baltimore Bio. Labs 
2A.1.4 Mammalian Cell Culture Reagents 
GIBCO BRL Life Technologies 
ICN Flow Ltd. 
Sera-Lab 
Sigma Chemical Co. 
2A.1.5 Radioactive Reagents 
Amersham International plc. 
a-32P-dCTP ..3000 Curies/mmole 
cz- 35S-dATP 600 Curies/mmole 
[3H]-hypoxanthine _7.9 Curies/mmole 
2A.1.6 Antibiotics 
ampicillin: Beecham Research Laboratories 
G418: GIBCO BRL Life Technologies 
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penicillin G: Sigma Chemical Co. 
Streptomycin: Sigma Chemical Co. 
2A.1.7 Antisera 
1131 limited: 
mouse anti-FLAG Ml monoclonal antibody (calcium dependent), 3. 1pg4t1 
and N-terminal FLAG.BAP control protein, 0.33p.g/p.l 
Promega: 
alkaline phosphatase-conjugated anti-mouse IgG 1mg/mi 
2A.1.8 Human DNA Ligase I cDNA 
The cDNA was kindly provided by Dr. Tomas Lindahl (Barnes et a! 1990). 
2A.1.9 Oligonucleotides 
Except for the universal primer (Pharmacia LKB Biotechnology) all 
oligonucleotides were synthesised by the Oswel DNA Service at the University of 
Edinburgh (Department of Chemistry). 
NAME SEQUENCE 5' TO 3' DESCRIPTION 
572M TFGTFCTCAGGAGATGTGGC human DNA ligase I cDNA, 5' 
end (e-) 
573M CACAGAGCCTCGCCI -I-IQCC human 6-actin promoter (->) 
027N GATCCGCCGCCCGTCCACAC human 13-actin promoter (-*) 
028N CCGCCAGGATCAGTCGAGGC cloning junction in pBAneo 
HL between promoter and 
cDNA (-*) 
482W ATGGGATGATAGTFATFCrF mouse DNA ligase I cDNA, 3' 
of Ba.mHI site (f-) 
483W GTCCGACTGCGGCCGCCATGG mouse DNA ligase I cDNA, 
ACTACAAGGACGACGATGATA introducing FLAG sequence 
AGCGAGAAAGTATFATGTCAT (-4) 
T 
887Y CTGAAGAAGGACTACTFGA human DNA ligase I, exon 23, 
5' end (-*) 
888Y CTFGCATATGGCCTGCAGCT human DNA ligase I, exon 23, 
3' end (-) 
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G4607 CTCAGAAGCCAGGTACATFG mouse DNA ligase I, for 
sequencing 
G4608 CTGCCAACATGCGAGAAAGT mouse DNA ligase I, for 
sequencing 
G8320 TCCFTCACTGACTGCTCAAG mouse DNA ligase I, for 
sequencing 
G8321 CCCTATGTGAGGATFGATGC mouse DNA ligase I, for 
sequencing 
G8322 CAGGCATCTFCAATG3GATG mouse DNA ligase I, for 
sequencing 
H2066 GTTCTCTGTCIIIGTCAGGc3 mouse DNA ligase I, for 
sequencing 
H3123 CAGTFCGACGCTITGGGAAT mouse DNA ligase I, for 
sequencing 
M13 reverse AACAGCTATGACCATG for sequencing 
IL universal GTAAAACGACGGCCAGT for sequencing 
2A.2 Media 
2A.2.1 Bacterial Media 
Luria Broth (LB): 
Difco Bacto-tryptone, lOg 
Difco bacto-yeast extract, 5g 
NaCl, 5g 
per litre, adjusted to pH 7.2 with NaOH 
Luna Agar: 
as LB with 15g per litre Difco agar 
Terrific Broth (TB): 
Difco bacto-tryptone, 12g 
Dilco bacto-yeast extract, 24g 
glycerol, 4m1 
per 900m1, plus lOOm! sterile 0. 17M KH2PO4J0.72M K2HPO4 after 
autoclaving 
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M9 Minimal Agar 
DilcoBactoAgar, 15g 
lox M9 salts, lOOmi 
20% glucose, 20m1 
O.1M MgSO4, lOmi 
1mg/mi vitamin Bi, lOmi 
O.1M CaC12, lOiiil 
per litre 






Baltimore BioLabs Trypticase, lOg 
Difco Bacto Agar, lOg 
NaCl, 5g 
per litre, adjusted to pH 7.0 with NaOH 
BBL Top Agar: 
Baltimore BioLabs Trypticase, lOg 
Difco Bacto Agar, 6.5g 
NaCl, 5g 
1OmMMgSO4 
per litre, adjusted to pH 7.0 with NaOH 
Antibiotics 
When required, ampicillin to a final concentration of lOOp.g/mI was added 
immediately prior to use. 
2A.2.2 Mammalian Tissue Culture Media 
Glasgow Modified Eagles (BHK21) Medium (McPherson, 1962, with 
modifications by W. House, Medical Research Council Institute of Virology, 
University of Glasgow, 1964) was supplied by GIBCO BRL Life Technologies as 
lox concentrate. 1X medium was supplemented with 1X non-essential amino acids, 
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1mM sodium pyruvate, 2mM L-Glutaniine, 10% foetal calf serum (GIBCO BRL 
Life Technologies), 50U/ml penicillin and 50ig/m1 streptomycin. 
2A.3 Bacterial Strains 
NAME GENOTYPE REFERENCE 





XL1-Blue F, TnlO, proAB, laclq , Bullock et al 1987 
ii(lacZ)M151recAl, endAl, 
gyrA96, (Nal'), thi, 
hsdR17, (ricmK), 
supE44, relAl, lac  
DH5a supE44, ziJacU169 Hanahan 1983 
(0801acZziM15), hsdRl 7, 
RecAl, endAl, gyrA96, 
thi-1  
BHB2688 N205, recA, [limrn43, 4, Hohn + Murray 1977 
clts, b2, red, Earn, Sam/l]  
BHB2690 N205, recA, [iirnm43, 4, Hohn + Murray 1977 
clts, b2, red, Dam, Sam/l]  
K802 Fe14, (McrA-) lacYl or Maniatis et al 1982 
Lt(lac)6, supE44, galK2, Woodcock et a! 1989 
gaiT22, rfbDl,  metBi, Bachmann 1987 
mcrBl, hsdk2 (r1cmK)  
NM514 hsdR, (r1cmK), Lyc7 obtained from N. Murray, 
A1mrn434 ci- Edinburgh 
BL21(DE3) F' hsdS, gal (DE3) Studier + Moffatt 1986 
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2A.4 Mammalian Cell Lines 
NAME DESCRIPTION REFERENCE 
E14 wild-type male mouse Handyside 1989 
embryonic stem cell line 
isolated from 129/01a  
blastocysts  
E14TG2a HPRT-deficient derivative of Hooper 1987 
E14 obtained by selection in 6-  
thiog!!anine  
HeLa human cervical carcinoma cell Puck + Marcus 1955 
line  
RJK88 HPRT-deficient Chinese Fuscoe 1983 
hamster lung fibroblast cell 
line  
46BR. 1G1 transformed human fibroblast Webster et a! 1982 
cell line with aberrant DNA 
gase I activity  
MRC5V1 transformed wild-type human Huschtscha + Holliday 
fibroblast cell line 1983 
2A5 Pilasmids and Cloning Vectors 
NAME DESCRIPTION REFERENCE 
pç8 general ppose cloning vector Norrander 1983 
pBluescriptll KS+ general purpose cloning vector Thummel 1988 
AEMBL4 replacement vector used to Frischauf et a! 1983 
construct genomic library  
ANM1 149 insertion vector used to obtained from N. Murray, 
construct cDNA library Edinburgh 
M13mp18 and vectors used to generate Yanisch-Perron a al 
M13mp19 single-stranded DNA for (1985) 
sequencing, with polylinkers 
in opposite orientations to 
allow both DNA strands to be L  gçnced  
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pLK444 expression vector utilising the Gunning et a! 1987 
human 13-actin promoter, with 
neoT driven by the SV40 early 
promoter  
pHL human DNA ligase I cDNA Barnes et a! 1990 
cloned in pBluescript SK-, 
under the control of a yeast 
promoter  
pDWM1 11 HPRT minigene cloned into Selfridge et al 1992, 
pUC8 Magin et a! 1992 
pHPT5 construct of full-length mouse Konecki et a!, 1982 
HPRT cDNA with poly A 
sequences 
2A.6 Buffers 
CA: 	24 parts chloroform, 1 part isoamylalcohol 
denaturing 0.5M NaOH, 1.5M NaC1 
buffer: 
HBS: 	8% NaCl, 0.37% KC1, 0.126% Na2HPO4 dihydrate, 1% D- 
glucose, 5% HEPES, pH to 7.2 with NaOH 
lox MOPS: 200mM 3-(N-morphohno) propane-sulphonic acid (MOPS), 
50mM sodium acetate, 10mM EDTA, to pH 7.0 with NaOH 
neutralising 3M NaCl, 0.5M Tris-HC1 pH 7.0 
buffer: 
PBS: 	8mM K2HPO4, 1.5mM KH2PO4, 150mM NaCl 
PCA: 	25 parts redistilled phenol, 24 parts chloroform, 
1 part isoamylalcohol 
phage buffer: 50mM Tris-HC1 pH 7.5, 100mM NaCl, 10mM MgSO4, 2% 
gelatine 
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sample buffer:20% glycerol, 100mM EDTA, 0.1% bromophenol blue 
20X SSC: 	3M NaCl, 0.3M tn-sodium citrate pH 7.0 
STh: 	10mM Tris-HC1 pH 8.0,1mM EDTA, 150mM NaC1 
lox TBE: 	0.9M Tris-HC1, 0.9M boric acid, 20mM EDTA, p118.0 
TE: 	10mM Tris-HC1 pH 8.0,1mM EDTA 
TM: 	50mM Tris-HC1 pH 8.0, 50mM Tris-HC1 pH 8.9, 50mM 
MgC12 
2B Methods 
2B.1 Bacterial Culture 
2B.1.1 Growth of Escherichia coli 
Cells were grown at 37 0C in LB or TB. Cells grown on L plates 
supplemented with ampicillin were incubated at 30°C to prevent growth of satellite 
colonies. 
2B.1.2 Storage of E. coil 
For short term storage (4-6 weeks) bacteria were streaked onto agar plates 
and stored at 4°C. Strains TG1 and XL1-blue were kept on minimal agar to maintain 
the F' plasmid. 
For longer term storage, 900.t1 fresh overnight culture was mixed with lOOpfl 
dimethyl sulphoxide (DMSO) and frozen at -70 0C. Cells were recovered by scraping 
the surface of the frozen culture with a sterile inoculating loop and streaking Out on 
an agar plate. 
2B.1.3 Transformation of E. coil 
Bacteria were transformed with DNA by the method of Mandel and Higa 
(1970) with modifications by Dagert and Ehrlich (1974). 0.5m1 of an overnight 
culture of the E. coli strain to be transformed was added to SOml of LB 
supplemented with imi of 1M MgCl2-  Cells were grown with vigorous shaking at 
37°C to OD600nm=0.2. The cells were chilled on ice for 5min then spun down at 
15,000rpm for 15min at 4 0C. Cells were resuspended in 20m1 ice-cold 
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transformation buffer (50mM CaC12, 10mM Tris-HC1 pH 7.5) and incubated for 
30min on ice. Cells were re-pelleted at 15,000rpm for 15min at 4 0C, resuspended in 
2m1 ice-cold transformation buffer and incubated overnight on ice (or for a minimum 
of 2 hours) prior to use. 
About lOng of DNA in a volume of 5-10W was added to lOOjtl of competent 
cells which were then incubated on ice for 30mm, followed by heat shocking at 37°C 
for 5mm. 400p.l warm LB was added and the cells incubated at 37 0C for 1 hour (to 
allow expression of antibiotic resistance) before plating to dryness on LB agar with 
ampidilhin selection. Plates were then incubated overnight at 30°C. 
If appropriate, 30j.fl of 2% X-Gal (in dimethylformamide) and 20.tl of 
100mM IPTG were also added per plate to aid identification of recombinants, with 
recombinant colonies appearing white and non-recombinants appearing blue. 
211.2 Nucleic Acid Isolation 
211.2.1 Small-Scale Preparation of Plasmid DNA 
The method used is a modification of the method described by Ish-Horowicz 
and Burke (1981). Bacteria were grown at 37 0C in 5m1 LB or TB supplemented with 
ampicillin. 1.5m1 of the culture was transferred to an Eppendorf tube and the cells 
pelleted by centrifugation for 5min in a microcentrifuge. Cells were resuspended in 
300t1 of solution P1 (50mM Tris-Hcl pH 8.0, 10mM EDTA, 100.tg/ml RNase A), 
then lysed by addition of 300jtl of solution P2 (20mM NaOH, 1% SDS) and gentle 
mixing by inversion. 300iLl of solution P3 (2.55M potassium acetate pH 4.8) was 
added followed by gentle mixing. Precipitated chromosomal DNA, SDS and protein 
were sedimented by centrifugation for 10min in a microcenirifuge. The supernatant 
was phenol extracted to remove contaminating proteins, then nucleic acids 
precipitated with 600i.tl of isopropanol and spun down for 10min in a 
microcentrifuge. The pellet was washed twice with 70% ethanol, dried and 
resuspended in 50iLl sterile distilled water and stored at -20°C. 
2B.2.2 Large-Scale Preparation of Plasmid DNA 
Bacteria were grown for 24 hours by vigorous shaking at 37°C in 80m1 of TB 
supplemented with ampicillin. Cells were pelleted by spinning at 4,000rpm for 
20min at 4°C. Cells were then lysed and chromosomal DNA and proteins 
precipitated as with the small scale plasmid preparation method, but using lOmi of 
solutions P1, 2 and 3. Following addition of solution P3, the lysed culture was 
incubated for 15min on ice and the precipitated chromosomal DNA/SDS/protein 
complex sedimented by centrifugation at 20,000rpm for 30min at 4 0C. The 
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supernatant was removed promptly, filtered and applied to a Qiagen-tip 500 column, 
previously equilibrated with lOmI of buffer QBT (750mM NaCl pH 7.0, 50mM 
MOPS, 15% ethanol, 0.15% Triton X-100). After washing twice with 30nil buffer 
QC (1M NaC1 pH 7.0, 50mM MOPS, 15% ethanol), the DNA was eluted with 15m1 
buffer QF (1.25M NaCl pH 8.2, 50mM MOPS, 15% ethanol). 12m1 of isopropanol 
was added to precipitate the DNA which was then spun down at 4,000rpm for 20mm 
at 40C. The DNA was washed with 70% ethanol, dried, resuspended in sterile 
distilled water and stored at -20°C. 
2B.2.3 Preparation of Genomic DNA from Manmiiallian Cells 
Genomic DNA was prepared by the method of Pefficer et al (1978). Cultured 
cells were harvested by scraping with a plastic policeman (Costar) and collected in 
lOml PBS. Two to four confluent 64 cm2 dishes were used, yielding 107- 108 cells 
depending on the cell line. Cells were pelleted by centrifugation at 1,300rpm for 
5min and then rinsed three times in PBS by pelleting and resuspending in lOmi of 
PBS. Cells were then gently resuspended in hypotomc solution (10mM Tris-HC1 pH 
8.0, 10mM NaCl, 3mM M902). The expanded cells were pelleted and resuspended 
in lOml hypotonic solution with 0.2% Triton X- 100. This caused cell lysis and intact 
nuclei were pelleted and resuspended in 7.6 ml of 10mM Tris-HC1 pH 8.0, 400mM 
NaCl, 10mM EDTA. 0.4m1 10% SDS and lOOp.! 30mg/mI proteinase K were added 
to the lysate which was incubated at 37 0C overnight. RNA was degraded by addition 
of 200p.l lOmg/ml RNase A and incubation at 370C for a further hour. Residual 
proteins and RNase A were hydrolysed by addition of 100p.l 30mg/mi proteinase K 
and incubation at 37 0C for another hour. This was followed by two phenol 
extractions, by addition of an equal volume of PCA and shaking for 15mm. The 
phases were separated by spinning at 4,000rpm for 15min at 4°C. After the second 
extraction, the aqueous phase was extracted with an equal volume of CA. DNA was 
then precipitated by addition of 0.25 volumes of SM NaCl and 2 volumes of cold 
100% ethanol. and recovered by spooling onto a sealed pasteur pipette. The DNA 
was rinsed by immersion in 70% ethanol, dissolved in lml sterile distilled water and 
stored at 40C. This method yielded 1-2mg of high molecular weight DNA. 
213.2A Preparation of RNA from Mammalian Cells 
RNA was prepared using a modification of the methods described by 
Strohman et a! (1977) and MacDonald et a! (1987). Cultured cells were harvested 
and washed in PBS as for preparation of genomic DNA. After the third PBS rinse 
cells were resuspended in 8m1 of 6M guanidine hydrochloride, 10mM DTT, 25mM 
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EDTA, pH 7.0. The cell suspension was transferred to a glass homogeniser and the 
cells macerated with 30 strokes of the homogeniser and transferred to a centrifuge 
tube. The homogeniser was rinsed Out to recover residual homogenate with 2m1 of 
the guanidine hydrochloride solution. 1/30 volume of potassium acetate, pH 5.0 and 
1/2 volume of cold 100% ethanol were added to the homogenate, mixed, and the 
solution left at -20 0C for at least 4 hours to precipitate the RNA. The RNA was 
pelleted by centrifugation at 12,000rpm for 20min at 4 0C. The supernatant was 
discarded and the RNA re-precipitated twice more. The resulting pellet was 
suspended in 3ml of 0.1M Tris-HC1 pH 8.9, 0.1M NaCl, 1mM EDTA, 1% SDS. An 
equal volume of PCA was added and the sample extracted by vigorous shaking for 
10mm, followed by centrifugation at 4,000rpm for 10mm. RNA was precipitated 
from the aqueous layer by addition of 115 volume of 3M sodium acetate, pH 5.0 and 
2 volumes of cold 100% ethanol. The RNA was left to precipitate for 4 hours at 
-200C and then pelleted by spinning at 15,000rpm for 25min at 4°C. The RNA pellet 
was resuspended in 0.5m1 sterile distilled water and precipitated by addition of 1/10 
volume 3M sodium acetate, pH 5.0, 2 volumes cold 100% ethanol and incubation at 
-70 0C for 15mm. RNA was pelleted by centrifugation for 10min in a 
microcentrifuge, washed twice with 70% ethanol, dried, resuspended in 50-100j.il of 
sterile distilled water and stored at -70°C. This method yielded 50-200pg of RNA 
depending on the cell line used. 
Polyadenylated RNA was prepared by incubating total RNA at 65°C for 
5mm, followed by cooling on ice and application to an oligo (dT)-cellulose column 
(Pharmacia LKB Biotechnology) according to the manufacturers instructions. 
Polyadenylated RNA was eluted from the column, reincubated at 65°C for 5min and 
applied to a second identical column. Following elution from the second column, 
RNA was precipitated by addition of 0.2 volumes of 2M NaCl and 3 volumes cold 
100% ethanol followed by incubation at -20 0C for at least two hours. Precipitated 
RNA was pelleted by centrifugation for 10min at 4°C in a microcentrifuge, the 
supernatant was discarded, and the polyadenylated RNA was redissolved in 20j.tl of 
TE buffer and stored at -70°C. 
2B.2.5 Smallfl-Scsille Preparation of B&ictealophage M113 Rellicative Form DNA 
50.d of an overnight culture of E. coli strain TG1 was added to 2mi of LB. 
To this was added one M13 plaque and the infected culture was grown for 4-4.5 
hours at 370C. imi of culture was removed to an Eppendorf tube and bacterial cells 
pelleted for 5min in a microcentrifuge. The supernatant was tipped off and any 
remaining removed carefully with a pipette. The pellet was resuspended in 100il of 
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solution 1 (50mM glucose, 10mM EDTA, 25mM Tris-HC1 pH 8.0), followed by 
addition of 200.tl of solution 2 (0.2M NaOH, 1% SDS) and the tube contents mixed 
by inversion. 150p.l of solution 3 (3M potassium acetate, 11.5% glacial acetic acid) 
was added, mixed by inversion and cell debris spun down for 5min in a 
microcentrifuge. The supernatant was phenol extracted and precipitated by addition 
of 1/10 volume of 3M sodium acetate and 2.5 volumes of cold 100% ethanol. DNA 
was spun down for 10min in a microcentrifuge, washed in 70% ethanol, resuspended 
in 25.fl TE buffer and stored at -20 0C. A typical yield from this method was about 
500 ng of M13 DNA. 
213.2.6 Preparation of Single-Stranded IBacteriopihiage M113 DNA 
50p.l of an overnight culture of E. coli strain TG1 was added to 2m1 of LB. 
One M13 plaque was added and the culture grown for 4-4.5 hours at 37°C. 1.5m1 of 
the culture was transferred to an Eppendorf tube and cells pelleted for 5min in a 
microcentrifuge. This was repeated with the supernatant. 1 .2m1 of supernatant was 
transferred to a fresh tube and phage precipitated by addition of 300p.l of 20% PEG 
6000, 2.5M NaCl. This was mixed by inversion and left to stand at room temperature 
for 15mm, followed by spinning for 20min in a microcentrifuge. The supernatant 
was removed and the tube spun again briefly and any remaining solution removed 
carefully with a pipette. The pellet was resuspended in 300.tl TE buffer and phenol 
extracted. Single-stranded DNA was precipitated from the upper aqueous layer by 
addition of 1/10 volume 3M sodium acetate and 2.5 volumes of cold 100% ethanol. 
The DNA was pelleted for 20min in a microcentrifuge, washed with 70% ethanol, 
resuspended in 12p.1 of sterile distilled water and stored at -20°C. This yielded 1-
2j.tg of DNA, sufficient for two sets of sequencing reactions. 
213.2.7 Preparation of l3acterlophage X DNA 
An overnight culture of E. coli was grown up in 5m1 LB supplemented with 
50p.l of 20% maltose and SOp.! of 1M MgSO4. SOp.! of the overnight culture and 3-5 
bacteriophage plaques were added to 22m1 of LB supplemented with 250p.l of 20% 
maltose, 250p.l of 1M M902  and 2.5m1 of 100mM CaC12. The culture was grown at 
370C in a conical flask with vigorous shaking for about 9 hours until cell lysis 
occured. A few drops of chloroform were added and the lysed culture shaken for a 
further 10mm. Cell debris was spun down at 15,000rpm for 15min at 4 0C and the 
supernatant stored at 4°C. 12mi of supernatant was transferred to an ultracentrifuge 
tube and 5p.l each of DNase I and RNase A (both 2mg/mi) added. The lysate was 
incubated at 37°C for one hour. Phage were then pelleted by ultracentrifugation at 
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27,000rpm for 90min at 100C. The phage pellet was resuspended in 200iil of 0.5M 
Tris-HC1 pH 8.0, transferred to an Eppendorf tube and 200p.l of proteinase K 
(2mg/mi) in 0.5M Tris-HC1 pH 8.0 added and left to digest for one hour at 37°C. 
Phage DNA was purified by addition of an equal volume of PCA, mixing for 5mm 
and spinning for 5min in a microcentrifuge. This was repeated with an equal volume 
of CA. DNA was precipitated from the upper aqueous layer by addition of 1/10 
volume of 3M sodium acetate and 2.5 volumes of cold 100% ethanol. The DNA was 
washed with 70% ethanol, dried, resuspended in 50-10Op.1 of sterile distilled water 
and stored at -200C. 
2B.3 Quantification of Nucleic Acids 
2B.3.1 Estimation of DNA Concentration 
DNA samples were diluted in lml of distilled water and the absorbance at 
260 and 280nm measured in a spectrophotometer (Perkin-Elmer, Lambda 15, 
UV/VIS Spectrophotometer). OD26O=1.0 represents a concentration of 50p.gIml 
for DNA. The ratio OD26ØrnpJOD280nm gives an estimate of nucleic acid purity. For 
DNA, a value of around 1.8 indicates a pure preparation. 
2B.3.2 Estimation of RNA Concentration 
RNA concentrations were measured as for DNA. ODj=1.0 represents an 
RNA concentration of 40p.g/ml. OD JjOD28o=2.0 indicates a pure preparation 
of RNA. 
2B.4 DNA Manipulation 
2B.4.1 Purification 
One volume of chloroform and one volume of redistilled phenol equilibrated 
in STE buffer were added to a solution of DNA to be purified. The mixture was 
vortexed for lmin and spun for 5min in a microcentrifuge to separate the phases. An 
equal volume of chloroform was added to the upper aqueous layer, which was then 
vortexed and centrifuged for 2mm. DNA was precipitated from the upper aqueous 
layer by addition of 1/10 volume 3M sodium acetate pH 5.0 and 2.5 volumes cold 
100% ethanol. DNA was pelleted by spinning for 10min in a microcentrifuge, 
washed with 70% ethanol, dried and resuspended in an appropriate volume of sterile 
distilled water. 
2B.4.2 Restriction of DNA with Endonucleases 
DNA was digested with about 5 units of endonuclease per p.g of DNA, using 
buffer and temperature conditions recommended by the manufacturer. For double 
digests involving enzymes with different buffer requirements, reactions were either 
carried out under buffer conditions intermediate between the requirements of the two 
enzymes, or DNA was digested in two steps. Reactions were halted by heating at 
650C for 10mm, by phenol extraction or by addition of sample buffer. 
2B.4.3 Dephosphorylation 
Bacterial alkaline phosphatase (BAP) hydrolyses 3' and 5' phosphates from 
DNA and RNA. It can be used for dephosphorylating vectors prior to insert ligation 
to prevent vector recircularisation and increase the frequency of recombinants. 
About ing of DNA in 90tl of sterile distilled water was mixed with 10Ll of lOX 
BAP buffer (0.65M Tris-HC1 pH 7.5, 95mM MgC12, 50mM DTF) and 66 units of 
BAP. The reaction mix was incubated for one hour at 650C,  followed by phenol 
extraction and two sodium acetate/ethanol precipitations to remove all traces of the 
enzyme. 
2B.4.4 Filling-In Recessed 3' DNA Termini 
5' overhanging DNA ends generated by restriction endonucleases were 
converted to blunt ends by "filling-in" with the Kienow fragment of E. coli DNA 
polymerase I. About 1ig of DNA in 39.tl of sterile distilled water was mixed with 
5p1 of nick translation buffer (500mM Tris-HC1 pH 7.5, 100mM M902, 10mM 
DTT, 500p.gjml BSA), 5i.tl  5mM dNTPs and 6 units of Kienow. The reaction mix 
was incubated at room temperature for one hour and the reaction halted by phenol 
extraction. Klenow was also used to remove 3' overhanging ends by means of a 
lesser exonuclease activity, under the same reaction conditions. 
2B.4.5 Ligation 
Ligations were carried out in a lOp.! reaction volume containing vector and 
insert DNA, 50mM Tris-HC1 pH 7.6, 10mM MgCl2, 1mM DTF, 1mM ATP, 5% 
PEG 8000 and 1 unit of T4 DNA ligase. Reactions were incubated for 1-3 hours at 
room temperature or overnight at 15 0C. Ligation products were then used to 
transform E. coli. 
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2B.4.6 Addition of Linkers 
500ig of linkers were dried and resuspended in 3p1 of TM buffer in a 
microcentrifuge tube. The tube was heated in a waterbath for 15min at 80°C then 
transferred to a 37°C waterbath for 15min to allow the linkers to anneal. 
The linkers were then idnased for 1.5 hours at 37°C by mixing 2jtl of 
annealed linkers with 1j.l of linker kinase buffer (2M Tris-HC1 pH 7.5, 1M M902, 
1M DiT, 50mM ATP, 10 mg/ml BSA), 10 units of T4 kinase and 6p.l of sterile 
distilled water. 
10j.l of kinased linkers were then ligated to 7tl of blunt-ended fragment in 
the presence of liii  of linker kinase buffer and 2 units of T4 DNA ligase. 
213.5 Electrophoresis of Nucleic Acids 
2B.5.1 Electrophoresis of DNA in Agarose Gels 
DNA fragments were separated in 0.8-2% BRL electrophoresis grade agarose 
with 0.5p.g/ml ethidium bromide in lx TBE buffer. DNA samples were mixed with 
1/10 volume sample buffer. Electrophoresis was carried out horizontally at 70-100V. 
Bacteriophage ? DNA cut with Hindifi and (I'X174 replicative form DNA cut with 
Haeffl or lOObp ladder (GIBCO BRL Life Technologies) were used as size markers. 
DNA was visualised by ultra-violet illumination. 
2B.5.2 Electrophoresis of RNA in Agarose Gels 
RNA samples were run out on denaturing agarose gels. 1.4% agarose gels 
were made up in 1X MOPS, 0.66M formaldehyde and 0.5pg/ml ethidium bromide. 
20p.g of total RNA in 20.tl of sterile distilled water was added to an equal volume of 
formamide sample buffer (2.3X MOPS, 12mM sodium acetate pH7.0, 50% 
deionised formamide, 11% formaldehyde) and 1/4 volume of sample buffer. 
Samples were heated for 5min at 650C and snap chilled on ice. Samples were then 
loaded onto the gel and run in 1X MOPS at 100V for 3-4 hours. 
2B.5.3 Recovery of DNA from Agarose Gels 
If the DNA was to be recovered by phenol extraction it was electrophoresed 
through low melting point agarose and cut out of the gel. An equal volume of lx 
TBE, 0.2M NaCl was added and the gel melted at 65°C. 3/4 volume redistilled 
phenol equilibrated in lx TBE, 0. 1M NaCl was added, the mixture'vortexed and 
then spun for 5min in a microcentrifuge. The phenol extraction was repeated with 
the upper aqueous layer. An equal volume of butanol was added, the solution 
vortexed and spun for 5min in a microcenirifuge. The lower aqueous layer was 
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precipitated with 1/10 volume of 3M sodium acetate pH 5.0 and 2 volumes of cold 
100% ethanol, spun for 10min in a microcentrifuge and the pellet washed twice with 
70% ethanol, dried and resuspended in a suitable volume of sterile distilled water. 
For DNA fragments larger than 500bp, DNA was run through a regular 
agarose gel and purified using Geneclean (Bio101 Inc.). 0.5 volume of "TBE 
modifier" (a concentrated salt solution) and 4.5 volumes of 6M Nal were added to 
the gel slice. The agarose was dissolved by heating at 55°C, then cooled on ice for 
5mm. An appropriate amount (5pJ/5p.g DNA and 2p.1/p.g DNA thereafter) of 
"glassmilk" (a silica matrix suspended in water) was added and incubated on ice for 
5min to allow the DNA to bind to the matrix. The "glassmilk" was pelleted by 
centrifugation for 5s in a microcentrifuge and the supernatant discarded. The pellet 
was washed three times in "NEW WASH" (NaCl, ethanol, water mix), by 
resuspending in 250.tl of the "NEW WASH" and pelleting. The DNA was eluted 
from the "glassmilk" by two cycles of resuspension in sterile distilled water 
(10.tl/5pi "glassmilk") and heating at 55°C, followed by spinning for 30s and 
removal of the supernatant. The DNA-containing supernatant was stored at -20°C. 
2B.6 Transfer of Nucleic Acids from Agarose Gells to Membranes 
2B.6.1I DNA Transfer 
This procedure was originally developed by Southern (1975) and modified 
by Smith and Summers (1980). 1-10jtg of genomic DNA was cut with an 
appropriate restriction enzyme for at least 6 hours to ensure complete digestion, then 
the resulting fragments were separated on a 0.8% agarose gel. DNA was 
electrophoresed overnight at 45V, then photographed. The gel was soaked in 
denaturation buffer with gentle agitation for 30mm. The DNA was transferred to 
Genescreen Plus nylon membrane (DuPont) by capillary action using denaturation 
buffer as the transfer medium (Reed and Mann 1985). A wick made of wet blotting 
papers was placed on a platform with both ends of the blotting paper immersed in 
denaturing buffer in a reservoir underneath the platform. The gel was placed on top 
of the wick and a sheet of membrane (previously equilibrated in denaturing buffer) 
cut to the same size as the gel was placed on top of the gel. The edges were sealed 
with plastic films. Three sheets of blotting paper soaked in distilled water were laid 
on top of the membrane, followed by a stack of dry paper towels. A glass plate was 
placed on top of the paper towels and a weight laid on top. Transfer was allowed to 
continue for 12-48 hours after which the membrane was neutralised for 30min in 
neutralising buffer and air dried before use. 
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2B.6.2 RNA Transfer 
Following electrophoresis the gel was photographed then soaked for two 
20min periods in lox SSC with gentle agitation. Transfer was as for DNA, except 
that lOX SSC was used as the transfer medium. When transfer was complete, the 
membrane was washed in 2K SSC and baked for 2 hours at 80 0C. 
2B.7 Nucleic Acid Hybridisation 
2B.7.1 Labelling DNA by Random Priming with Hexadeoxy-ribonucleotide 
Primers 
DNA labelled to high activities was obtained using the randomly primed 
DNA labelling method (Feinberg and Vogelstein 1983). This method allows DNA 
available only in small amounts to be labelled. It is based on the hybridisation of a 
mixture of hexanucleotides to the DNA to be labelled. Many sequence combinations 
are represented in the hexanucleotide primer mixture, which leads to binding of 
primer to template in a statistical manner. The complementary strand is synthesised 
from the 3' hydroxyl termini of the hexanucleotide primers using Klenow enzyme, 
during which radiolabelled dNTP is incorporated into the newly synthesised DNA 
strand. 
OLB buffer containing nucleotides and random primers is required. It is 
prepared by mixing 50j.tl solution A (1.25M Tris-HC1 pH 8.0, 0.125M M902, 
25mM B-mercaptoethanol, 0.5mM each of dGTP, dATP and dTTP), 125l of 
solution B (2M HEPES buffer adjusted to pH 6.6 with NaOH) and 75j.tl of solution 
C (random hexanucleotides OD260n m =90 in TE buffer, Pharmacia LKB 
Biotechnology). 
DNA probes were purified by electrophoresing through agarose gels twice 
prior to labelling. bOng of DNA probe in 32jd sterile distilled water was denatured 
by boiling for 5mm, followed by incubation at 37 0C for 10mm. 12.t1 of OLB buffer, 
2tl of 10mg/mi BSA, 5.tl of a- 32P-dCTP (50 .tCi) and 2 units of Kienow were 
added to the denatured DNA at room temperature. Incubation was continued for 4 
hours at room temperature, then unincorporated nucleotides were separated from 
labelled DNA by chromatography on a Sephadex G-50 column. 
2B.7.2 Separation of Unincorporated Nucleotides from labelled DNA 
A Sephadex G-50 column was used to remove unincorporated a- 32P-dCTP 
from labelled DNA probe (Sambrook 1989). The column was prepared by packing a 
lml blue tip with Sephadex G-50 suspended in sterile distilled water. The Sephadex 
was washed with lOj.tl of denatured herring sperm DNA (10mg/mi) by centrifugation 
for 5min at 900rpm. The labelling mix was then applied to the column and eluted 
into an Eppendorf tube by centrifugation. 450g1 of herring sperm DNA (10mg/mi) 
was added to the purified probe which was then boiled for 5min to denature the 
DNA prior to hybridisation. 
2B.73 Hybridisation 
Filters were prehybridised in 30-50m1 of 6X SSC, 1% SDS, 10% dextran 
sulphate and 100Lg/ml of denatured herring sperm DNA (10mglml) in a 
hybridisation oven (Hybaid Limited) for two hours at 650C. 
Hybridisation was performed by adding the denatured probe to the 
prehybridisation mixture and incubating in the hybridisation oven overnight at 650C 
for Southern filters or at 60 0C for Northern filters. 
Non-specifically bound DNA molecules were removed by washing the filter, 
twice for 5min in 2X SSC at room temperature, twice for 30min in 2X SSC, 1% SDS 
at 650C or 600C and twice for 10min in 0. lx SSC at room temperature. Radioactive 
DNA molecules bound to the filter were then visualised by autoradiography. 
2B.7.4 Autoradiography 
Following the washing procedure filters were sealed in a plastic bag to 
prevent drying out. Autoradiography was performed using X-OMAT AR (Kodak) or 
Cronex (Du Pont) X-ray film in a cassette with intensifying screens (Cronex 
Lightning Plus, Du Pont). Cassettes were stored at -70°C during exposure to slow 
the reversal of activated bromide crystals to their stable form, to give a sharper 
signal. 
2B.7.5 Stripping Probes from Filters 
Radiolabelled DNA probes hybridised to single-stranded nucleic acid 
immobilised on nylon were removed by the method described in thee manual supplied 
with Genescreen Plus membranes. Southern filters were boiled three times for 10mm 
in 0.1X SSC, 1% SDS. Northern filters were washed five times for 3min in hot 0.1X 
SSC, 0.01% SDS. Stripped filters were autoradiographed to confirm that deprobing 
was complete. Filters were then incubated in prehybridisation solution and 
hybridised as usual. 
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2B.8 cDNA and Geiniomic Libraries 
21B.81 cIDNA Synthesis 
Synthesis of cDNA was performed using a You-Prime eDNA Synthesis Kit 
(Pharmacia LKB Biotechnology). Mouse (E14) polyadenylated RNA was denatured 
for 10min at 65°C, then chilled on ice. Murine reverse transcriptase catalysed oligo 
dT-primed first strand synthesis for one hour at 37 0C in the presence of RNAguard, 
RNase/DNase-free BSA and dNTPs.The second DNA strand was synthesised by 
incubation in the presence of RNase H, Kienow and dNTPs for one hour at 12 0C, 
followed by one hour at 22°C. RNase H nicks the RNA strand of the RNA/DNA 
duplex, allowing the Kienow to replace the RNA with DNA by nick translation. Pure 
Klenow was then added for 30min at 37 0C to fill in any overhangs and ensure all 
cDNA ends were blunt. The cDNA was then phenol extracted and purified on a 
Sephacryl S-300 spun column. EcoRl/NotI adaptors were ligated on to the cDNA 
ends overnight at 15 0C and the EcoRI-ended cDNA phosphorylated with T4 
Polynucleotide Kinase for one hour at 37 0C. The cDNA was again phenol extracted 
and purified on a spun column to remove excess adaptors. This method produced 
cDNA up to about 7kb, with most about 4kb in size. 
2B.8.2 Preparation of Packaging Extracts for in vitro Packaging of 
lBacterioplliiage ? 
Packaging extracts were prepared by the method of Hohn and Murray (1977), 
with modifications by Scalenghe et al (1981). There are two components to the 
packaging extracts, a freeze thaw lysate and a sonicated extract, both prepared from 
induced phage lysogens. The sonicated extract was prepared from E. coli BHB2690, 
a strain unable to synthesise D protein which is required during maturation of the 
phage capsid. The freeze thaw lysate was prepared from E. coli BHB2688 which 
cannot synthesise phage proheads, but accumulates D protein. Neither extract can 
package phage DNA in isolation, but the mixed extracts can. 
The freeze thaw lysate was prepared by inoculating lOml of an overnight 
culture of BHB2688 into 3X two litre flasks containing 500m1 of LB and growing to 
OD600nm 0.3 at 300C while shaking vigorously (about 2 hours). Cells were then 
induced by standing the flasks in a 45°C waterbath for lSmin followed by further 
propagation at 37 0C for 2hr with vigorous shaking. Cells were spun down at 
7,500rpm for 10min at 40C and the supernatant discarded. Cells were resuspended in 
3m1 of ice cold freeze thaw buffer (10% sucrose, 50mM Tris-HCJ pH 7.5) and 150p.l 
of lysozyme (2mg/mi in 250mM Tris-HC1 pH 7.5) added, then mixed gently by 
inversion. The solution was quick frozen by immersion in liquid nitrogen. The lysate 
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was then thawed at room temperature and transferred to ice immediately on thawing. 
150iiJ of buffer Ml (6iil 500mM Tris-HC1 pH7.5, 3001.Ll 500mM spermidine/lOOmM 
putrescine pH 7.0, 9t1 1M M902, 75tl 10mM ATP, liii  14M B-mercaptoethanol) 
was added. Cell proteins were partially purified by ultracentrifugation at 40,000rpm 
for 1 hour at 40C. 30tl aliquots of the supernatant were dispensed into pre-cooled 
Eppendorf tubes and snap frozen by immersion of the tube into liquid nitrogen. 
Aliquots of freeze thaw lysate were stored at -70 0C. 
To prepare the sonicated extract, E. coil BHB2690 was grown, induced and 
pelleted as for the freeze thaw lysate. The supernatant was discarded and the pellet 
resuspended in 5.6m1 buffer A (20mM Tris-HC1 pH 8.0, 3mM M902, 0.5% B-
mercaptoethanol, 1mM EDTA). The suspension was sonicated in 3 second bursts, 
with 60 second cooling on ice in between to prevent the temperature rising above 
4°C. Sonication was continued until the solution was clear, then the cell debris was 
pelleted by centrifugation at 10,000rpm for 10min at 4°C. 1/6 volume buffer Ml was 
added to the supernatant and 50p..l aliquots were distributed into pre-chilled 
Eppendorfs, snap-frozen in liquid nitrogen and stored at -70°C. 
2B.83 Library Construction 
5p.g of A. DNA (A.NM1 149 and A.EMBL4 for cDNA and genomic libraries 
respectively) and 10ig of insert DNA (cDNA or EcoRI-digested genomic DNA) 
were digested to completion, mixed and ligated in a total volume of 20.tl. The 
ligation mix was packaged in vitro by mixing 7jtl buffer A, 1-5tl ligation mix, lp.l 
buffer Ml, lOi.i.l sonicated extract and 12p.l freeze thaw lysate (see section 213.8.2). 
Packaging was allowed to continue at room temperature for one hour, then SOOR' 
phage buffer was added and the phage plated out on a suitable strain of E. coil (strain 
NM514 was used for the cDNA library, K802 was used for the genomic library). 
2B.8.4 Plating out Bacteriophage A. to Generate Plaques 
50m1 LB supplemented with imi of 20% maltose and 0.5m1 1M MgSO4 was 
inoculated with a single colony of E. coli and the cells allowed to grow to log phase 
(ODj=0.3-0.5). Cells were spun down for 15min at 1,500 rpm and resuspended 
in 5m1 10mM MgSO4. Phage were added to lOOp.l of cells and left at room 
temperature for 15min to allow phage adsorption. 3m! molten BBL top agar (47 0C) 
was added to the cells and phage, then poured over dried BBL plates, followed by 
incubation at 37°C until plaques were visible (12-16 hours). 
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2B.8.5 Probing Libraries 
Phage were plated out and the plates chilled to 4 0C. Nylon filters (Hybond-
N, Amersham International plc.) were placed on the surface of the agar and the 
phage allowed to adsorb for 5mm. Filters were oriented on the plates by piercing 
through the membrane and agar with a needle in an asymmetric pattern. Filters were 
then lifted off without removing the top agar and placed, DNA side up, on filter 
paper soaked in denaturing buffer for 5mm. They were then transferred to 
neutralising buffer for 5mm, followed by a 5min wash in 2X SSC. Filters were then 
air dried and baked for 10-20min at 120 0C. 
Filters were prehybridised for one hour at 65°C in 7% SDS, 0.5M NaHPO4 
(0.5M Na2HPO4 to pH 7.0 with 0.3M NaH2PO4) in a hybridisation oven (Hybaid 
Limited). Radiolabelled probe was then added and allowed to hybridise overnight at 
65°C. Filters were then rinsed twice in 5% SDS, 0.04M NaHPO4 at room 
temperature and twice in 1% SDS, 0.04M NaHPO4 for 5min at 65°C and 
autoradiographed. 
Aided by the orientation marks, plaques corresponding to positive signals 
were picked and the phage allowed to elute overnight at 4 0C in imi phage buffer 
with 50.tl chloroform added. 
2B.9 DNA Sequencing 
2B.9.1 Templates for Sequencing 
Single-stranded templates were generated by cloning DNA fragments to be 
sequenced into M13mp18 or M13mp19. Phage were then plated out and 
recombinants selected with X-Gal/IPTG. Phage from recombinant white plaques 
were grown up for DNA preparation (213.2.6). 
Double-stranded templates were DNA inserts cloned in pBluescriptll KS+. 
DNA was propagated in E. coli strains DH5a or XL1-Blue and prepared by the 
large-scale method (213.2.2). 
2B.9.2 Annealing Primer to Template DNA 
For single-stranded templates, lOp.l of template (1-2p.g of DNA) was mixed 
with 2i.tl  of primer (4p.g/ml) and 2j.i.l of annealing buffer (1M Tris-HC1 pH 7.6, 
100mM M902, 160mM D1'T) and incubated at 70°C for 3mm. Following a 5min 
incubation at room temperature the annealed template and primer was ready for 
sequencing. 
4-8p.g of double-stranded plasmid DNA was mixed with 16p.l of 1M NaOH 
and sterile distilled water up to a total volume of 40.tl. This was incubated at room 
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temperature for 10mm, then 3p.l of sterile distilled water, 7.tl of 3M sodium acetate 
pH 5.0 and 120p.l of cold 100% ethanol were added to precipitate the denatured 
DNA. DNA was pelleted for 10min in a microcentrifuge, washed with lOOj.tl of 70% 
ethanol and dried briefly. The DNA was redissolved in lOp.l of sterile distilled water, 
and 2p.1 of primer (2p.g/ml) and 2p.l of annealing buffer added. The mixture was 
incubated at 65°C for 5mm, 370C for 10min and room temperature for 5mm, after 
which it was ready to proceed with sequencing. 
2B.9.3 Sequencing 
Sequencing by the dideoxy chain termination method was carried out using 
the 17 Sequencing Kit (Pharmacia LKB Biotechnology). Reactions were the same 
for both single and double-stranded templates. 
14 p.1 of annealed template/primer was mixed with 3p1 of dATP labelling mix 
(1.375p.M each of dGTP, dTTP, dCTP and 333.5mM NaCl), 1p.l of a- 35S-dATP and 
2p.l of 17 DNA polymerase (lU4tl diluted in 20mM Tris-HC1 pH 7.5, 5mM DTT, 
100p.g/ml BSA, 5% glycerol). The mixture was incubated for 5min at room 
temperature to allow the synthesis of short labelled DNA molecules. 
Meanwhile, 2.5j.tl of termination mixes were dispensed into Eppendorf tubes 
and prewarmed to 37 0C. Termination mixes were chosen to allow the reading of 
sequence from the primer to position 500 ("short") or from position 50-800 ("long"). 
TERMINATION MIXES 
'A' Mix - Short 840p.M each of dCTP, dGTP and 
dTTP, 93.5p.M dATP, 14p.M ddATP, 
40mM Tris-HC1 pH 7.6, 50mM NaCl 
'C' Mix - Short 840p.M each of dATP, dGTP and 
dTTP, 93.5p.M dCTP, 17p.M ddCTP, 
40mM Tris-HC1 pj7.6, 50mM NaCl 
'G' Mix - Short 840p.M each of dATP, dCTP and 
dTFP, 93.5p.M dGTP, 14p.M ddGTP, 
40mM Tris-HC1 pj7.6, 50mM NaCl 
T Mix - Short 840p.M each of dATP, dCTP and 
dGTP, 93.5p.M dTTP, 14p.M ddTTP, 
40mM Tris-HC1 pH 7.6, 50mM NaCl 
'A' Mix - Long 840p.M each of dCTP, dGTP and 
dFP, 93.5p.M dATP, 2.1p.M ddATP, 
40mM Tris-HC1 pH 7.6,50mM NaCl 
'C' Mix - Long 840i.LM each of dATP, dGTP and 
dTFP, 93.5.tM dCTP, 2.8p.M ddCTP, 
40mM Tris-HC1 pH 7.6,50mM NaCl 
'G' Mix - Long 840p.M each of dATP, dCTP and 
dTTP, 93.5.tM dGTP, 2.8j.tM ddGTP, 
40mM Tns-HC1 pH 7.6,50mM NaCl 
'T Mix - Long 840p.M each of d.ATP, dGTP and 
dCTP, 93.5 p.M dTTP, 2.8p.M ddTFP, 
40mM Tris-HC1 pH 7.6,50mM NaCl 
Following the labelling reaction, 4.5p.l of reaction mix was added to each of the four 
pre-warmed termination mixes and incubated for 5min at 37 0C. Reactions were 
stopped by addition of 5p.l of sample buffer (0.3% Bromophenol Blue, 0.3% Xylene 
Cyanol FF, 10mM EDTA pH 7.5, 97.5% deionised formamide). Prior to loading on 
a gel, samples were heated for 2min at 80 0C. 
213.9.4 Electrophoresis of Sequenced DNA 
DNA was electrophoresed through a 0.2mm thick 0.8% polyacrylamide gel 
using a Bio-Rad Sequi-Gen Sequencing Cell. Acrylamide solution was made up with 
50g of urea, 30m1 of distilled water, lOmi of lOX TBE buffer and 20m1 of 40% 
acrylamide/2. 105% bisacrylamide (Easigel, Scotlab). Gels were polymerised by 
addition of 640p.l of 1% ammonium persuiphate and 30p.l of TEMED. Gels were 
typically run at 50-60W to maintain the gel at a temperature of 55°C during the run. 
Gels were transferred to filter paper, covered with cling film and dried for two hours 
under vacuum at 80°C. Ladders of bands were visualised by autoradiography. 
2B.10 Amplification of DNA by the Polymerase Chain Reaction 
213.10.1 Polymerase Chain Reaction Experiments 
A typical PCR reaction consisted of 1-lOng of plasmid DNA or bOng of 
genomic DNA, with 1p.l of 5mM dNTPs, 5i.i.l  of lox PCR buffer (500mM KC1, 
15mM M902, 0.1% gelatin, 0.1M Tris-HC1 pH 8.5, 4.5% Triton X-100, 4.5% 
Tween 20), 0.5p.l of Taq DNA polymerase, lOOng of each primer, and sterile 
distilled water up to a final volume of SOp.!. Conditions varied for different primers, 
but denaturation was generally carried out at 94 0C for 1mm, followed by appropriate 
annealing, and synthesis at 720C for 30s to I min depending on the size of the desired 
product. 35 cycles of these conditions were used in each experiment. All 
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experiments were carried out using a Dri-Block cycler (Techne PHC-2). 10-20p1 of 
each reaction was then electrophoresed through an agarose gel to visualise products. 
2BJ10.2 Screening Cofioimfis using the Polly rase Chain Reaction 
PCR was performed on genomic DNA from cultured mammalian cells 
without the need for a lengthy DNA preparation to be carried out. This was done by 
the method of McMahon and Bradley (1990). Half a colony (about 1,000 cells) was 
spun down in a microcentrifuge for 30s and the medium removed using a pipette. 
The cell pellet was resuspended in lx PCR buffer with proteinase K (0.1mg/nil) and 
incubated at 65°C for two hours. The proteinase K was inactivated by heating at 
900C for 15min after which the samples were ready to be used in PCR reactions. 10-
20p.l of sample was used per reaction. 
21Bi11 Cellil Cuilture 
2B. In. Growth of Marnuallian Cellils 
Mammalian cells were maintained in Glasgows modified Eagles medium 
supplemented with 1X non-essential amino acids, 1mM sodium pyruvate, 2mM L-
glutamine, 10% foetal calf serum, 50U/ml penicillin and 50ig/ml streptomycin. 
Cultures were incubated at 37°C in 5% CO2 in a humidified incubator. 
21B.1I1.2 1Ellectroporaton 
Prior to electroporation plasmid DNA was phenol extracted, precipitated and 
resuspended in sterile distilled water. 30ig of DNA in 100.tl of sterile distilled water 
was added to 5X10 5 cells in 0.8m1 of serum-free 1X medium. Cells were pulsed at 
250V, 500pF (Gene Pulse apparatus, Biorad), incubated at room temperature for 
10min and plated out between two 100mm dishes. G418 selection (500pg/ml) was 
applied to the cells two days later. 
213.113 Caliciiuim Phosphate/DNA Precipitation and Colloony4Forinming Assay 
RJK88 cells were plated out in 60mm dishes at a density of 1.2 X10 5 cells/ 
dish on the day prior to transfection. To 10-20p.g of DNA was added imi of HBS 
and 62p.l of 2M CaCl2. The CaC12 was added slowly, dropwise, and the solution left 
to precipitate for 45min at room temperature. The precipitate was then added to the 
cells and left at room temperature for 20mm, with frequent agitation. lOmi of 
medium was added to the dishes and the cells incubated overnight. The medium was 
then removed and replaced with medium containing HAT (1mM hypoxanthine, 
lOp.M aminopterin, 100.tM thymidine). Two days later the medium was replaced 
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with fresh HAT medium and the cells left to form colonies. After one week colonies 
were fixed (Camoy's Fixative, 3parts methanol, ipart glacial acetic acid) and stained 
(10% crystal violet). 
2B.11.4 Ethyl Methane Suiphonate Survival Assay 
Cells were plated out in 30mm dishes using 5X10 4 cells per dish for 
MRC5V1 and 2.5X10 5 cells for 46BR.1G1 and its transfected derivatives. Cells 
were incubated overnight, then exposed to 0-15mM EMS in complete medium for 
two hours. Each dose point was carried out in duplicate. Cells were then rinsed twice 
in warm PBS and incubated in complete medium for five days. Surviving cells were 
counted using a [3H]-hypoxanthine incorporation assay (Cleaver 1989). Cells were 
washed twice in serum-free medium and incubated in serum-free medium with 
0.5pCi/ml [3H]-hypoxanthine for 4-5 hours. Cells were washed twice in PBS and 
lysed with 1% SDS. The lysate was collected and RNA and DNA precipitated by 
addition of 0.8 volumes of 20% trichloroacetic acid. The precipitate was collected 
onto Whatman GF/C filters and the incorporation measured by scintillation counting. 
The percentage survival was calculated as (mean growth in EMS/mean growth in 
control medium) X100. 
2B.11.5 3-Aminobenzamide Survival Assay 
Cells were plated out in 60mm dishes using 200 cells per dish for MRC5V1 
and 1000 cells per dish for 46BR.1G1 and its transfected derivatives. Cells were 
incubated overnight then exposed to 0-8mM 3AB in complete medium. Each dose 
point was done in duplicate. Dishes were fixed and stained after 10-15 days. Cell 
survival was determined by eluting the stain with Sm! 70% ethanol and measuring 
the absorbance at 595nm. The percentage survival was calculated as (mean plating 
efficiency in 3AB/mean plating efficiency in control medium) X100. 
2B.12 Protein Methods 
2B.12.1 Expression of Proteins in E. coli 
Sequences cloned in pBluescriptll KS+ under control of the 17 promoter 
were expressed in E. coli strain BL21(DE3) which is a ? DE3 lysogen. DE3 is a 
derivative, carrying a DNA fragment containing a single copy of the gene encoding 
17 RNA polymerase under control of the lacUV5 promoter. Addition of IPTG 
induces the lacUVS promoter to produce 17 RNA polymerase. Following induction, 
any genes present within the cell under control of a 17 promoter will be transcribed. 
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Cells were grown and induced by a modification of the method of Studier 
and Moffatt (1986). Cells were grown overnight in 5m1 of LB supplemented with 
ampicillin (where appropriate) and 1/2m1 of fresh overnight culture was diluted into 
5m1 of LB supplemented with ampidillin (as appropriate). After growth for 30mm, 
IPTG was added to a final concentration of 2mM. imI aliquots of cells were taken at 
0, 1, 2 and 3 hours following induction. Cells were spun down for 5min in a 
microcentrifuge and resuspended in 100-200.tl of protein sample buffer (25% 
stacking gel buffer [see later], 15% glycerol, 3% SDS, 20mM DTT, 0.1% 
bromophenol blue). The samples were denatured by boiling for 10mm, then the cell 
extracts were electrophoresed through a polyacrylamide gel. 
2B.12.2 Preparation of Protein Extracts from Mannnaflan C&!lls 
6X106 cells were pelleted by centrifugation for 5min at 13001pm, washed in 
PBS and repelleted. The cell pellet was then resuspended in 200.tl of protein sample 
buffer (see above) and denatured by boiling for 10mm. 50.tl of protein extract was 
loaded onto each gel. 
213.12.3 Eliectroplliioresis of Proteins 
Molecular weight markers were obtained from Sigma Chemical Co. Markers 
were either low molecular weight, from 14.2kDa to 66kDa, or high molecular 
weight, from 30kDa to 200kDa. 
Gels consisted of a stacking gel upon a 7.5% separating gel. The separating 
gel was poured first and was made up with lOmI of lower Tris (1.5M Tns-HC1, 0.4% 
SDS, pH 8.8), 7.5m1 of 40% acrylamide/2.105% bisacrylamide (Easigel, Scotlab) 
and 22.5ml of distilled water, then polymerised by addition of 120p.l of 10% 
ammonium persulphate and 60p.l of TEMED. The stacking gel was made up with 
5m1 of upper Tris (0.5M Tris-HC1, 0.4% SDS, pH 6.8). 2.2m1 of acrylamide solution 
and 12.8m1 of distilled water, then polymerised by addition of 40tl of 10% 
ammonium persulphate and 80p.l of TEMED. 
Gels were run in 1X electrode buffer (lOX electrode buffer consists of 28g of 
Tris-HC1, 20g of SDS and 143g of glycine per litre) at 30W until the dye front 
reached the end of the gel. Gels were then either blotted onto nylon membranes or 
fixed (6g of trichioroacetic acid, 200m1 of methanol and 70mi of ethanol per litre) 
and stained (ig of Coomassie blue, 50m1 of methanol and 50m1 of distilled water, 
diluted 12rnl into 500m1 of fix). Following staining for 30mm, gels were destained 
(10% glacial acetic acid, 30% isopropanol) to visualise the protein bands. Destained 
gels were sealed in plastic bags for storage. 
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2B.12.4 Transfer of Proteins from Polyacrylamide Gels to Membranes 
Proteins were transferred from gels to Genescreen Plus nylon membrane (Du 
Pont) by electroblotting using a Trans-Blot SD semi-dry transfer cell (Bio Rad) 
according to the manufacturers instructions. Essentially, the gel and membrane cut to 
the same size were equilibrated in Bjerrum and Schafer-Nielsen transfer buffer 
(48mM Tris-HC1 pH 9.2, 39mM glycine, 20% methanol) for 30mm. The unit was 
then assembled for blotting by placing in the unit, in order, a piece of blotting paper 
soaked in transfer buffer, the nylon membrane, the gel and another piece of blotting 
paper soaked in transfer buffer. Proteins were transferred from large gels for 30- 
60min at 25V with a limiting current of 3mA/cm 2 and from mini-gels at 15V with a 
limiting current of 5.5mA/cm 2 . 
2B.12.5 Probing Protein Blots with Antibodies 
Western blots were blocked for 1 hour in 1% Boehringer blocking agent 
(Boebringer Mannheim plc), then incubated with lOOp.l of the primary antibody (Ml 
mouse anti-FLAG monoclonal antibody, lOpg/ml in PBS) in 50m1 of incubation 
solution (1% blocking agent, 0.3% Tween-20, 1mM CaC12 in PBS) for 1 hour. The 
membrane was washed three times for 5min in washing solution (0.3% Tween-20, 
1mM CaCl2 in PBS) then incubated with 6p.l of the secondary antibody (alkaline 
phosphatase-conjugated anti-mouse IgG, 1mg/mi, Promega) per 50m1 of incubation 
solution. The membrane was washed five times for 5min then blotted dry and sealed 
in a plastic bag with colour substrate solution. This consisted of lOmi of 100mM 
Tris-HC1 pH 9.5, 100mM NaCl, 50mM M902  with 45p.l of NBT solution and 35p.l 
of X-phosphate solution (both from the nucleic acid detection kit, Boehringer 




PHENOTYPIC CORRECTION OF THE HUMAN CELL LINE 
46BR 
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The human cell line 46BR carries a mutation at each allele of the DNA ligase 
I gene (Barnes et al 1992b). The first mutation, a change of G1u566 to Lys renders 
the enzyme completely inactive. The second mutation, Arg77 1 to Trp leaves the 
enzyme with some residual activity. Therefore, 46BR cells lack a completely 
functional DNA ligase I enzyme. However, a direct link between the DNA ligase I 
mutations and the phenotype of the cells still remains to be demonstrated. This 
chapter describes demonstration of this link by complernentation of the DNA ligase I 
mutations with wild-type DNA ligase I cDNA. This work was carried out in 
association with Dr. Nik Somia and published in Mutation Research (294: 5 1-58). A 
reprint of the paper is at the back of this thesis. 
3.1 Construction of a Vector Expressing IHluamaini DNA Ligase 11 eDNA 
An expression vector was constructed for the purpose of expressing wild type 
human DNA ligase I cDNA in the cell line 46BR. A 4.3kb EcoRT/Hindill fragment 
was cut out of plasmid pLK444 (Gunning et al 1987) and cloned into pBluescriptll 
KS+. This fragment contains the human 13-actin promoter (3kb), a 78bp 5' 
untranslated region and the first intron of the human 13-actin gene (832bp). The 
intron is included because it contains an enhancer sequence. A 2.4kb EcoRl 
fragment containing the bacterial neomycin phosphotransferase gene under control 
of the mouse metallothionein promoter (Selfridge et a! 1992) was cloned into the 
EcoRI site, upstream of the 13-actin promoter. This was introduced to provide 
selection for transfected cells, by acquisition of resistance to the synthetic antibiotic 
G418. Because both ends of this fragment had EcoRI overhangs it could ligate into 
the vector facing either way, but an orientation was selected so that transcription 
would proceed in the same direction from both promoters. This completed 
construction of the expression vector which was designated p13Aneo (figure 3.1). 
There is no polyadenylation signal built into the vector which therefore relies on 
cloned sequences to provide one. 
Wild type human DNA ligase I cDNA was isolated from pilL (Barnes et a! 
1990) as a 3.2kb KpnI fragment. This fragment contains a virtually intact cDNA, 
complete with poly A tail and lacking only about 90 bases from the 5' untranslated 
region. It was isolated from a cDNA library by complementation of S. cerevisiae 
DNA ligase-deficient cdc9 mutants and therefore encodes a functional protein. XhoI 
linkers were attached to the ends of this fragment which was then ligated into the 
Sail site of p13Aneo. Again the insert was clonable in either direction and the correct 
orientation was selected so that the 5' end of the cDNA was positioned adjacent to 
the 6-actin promoter. This plasmid was designated pBAHLneo. 
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Figure 3.1: Expression vector pBAHLneo. Human DNA ligase I cDNA (open box) 
was placed under the control of the human 3-actin promoter (heavy shading) which 
includes the 5' untranslated region (UTR, closed box) and first mtron (1VS 1, light 
shading). The bacterial neomycin phosphotransferase gene driven by the mouse 
metallothionein promoter (neo, open box) lies upstream. Arrows indicate the 
direction of transcription. Key restriction sites are shown. EcoRI sites generating the 
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3.2 Transfection 
Prior to transfection into cultured cells, plasmids pBAneo (a negative control) 
and p8AHLneo were linearised by restriction with Scal which has arecognition site 
within the ampidihin resistance gene of pBluescript. Random integration into the 
genome is likely to occur via DNA ends therefore linearisation at this position 
maximises the probability that the neoT gene and the cDNA will be cotransfected. 
Both plasmids were transfected into the human fibroblast cell lines MRC5V1 
and 46BR.1G1 by electroporation. MRC5V1 is an SV40-transformed wild-type cell 
line, while 46BR.1G1 is derived from the DNA ligase I-deficient cell line 46BR by 
transformation with pSV3gpt. This 46BR derivative is homozygous or hemizygous 
for the DNA ligase I mutation at Arg77 1, since the other allele with the Glu566 to 
Lys mutation was lost during transformation (Barnes et al 1992b). 20 to 30 G418-
resistant colonies were obtained from 5X10 5 transfected cells and were grown either 
as pools or separately as clones. 
3.3 Detection of DNA Ligase 11 Transfectanils 
Genomic DNA was prepared from 46BR.1G1 and pools of 46BR.1G1 
transfected with pBAneo and pBAHLneo, as well as six 46BRp13A}lLneo clones. The 
DNA was digested with EcoRI, electrophoresed and blotted. The Southern blot was 
then probed with human DNA ligase I cDNA (figure 3.2). This revealed seven bands 
from all cell types, specific to the DNA ligase I gene, of sizes 10.7kb, 7.5kb, 5.3kb, 
4.4kb, 3.6kb, 3.3kb and 2.5kb. Three bands arising from the presence of the plasmid 
in the cells were also expected (figure 3.1). A band of about 4.8kb would result from 
the cDNA probe hybridising to an EcoRI fragment containing the 13-actin promoter 
and 5' end of the cDNA. A band of this size is clearly present in the 46BRpI3AHLneo 
pool as well as in 46BRpI3AHLneo clones two and six. A band of unpredictable size 
will be derived from the 3' end of the cDNA. Its size depends on the extent of DNA 
between the plasmid integration site and the next EcoRI site, and there are a number 
of bands present which could result from this. A 1.5kb band arising from an EcoRI 
fragment present within the cDNA was used as a marker for the presence of the 
eDNA within the cells. It is visible in the 46BRp13AHLneo pool and in all 
46BRpI3AHLneo clones except clone four, which therefore all contain wild type 
human DNA ligase I cDNA. Presence of the cDNA was undetectable in clone four 
cells although they must have integrated some plasmid sequence since they are 
resistant to G418. The 1.5kb band was not visible when the cells were untransfected 
or when they were transfected with the control plasmid, confirming that it is specific 
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Figure 3.2: Southern blot of genomic DNA from 46BR.1G1 and transfectants 
digested with EcoRI and probed with human DNA ligase I cDNA. The diagnostic 
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for the cDNA. When the intensity of the 1.5kb band is compared to that of the gene-
specific bands it is apparent that the clones have integrated differing numbers of 
copies of the cDNA. For example, clones one and six carry more cDNA inserts than 
clone three. 
3.4 Expression of Wild Type Human DNA Ligase I cDNA 
Five of the 46BRpBAHLneo clones have wild-type DNA ligase I cDNA 
sequences integrated into the genome. However it does not follow that the cDNA is 
being expressed in the cells. Demonstration of expression at the protein level was 
unlikely to be successful since the endogenous mutant and exogenously introduced 
wild-type enzymes differ by only one amino acid. Attempts to demonstrate 
expression were consequently carried out at the messenger RNA level. Plasmid 
derived messages should be slightly longer than the endogenous 3.2kb mRNA due to 
the extra 78bp 5 untranslated region from the B-actin promoter. This small size 
difference was undetectable when RNA was prepared, blotted and probed with full-
length human DNA ligase I cDNA (figure 3.3). Only the endogenous 3.2 kb band 
specific for DNA ligase I was visible. There was also no obvious difference in levels 
of the 3.2kb DNA ligase I message, therefore cDNA transcription from the plasmid 
was not significantly increasing the total amount of the 3.2kb mRNA within the 
cells. However, high molecular weight transcripts in the range 6-9kb were seen, 
corresponding to the presence of the cDNA within the cells (figure 3.3). The size of 
these novel transcripts suggests faulty initiation or termination of transcription. It is 
possible that transcription could be initiating from the mouse metallothionein 
promoter and continuing right through to the end of the cDNA, and the Northern blot 
was probed with the neor gene to investigate this possibility, if the high molecular 
weight DNA ligase I-specific transcripts were initiating from the metallothionein 
promoter they would include neo sequences and would be detectable with the neo 
probe. However, only messages arising from transcription of the neor  gene itself 
were detectable. The neo probe did not visibly hybridise to any high molecular 
weight transcripts (data not shown). The lack of hybridisation between the 
transcripts and neo therefore indicates that ligase transcript initiation is not occuring 
from the metallothionein promoter. 
A different approach was tried, using the 78bp untranslated region as a probe, 
but this probe showed only non-specific binding to the ribosomal RNA subunits 
(data not shown). 
The 78bp 5' untranslated region was used to try to demonstrate expression by 
other means. Twenty base PCR primers specific for this region were designed 
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Figure 3.3: Northern blot of RNA from MRC5V1, 46BR.1G1 and transfectants 
probed with human DNA ligase I cDNA. The arrow 'a' marks the position of the 
endogenous 3.2kb DNA ligase I transcript. Region 'b' marks vector-derived 
transcripts. The asterisk indicates the position of the 28S ribosomal RNA subunit. 
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(573M, 027N, 028N), to be used in conjunction with a primer specific for the 5' end 
of the cDNA (572M). Any DNA amplified using these primers could only arise from 
the plasmid, giving a product of about 1.2kb in size, or from an mRNA arising from 
transcription from the plasmid, giving a PCR product of about 500bp due to intron 
splicing. However, due to their high GC content, the 13-actin primers showed cross-
hybridisation and the PCR experiments failed (data not shown). The presence of the 
high molecular weight transcripts remained the only demonstration of expression of 
wild-type human DNA ligase I in the transfected cells. 
There appears to be a correlation between the number of cDNA inserts in a 
cell line and the extent of transcription of the cDNA. For example figure 3.2 shows 
that 46BRpBAHLneo clone 2 has integrated more copies of the plasmid than the 
other clones. There is a corresponding increase in the level of plasmid-derived DNA 
ligase I transcripts (figure 3.3). 
3.5 Correction of Ethyl Methane Suiphonate Sensitivity in 46BR 
EMS causes damage to DNA by alkylation, which can occur at a number of 
different reaction sites, both within bases and along the DNA backbone. 06.. 
alkylguanine is one of the major mutagenic reaction products and is removed 
directly from DNA in mammalian cells by 0 6-methylguanine methyl transferase 
(Friedberg 1985 and references therein). Other alkylation damage is removed by the 
nucleotide excision repair system. 46BR cells are sensitive to EMS, probably due to 
a defective ligation step during nucleotide excision repair, whereas wild-type cells 
are relatively insensitive because their DNA repair mechanisms are functional and 
the alkylation damage can be removed. 
Along with MRC5V1, 46BR.1G1, two control clones of 46BRpf3Aneo and 
pooled 46BRpBAHLneo cells, 46BRpI3AHLneo clones 1, 2 and 6 were selected for 
use in the EMS survival assay since all three clones express the wild-type cDNA at 
higher levels than the other clones. 
Cells were exposed to EMS at a range of concentrations from 0 to 15mM and 
the number of cells surviving was determined (figure 3.4). As anticipated, MRC5V1 
cells were relatively insensitive, with 30% of cells surviving at the highest dose. 
46BR.1G1 and the 46BRpBAneo clones were extremely sensitive with a maximum 
of 0.4% of cells surviving the highest dose of EMS. The three 46BRpBAHLneo 
clones expressing wild-type DNA ligase I showed an ability to survive EMS 
intermediate between that of wild-type MRC5V1 and 46BR, with between 2% and 
4% of cells surviving at the highest dose. All three clones were rescued to the same 
extent and there was no correlation with the number of integrated cDNA copies. 
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Figure 3.4: Cell survival following EMS treatment of MRC5V 1, 46BR. 1(31 and 
transfectants. a, b and c are points used to calculate the extent of rescue. For each 
point standard errors of the mean were less than 7% of the survival value plotted. / 
+ MRC5V1 
x46BR 101 
o 46BRpBAneo clone 1 
46BRpBAneo clone 2 
O 46BRpI3AHLne0 clone 1 
A 46BRpI3AIHLneo clone 2 
A 46BRpBAHLneo clone 6 






The extent of correction was calculated by dose modification at constant 
survival (Cleaver 1990). This was done by expressing the ratio of the differences in f 
EMS concentration between 46BR and the correctants, and between 46BR and 
MRC5V1, where 50% of cells survive ((b-a)/(c-a) in figure 3.4). By this calculation, 
transfection with wild-type DNA ligase I sequences has corrected the EMS / 
sensitivity of 46BR by about 60%. 
3.6 Correction of 3-Aminobenzamide Sensitivity in 46BR 
3AB is an inhibitor of the enzyme polyADP-ribose polymerase which is 
required along with ligase for efficient ligation. Sensitivity to 3AB is therefore a 
direct measure of ligation. All cells are sensitive to 3AB at high doses, but 46BR 
cells are hypersensitive to 3AB since they are killed even at much lower doses. 
Survival in 3AB of MRC5V1, 46BR.1G1, 46BRpBAneo clone 1 and 
46BRpBAHLneo clone 2 was investigated. 
Cells were exposed to 3AB at a range of doses from 0 to 8mM and surviving 
cell numbers determined (figure 3.5). MRC5V1 cells showed 100% cell survival up 
to 8mM, where survival dropped to 50%. 46BR. 1G1 and 46BRpl3Aneo clone 1 were 
extremely sensitive even at low doses. However 46BRpBAHLneo clone 2 cells 
exhibited 100% cell survival at all doses, displaying complete correction of the 3AB 
hypersensitivity phenotype of 46BR upon introduction of wild-type DNA ligase I. 
Survival in EMS is a measure of DNA repair, while survival in 3AB is a 
more direct measure of ligation activity, which could account for the discrepancy 
between correction of sensitivity to EMS and 3AB. 
The correlation between the presence of wild-type DNA ligase I sequences in 
cells, the ligase-specific high molecular weight transcripts and rescue of the mutant 
phenotype demonstrates that the mutations identified in the DNA ligase I gene of 
46BR are responsible for the mutant phenotype of these cells. 
Figute 3.5.: Cell survivalz following 3AB treatment of MRC5Y1, 46BR.iG•1 and 
ansetants. Each paint is the mean from two separate determinations. 
+ MRC5V1 
x 46BR.1G1 
o 46BRpl3Aneo clone 1 
A 46BRpBAHLneo clone 2 








MOUSE DNA LIGASE I cDNA 
91 
Following the demonstration that the abnormalities in the human cell line 
46BR, and the clinical symptoms of the patient from whom the cell line was derived, 
arise from a mutation at the DNA ligase I locus, work towards creating a mouse 
model for DNA ligase I deficiency began. Before any gene targeting experiments 
could be carried out, information on the structure of the mouse DNA ligase I gene 
was required. The first step in obtaining  this information was the cloning and 
sequencing of mouse DNA ligase I cDNA. 
4.1 Cloning of Mouse DNA Ligase I cDNA 
A mouse embryonic stem cell cDNA library (titre= 106  pfu) constructed in 
XNM1 149 (with the help of Dr. Nik Somia) was screened using full-length human 
DNA ligase I cDNA, isolated as a KpnI fragment from pHL, as a probe. Ligase-
specific signals were obtained at a frequency of about 1/10,000. Seven clones were 
obtained and the ligase inserts subcloned into the EcoRI site of pBluescriptll KS+. 
The inserts were all different, of sizes 0.9kb, 1.7kb, 2.4kb, 2.6kb, 2.7kb, 2.9kb and 
3.2kb (figure 4. la), but share some common sequence, since the largest, 3.2kb, 
CDNA insert hybridised to them all (figure 4.1b). 
All of the ligase clones were expected to be complete right up to the 3' end 
and foreshortened from the 5' end, if at all. This is due to the nature of cDNA 
synthesis. When cDNAs are synthesised, reverse transcriptase initiates at the 3' end 
of the messenger RNA, using an oligo dT primer which anneals to its poly A tail. 
That all the clones were apparently complete at the 3' end and truncated from the 5' 
end was confirmed by restriction mapping (data not shown). The five longest clones 
all have a Bam}iI recognition site 2kb from the 3' end, and a variable distance from 
the 5' end depending on the size of the insert. The two smaller clones are shorter than 
2kb and therefore lack the BamHI site. 
4.2: The Ligase Clones Encode Mouse DNA Ligase I 
The largest mouse ligase insert is approximately 3.2kb in size. This is equal 
in size to the human DNA ligase I messenger RNA, and slightly longer than the 
human DNA ligase I cDNA used as a probe, which lacks about 90bp from the 5' end. 
The 3.2kb mouse ligase insert hybridises to a single 3.2kb message from both mouse 
and human RNA (figure 4.2) and these same transcripts are detected by reprobing 
with the human DNA ligase I cDNA (figure 4.2). The mouse ligase clone therefore 
encodes mouse DNA ligase I and is apparently full-length. 
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igure4.i: Mouse DNA ligase I cDNA clones, a) ?.NMl 149 DNA was digested with 
Nod and electrophoresed through a 1% agarose gel. The positions of the 19.9kb and 
8.8kb 2L arms are indicated. b) The DNA fragments were transferred to a nylon 
membrane and probed with the 3.2kb cDNA insert. Molecular weight marker sizes 



















Figure 4.2: Northern blot of human (HeLa) and mouse (E14) total RNA probed with 
the 3.2kb mouse cDNA (ML) and human DNA ligase I cDNA (HL). Molecular 
weight marker sizes are in kb. The intensity differences arise because ML hybridises 
more strongly to the mouse DNA ligase I mRNA, while HL hybridises more 
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4.3 Restriction Analysis of Mouse DNA Ligase 11 eDNA 
Recognition sites within the 3.2kb mouse DNA ligase I clone were 
determined for a number of enzymes by restriction mapping (figure. 4.3). When this 
map is compared to the human DNA ligase I cDNA restriction map a number of 
sites appear to be conserved. The two PstJ sites, the SstI, BamHI and Bglll sites, and 
two of the Pvull sites seem to correspond to sites within the mouse sequence. This 
further confirms that the mouse clone is related to the human DNA ligase I cDNA. 
4.4 Sequencing of Mouse DNA Ligase TE cDNA 
Mouse DNA ligase I cDNA was sequenced by the dideoxy method using a 
combination of single and double stranded sequencing. About 300 bases of the 
sequence was obtained by Carolanne McEwan. The nucleotide sequence of the 3.2kb 
mouse DNA ligase I cDNA clone is given in figure 4.4. This clone consists of 
exactly 3172 bases. The sequencing confirmed that the above-mentioned BamHI, 
Bglll and Pvull sites are equivalent to sites within the human sequence, while the 
PstI and SstI sites do not correspond to human sites. 
The cDNA has a 5' untranslated region of 256 bases up to the first ATG. 
Three ATGs within 66 bases follow, all in frame, and sequence homology with the 
human cDNA begins after the second ATG. The second ATG is also part of an 
initiation sequence (Kozak 1984), CCAACATGC, with only two base changes from 
the concensus, an A at position -2 instead of a C, and a C at position +4 instead of a 
G. The human cDNA has two ATGs. The first is part of the same Kozak sequence as 
in mouse, and is the translation start codon. It seems likely, therefore, that the second 
ATG in the mouse cDNA is the start codon. Assuming that this is correct, the mouse 
DNA ligase I cDNA encodes a protein of 916 amino acids. This is very similar in 
size to the 919 amino acid human DNA ligase I (Barnes et al 1990). 
At the amino acid level, sequence conservation between mouse and human 
DNA ligãse I cDNAs is extremely high, at 84% (figure 4.5). There are 147 amino 
acid differences between the two species. The C-terminal domains (amino acids 250-
919 in the human enzyme, Kodama et a! 1991) are virtually identical, while there is 
some sequence divergence towards the N-terminus. In particular, there are two 
regions of nonhomology with the human enzyme at positions 102-108 and 167-212 
in the mouse enzyme (figure 4.5). This is consistent with the C-terminal domain of 
DNA ligase I being required for catalysis, while the N-terminus is regulatory, via 
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Figure 4.3: Restriction map of mouse DNA ligase I cDNA. For comparison a 
estriction map of the human DNA ligase I cDNA is also shown. Sites which are 
ipparently conserved between the two cDNAs are shown in bold type. 
Figure 4.4: Nucleotide sequence of mouse DNA ligase I cDNA. ML: Sequence of 
the 3.2kb clone obtained by probing an embryonic stem cell cDNA library with full-
length human DNA ligase I cDNA. MLP: Sequence of the clone obtained by Savini 
et al (1994). The 5' and 3' untranslated regions are given in lower case, and the 
coding region is given in upper case. Vertical lines between nucleotides indicate 
homology, while spaces indicate a lack of conservation. Dots indicate gaps in the 
sequence. The upstream ATG, the initiation and termination codons, and the 
polyadenylation signal, AATAAA are given in bold print with double underlining. 
The primers listed were used for sequencing: 887Y, 888Y, G4607, G4608, G8320, 
G8321, G8322, H2066, H3123, and M13 universal primer. These primers were used 
to obtain sequence as follows: 
bases 1-337 	M13 universal primer, by single-stranded sequencing in M13 
bases 338-490 G4608, by double-stranded sequencing in pBluescriptll KS+ 
bases 491-628 H3123, by double-stranded sequencing in pBluescriptll KS+ 
bases 629-859 H2066, by double-stranded sequencing in pBluescriptll KS+ 
bases 860-1087 G8322, by double-stranded sequencing in pBluescriptll KS+ 
bases 1088-1396 M13 universal primer, by single-stranded sequencing in M13 
bases 1397-1654 M13 universal primer, by single-stranded sequencing in M13 
bases 1655-1984 G4607, by double-stranded sequencing in pBluescriptll KS+ 
bases 1985-2215 M13 universal primer, by single-stranded sequencing in M13 
bases 2216-2428 G8320, by double-stranded sequencing in pBluescriptll KS+ 
bases 2429-2588 888Y, by double-stranded sequencing in pBluescriptll KS+ 
bases 2589-2793 887Y, by double-stranded sequencing in pBluescriptll KS+ 
bases 2794-2992 G8321, by double-stranded sequencing in pBluescriptll KS+ 
bases 2993-3172 M 1 universal primer, by double-stranded sequencing in 
pBluescriptll KS+ 
ML 	1 cgagaagactaccagtcgctgctggcaccacttgtcgaagaagcggctga 50 
MLP 
ML 	51 actcagcccaagagaagaaagttcgatccaacaattcctgttcctcctt 100 
MLP 
ML 101 tgcacggctgcgctcggtaagggctctgtcagctccatcctgggaccttg 150 
ML? 
ML 151 agtagaagtggggagaagagctggacatcagacccatctccacctgggtt 200 
MLP 
ML 201 accacaatttcatcatcagactgtcttatcagctactgcgtcctcaggta 250 
11111 
ML? 	1 .............................................aggta 5 
ML 	251 caactgatqagaaaaaaagagcaagagaggaaaggagagacttctgctgc 
I 	Iii 	Il-fl- I 	Hill111111 	111111111(111 	I 	11111111 	I 	Ill 	I 
300 













































































ML 851 TCTGAGCCCACAAAGTCCCCTGAGTCAGTAACCCTGACAAAGACAGAGAA 900 
I 	I III 	1111111111111111111111! 	11111111111111111111 
MLP 606 TCTGAGCCCACAAAGTCCCCTGAGTCAGTAACCCTGACAAAGACAGAGAA 655 
ML 901 CATTCCAGTGTGTAAGGCAGGAGTGAAACTGAAGCCTCAGGAAGAGGAAC 950 
I 	I 	I 	lIlIlI.11IIi 	I 	111111111111111111111111111 	I 	liii 	I 	I 
MLP 656 CATTCCAGTGTGTAAGGCAGGAGTGAAACTGAAGCCTCAGGAAGAGGC 705 
ML 951 AGAGCAAACCTCCTGCTAGAGGTGCCAAGACACTGAGCAGTTTCTTCACA 1000 
11111111111111111111111111111111111111111 	111111 
MLP 706 AGAGCAAACCTCCTGCTAGAGGTGCCAAGACACTGAGCAGTTTCTTCACA 755 
ML 1001 CCCCGAAAACCAGCAGTGAAAACTGAAGTCWCAAGAAGAGTCAGGCAC 1050 
Ill 	111111 	11111111111111! 	1111111 	I 	11111111111 	I 	I 	I 
MLP 756 CCCCGAAAACCAGCAGTGAAAACTGAAGTCAAACAAGAAGAGTCAGGCAC 805 
ML 1051 TCTAAGGAAGGAAGAGACCAAGGGAACCCTGGATCCAGCAAATTATJTC 1100 
11111111111 	III 	1111111 	I I 	I 	I 	1111111 	I 	I 	11111111 	I 	III 
MLP 806 TCTAGGAGGAAGAGACCAAGGGAACCCTGGATCCAGCAAATTATAATC 855 
ML 1101 CTTCCAAGAATAACTATCATCCCATTGAAGATGCCTGCTGGJCATGGC 1150 
Ill 	liii 	I 	I 	III 	III 	IllIlIlIll 	I 	I III 	I II 	III!! 	III 	I 
MLP 856 CTTCCAAGAATACTATCATCCCATTGAAGATGCCTGCTGGCATGGC 905 
ML 1151 CAGAAGGTCCCTTTTCTCGCCGTGGCCCGGACATTTGAGGATTGAGGA 1200 
111111 	III 	IIIIII1III 	IlIllilIllIll 	III 	liii 	1111111 
MLP 906 CAGAAGGTCCCTTTTCTCGCCGTGGCCCGGACATTTGAGAAGATTGAGGA 955 
ML 1201 GGTTTCTGCTAGGCTCAAGATGGTGGAGACATTGAGCCCTGCTGCGCT 1250 
11111111 	III 	1111111 	11111111111111 	I 
MLP 956 GGTTTCTGCTAGGCTCAAGATGGTGGAGACATTGAGCAACCTGCTGCCTT 1005 
ML 1251 CCGTGGTGGCCCTGTCCCCTCCAGACTTGCTCCCTGTTCTCTATCTCAGC 1300 
111111 	I ii 	I 	III 	111111 	I 	liii 	11111111 	I 	I I 	1111111111 
MLP 1006 CCGTGGTGGCCCTGTCCCCTCCAGACTTGCTCCCTGTTCTCTATCTCAGC 1055 
ML 1301 CTCACCGCCTCGGGCCACCTCAGCAGGGACTAGAGCTGGGTGTTGGTGA 1350 
111111111111111111111111111111111 	lilt 	1111111111111 
MLP 1056 CTCAACCGCCTCGGGCCACCTCAGCAGGGACTAGAGCTGGGTGTTGGTGA 1105 
ML 1351 TGGTGTCCTCCTCAAGGCCGTTGCCCAÔGCCACAGGTCGTCAGCTGGAGT 1400 
111111111111111111111111 	1111111111111111111111111 
MLP 1106 TGGTGTCCTCCTCAAGGCCGTTGCCCAGGCCACAGGTCGTCAGCTGGAGT 1155 
ML 1401 CCATCCGGGCTGAGGTAGCTGAGAAGGGGGATGTGGGGCTGGTCCGAG 3.450 
111111111111111 	11111111 	liii 	11111111111 	liii 	11111111 
MLP 1156 CCATCCGGGCTGAGGTAGCTGAGAAGGGGGATGTGGGGCTGGTGGCCGAG 1205 
ML 1451 AACAGCCGCAGCACTCAGAGACTCATGCTGCCTCCACCTCCACTTACTAT 1500 
11111111111111111111111111111111111111111111111111 
MLP 1206 AACAGCCGCAGCACTCAGAGACTCATGCTGCCTCCACCTCCACTTACTAT 1255 
ML
- 
 1501 TTCTGGAGTCTTCACCAAATTCTGTGACATTGCCCGGCTCACTGGCAGTG 1550 
11111111111111111111111111111111111111111111111111 
MLP 1256 TTCTGGAGTCTTCACCAAATTCTGTGACATTGCCCGGCTCACTCAGTG 1305 
ML 1551 CTTCCATGGCCAAGAAGATGGACATTATCGGGCCTTTTTGTTGCCTGC 1600 
1111111111111111111111 	I 	11111111 	111111111111111111 
MLP 1306 CTTCCATGGCCAAGAAGATGGACATTATCGGCCTTTTTGTTGCCTGC 1355 
ML 1601 CGCCACTCAGGCCAGGTACATTGCCAGGTCCCTGCGGGCCTGCG 1650 
1111111111111111111111111111111 	111111111111111111 
MLP 1356 CGCCACTCAGAAGCCAGGTACATTGCCAGGTGCCTGCGGGCGGCTGCG 1405 
ML 1651 CCTTGGCCTAGCTGAGCAGTCGGTACTGGCTGCTCTTGCCCAGGCTGTGA 1700 
HIM III	liii 	I 11111111 I 11111 	1111111111 	11111 liii I 
MLP 1406 CCTTGGGCTAGGTGAGCAGTCGGTACTGGCTGCTCTTGCCCAGGCTGTGA 1455 
ML 1701 GCCTCACACCCCCTGGCCAAGAATTTCCCACGGTGGTGGTGGATGCTGGG 1750 
I 	I 	I 	I 	I I 	I 	I 	I 	I I 	I 	I 	I 	I 	I I 	I 	I I 	I I 	I 	I 	I 	I 	I I 	I 	I I 	I 	F I 	I 	I 	I 	I 	11111 
MLP 1456 GCCTCACACCCCCGGGCCAAGAATTTGCCACGGTGGTGGTGGATGCTGGG 1505 
ML 1751 AAGGGCAAGACAGCAGAGGCCAGAAAGATGTGGTTGGAAGAACAAGGCAT 1800 - 
I 	IIIIIIIIIII 	III 	III 
MLP 1506 AAGGGCAAGACAGCAGAGGCCAGAAAGATGTGGTTGGAAGAACAAGGCAT 1555 
ML 1801 GATCTTGAAGCAGACCTTCTGTGAGGTTCCTGACCTGGATCGTCATCC 1850 
11111111111 	11111111111 	I I 	I I 	11111 	I I 	111111 	I I 	I 	I I 	I I 	I I 	I I 
MLP 1556 GATCTTGAAGCAGACCTTCTGTGAGGTTCCTGACCTGGATCGTCATCC 1605 
ML 1851 CTGTGCTGCTGGAACATGGCCTGGAACGTCTCCCAGAGCACTGCGCTG 3.900 
111111111 	tIll 	I Ill 	liii 	lIllIllIllil 	I liii 	II 11111 
MLP 1606 CTGTGCTGCTGGAACATGGCCTGGAACGTCTCCCAGAGCACTGCAAGCTG 1655 
ML 1901 AGCCCAGGGGTCCCTCTTACCATGCTGGCTCATCCCACTCTGT 1950 
I 	11111 	111111 	1111111 	11111 	II 	I 
MLP 1656 AGCCCAGGGGTCCCTCTTAAACCAATGCTGGCTCATCCCACTCGGGGTGT 1705 
ML 1951 CAGTGAGGTCCTAAAACGCTTTGAGGAGGTCGACTTCACCTGTGTATA 2000 
	
111111 	1111111111 	I 11111111 	I I 	11111111 	111111 
MLP 1706 CAGTGAGGTCCTAAAACGCTTTGAGGAGGTCGACTTCACCTGTGAATATA 1755 
ML 2001 AATACGATGGGCAGCGAGCACAGATACATGTTCTGGAAGGTGGAGGTG 2050 
I 	I III 	11111111111111111 	I 	I I 	I I I 	I I 	1111111 	I 111111 	I 
MLP 1756 AATACGATGGGCAGCGAGCACAGATACATGTTCTGGAAGGTGGAGAAGTG 1805 
ML 2051 AAGATCTTCAGCAGGAACCAGGAAGACAACACAGGJGTATCCTGACAT 2100 
111111 	IlllllllI1II1l1I1I 	I I 1111111111 	11111111111 
MLP 1806 AAGATCTTCAGCAGGAACCAGGAAGACAACACAGGJAGTATCCTGACAT 1855 
ML 2101 TATCAGCCGCATCCCCAAGATTAAACACCCCTCAGTCACATCTTTCATTC 2150 
111111111 	1111111111 	I liii 	11111111 	I 	I 11111111111 	III 
MLP 1856 TATCAGCCGCATCCCCAAGATTAAACACCCCTCAGTCACATCTTTCATTC 1905 
ML 2151 TGGACACTGAGGCTGTGGCCTGGGACCGGGAAAAGAAGCAGATCCAACCA 2200 
111111111111111111 	I 1111111111111111111111111111111 
MLP 1906 TGGACACTGAGGCTGTGGCCTGGGACCGGGAAGAAGCAGATCCCCA 1955 
ML 2201 TTCCAAGTACTCACCACGCGCAAGCGCAAGGAGGTTGATGCATCGGAGAT 2250 
11111111111111111111111111111111111111111111111111 
MLP 1956 TTCCAAGTACTCACCACGCGCAAGCGCAAGGAGGTTGATGCATCGGAGAT 2005 
ML 2251 ACAGGTGCAAGTGTGTCTGTATGCTTTTGACCTCATCTACCTCCGGAG 2300 
11111111111111111111111111111111111111111111111111 
MLP 2006 ACAGGTGCAAGTGTGTCTGTATGCTTTTGACCTCATCTACCTC1JCGGAG 2055 
ML 2301 AGTCCCTGGTTCGCCAGCCCCTGTCTCGACGCCGGCAGCTGCTCCGTGAG 2350 
11111111111111111111111111111111111111111111111111 
MLP 2056 AGTCCCTGGTTCGCCAGCCCCTGTCTCGACGCCGGCAGCTGCTCCGTGAG 2105 
ML 2351 AACTTCGTGGAGACAGAGGGTGAGTTTGTCTTCACCACCTCTTGGACAC 2400 
11111111111111111111111111111 	11111111111 	I 111111111 
MLP 2106 AACTTCGTGGAGACAGAGGGTGAGTTTGTCTTCACCACCTCTTTGGACAC 2155 
ML 2401 CGGACACCGAGCAGATTGCTGAGTTCTTAGCAGTCAGTGGGACT 2450 
MLP 2156 CGGACACCGAGCAGATTGCTGAGTTCTTAGCAGTCAGTGACT 2205 
ML 2451 CCTGTGAGGGCCTGATGGTGAAGACCTTGGATGTTGATGCCACTTATGAG 2500 
III 	11111 	111111111111111111111111111111111111111 
MLP 2206 CCTGTGAGGGGCTGATGGTGAAGACCTTGGATGTTGATGCCACTTATGAG 2255 
ML 2501 ATTGCCAAGAGGTCACACAACTGGCTCAAGCTGAAGAAGGACTACCTTGA 2550 
II 	1111111 	1111111111 	111111111111111111 	I 1111111 
MLP 2256 ATTTCCAAGAGGTCACACAACTGGCTCAAGCTGAAGAAGGACTACCTTGA 2305 
ML 2551 CGGTGTGGGTGACACTCTGGACCTTGTGGTGATTGGTGccTAccTGcc 2600 
1111111 	iiiiiiiiiiiii; 	11111111 	1111111111 	I 111111 
MLP 2306 CGGTGTGGGTGACACTCTGGACCTTGTGGTGATTGGTGCCTACCTGGGCC 2355 
ML 2601 GGGGGAAGCGGGCTGGCCGGTATGGAGGCTTCCTGTTGGCTGCCTACGAT 2650 
I 	III 	I 	11111 	I 	111111111111111111 	I 	1111 	1111111111 	II 
MLP 2356 GGGGGAAGCGGGCTGGCCGGTATGGAGGCTTCCTGTTGGCTGCCTACGAT 2405 
ML 2651 GAGGAGAGTGAAGAGCTTCAGGCTATATGCAAGCTG3GAACTGGATTCAG 2700 
11111111111111111 	I 	I 	1111 	I 	11111111111 	I 	I 	1111111111 	III 
MLP 2406 GAGGAGAGTGAAGAGCTTCAGGCTATATGCAAGCTGGGAACTGGATTCAG 2455 
ML 2701 CGATGAGGAGCTGGAGGAACACCACCAGAGCCTGCAGGCCCTGGTATTGC 2750 
liii 	I 	1111111111 	I 	I 	I 	11111111 	III 	11111111111 	II 	III 
MLP 2456 CGATGAGGAGCTGGAGGAACACCACCAGAGCCTGCAGGCCCTGATATTGC 2505 
ML 2751 CTACCCCACGCCCCTATGTGAGGATTGATGGGGCAGTGGCCCCAGACCAT 2800 
11111 	1111111111 	I 	1111111 	1111111111 	II 	I 	I 	I II 	III 
MLP 2506 CTACCCCACGCCCCTATGTGAGGATTGATGGGGCAGTGGCCCCAGACCAT 2555 
ML 2801 TGGCTGGACCCAAGCATTGTGTGGGAGGTGAAGTGTGCTGATCTTTCCCT 2850 
111111111111111111111 	I I 	1111111 
MLP 2556 TGGCTGGACCCAAGCATTGTGTGGGAGGTGAAGTGTGCTGATCTTTCCCT 2605 
ML 2851 GTCCCCCATCTACCCTGCTGCACGGGGCCTGGTGGACGGGGA 2900 
1111111 	I 	liii 	III 	1111111 	11111111111 	111111111 	I 	I 
MLP 2606 GTCCCCCATCTACCCTGCTGCACGGGGCCTGGTGGACGAAGGGA 2655 
ML 2901 TCTCTCTTCGTTTTCCTCGGTTCATTCGTGTCCGTGACGCAGCCA 2950 
1111111 	liii 	1111111111111 	III 	I 	1111111 	I 	I 	I 	III 	H 	11111 
MLP 2656 TCTCTCTTCGTTTTCCTCGGTTCATTCGTGTCCGTWGACAAGCAGCCA 2705 
ML 2951 GAGCAGGCCACTACCAGTAACCAGGTTGCCTCTTTGTACCGGGCAGAG 3000 
I 	111111 	I 	I 	I 	I 	111111111 	I 	11111111 	I 	IIIIIIIIIIIIIIIIII 	I 	I 
MLP 2706 GAGCAGGCCACTACCAGTAACCAGGTTGCCTCTTTGTACCGGAAGCAGAG 2755 
ML 3001 TCAGATTCAGAACCAACAAAGCTCAGACTTGGACTCCGACGTTGAAGACT 3050 
1111111111 	I 	11111111 	I 	111111111111111111111111111111 
MLP 2756 TCAGATTCAGAACCAACAAAGCTCAGACTTGGACTCCGACGTTGAAGACT 2805 
ML 3051 ATcctcctgctctcctggggcctggggtggaggttgcgagaacatgg 3100 
I ITTTI 11111111111 II 	11111111111 11111111111 	111111 	I 
MLP 2806 ATcctcctgctctcct . gggcctggggtggaggttgcgagaacat . g 2853 
ML 3101 ggcactgttggattggtggtgttgattggtgtgtgtggagtcacaggagt 3150 
11111111111111111111111111111111111111111111111111 
MLP 2854 ggcactgttggattggtggtgttgattggtgtgtgtggagtcacaggagt 2903 
ML 3151 gagatcctggggctggaatgct ............................ 3172 
1111111111111111111111 
MLP 2904 gagatcctggggctggaatgctttattttcttcaataaatgacttcttag 2953 
ML 
NLP 2954 ataccccg .......................................... 2961 
Figure 4.5: Amino acid sequence of DNA ligase I. MLP: Sequence of the mouse 
clone obtained by Savini et al (1994). ML: Sequence of the 3.2kb clone obtained by 
probing an embryonic stem cell cDNA library with full-length human DNA ligase I 
cDNA. HL: Sequence of human DNA ligase I (Barnes et al 1990). •: Amino acids 
conserved between all three sequences. I: Amino acids conserved between mouse 
sequences, but not human. *: Amino acids conserved between the mouse sequence 
presented in this thesis and the human sequence, but not the published mouse 
sequence. -: Amino acids that lack an equivalent in either the human or mouse 
enzyme. Putative phosphorylation sites (S_ _E motifs and the two 'strong' human 
sites SEGEEEDE and S141EDEDRE), the ATP binding site (KYDG) and the 
amino acids equivalent to the mutations in 46BR at glutamate 566 and arginine 771 
are indicated by underlining. 
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therefore be expected to be highly conserved, while the N-terminal portion could 
have evolved to interact with species-specific cellular factors. 
Human DNA ligase I has been shown to require activation by casein kinase 
II phosphorylation in its N-terminal domain, and several putative sites for 
phosphorylation at serine residues have been identified within the enzyme (Prigent et 
al 1992). These sites consist of S-- E  motifs and are all possible substrates for 
casein kinase H (Kemp and Pearson 990). However, two appear to be 'stronger' 
phosphorylation sites encompassing an S_ _E motif and it was suggested that one or 
other is the substrate for casein kinase R. The sequences of these two 'strong' sites 
areSEGEEEDE and S141EDEDRE. It is notable that the mouse enzyme lacks both 
of these two 'strong' casein kinase II phosphorylation sites (figure 4.5). It is therefore 
unlikely that Ser66 or Serl4l is the site of phosphorylation in the human enzyme. A 
number of other S _E motifs are present in the mouse enzyme and many of these 
are homologous to sites within the human enzyme. In particular there are two motifs 
present in the N-terminal domains of both human and mouse enzymes at positions 
27 and 163 (human) or 161 (mouse). It is possible that one or other of these is the 
site of phosphorylation by casein kinase H. Further work on the phosphorylation 
patterns of these enzymes is required to clarify this point. 
Amino acid sequence around the ATP binding site is highly homologous to 
the human cDNA. A stretch of 77 amino acids has only two conservative alterations. 
This region includes the Lys-Tyr-Asp-Gly motif observed in all eukaryotic DNA 
ligases studied so far (Tomkinson et al 1991b). DNA ligases from the viruses 
Vaccinia, T3 and 17 also have this motif. The Lys residue in the motif is the site of 
ATP binding, via a phosphoamide bond. The Glu residue two amino acids upstream 
from the ATP-binding site motif (position 564) is equivalent to the site at which the 
Glu566 to Lys mutation occured in 46BR (Barnes et al 1992b). 
Sequence in the region equivalent to that in which the Arg77 1 to Trp 
mutation occured in 46BR is also highly conserved. At the amino acid level, the 
sequences are virtually identical and there is an arginine residue in mouse (position 
769) corresponding to human Arg77 1. 
The 3.2kb mouse DNA ligase I cDNA clone is not quite full-length. There is 
a 3' untranslated region of 117 bases, shortened by the loss of several bases from the 
3' end. This includes the polyaclenylation signal (Proudfoot and Brownlee 1976) and 
poly A tail. Two of the shorter cDNA clones, of sizes 2.7kb and 2.9kb, were 
sequenced from the 3' end and sequence obtained from the 2.7kb clone is given in 
figure 4.6. This clone includes a further 33 bases, containing a polyadenylation 
signal, AATAAA, but still lacking a poly A tail. The 2.9kb clone has a shorter 3' 
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Figure 46: Nucleotide sequence of the 3' untranslated region of the 2.7kb mouse 
DNA ligase I cDNA clone. The polyadenylation signal, AATAAA, is underlined. 
The end of the 3' untranslated region of the 3.2kb mouse DNA ligase I cDNA clone 
is indicated by an arrow. 
CCTCCTGCTCTCCTGGGGCCTGGGGTGGAGGTTGCGAGAACATGGGGCAC 
TGTTGGATTGGTGGTGTTGATTGGTGTGTGTGGAGTCACAGGAGTGAGAT 
CCTGGGGCTGGAATGC A i i I I CTTCAATAAATGACTTCTTAGATGCC 
untranslated region than the 2.7kb clone, but also has a polyadenylation signal and 
no poly A tail. 
Mouse DNA ligase I cDNA has also been cloned and sequenced very 
recently by Savini et al (1994). Their clone (figure 4.4, figure 4.5) is virtually 
identical to the eDNA clone described in this chapter, showing 99% identity at both 
the nucleotide and amino acid levels. There are 11 base changes within the coding 
region, but most of the nucleotide alterations are silent, resulting in only six amino 
acid differences between the two clones, differences which may have arisen simply 
because the RNA used was obtained from separate mouse strains. Savini et a! used 
RNA from NIH 3T3 Swiss mice (Todaro and Green 1963) while the RNA used in 
this work was taken from cells derived from 129/01a mice (Olac Ltd 1976). 
However, it is notable that in every case, the mouse sequence presented here agrees 
with the human sequence, while the published sequence is the one that differs. Many 
of the alterations are conservative, such as the exchange of serine for alanine and 
isoleucine for valine at positions 734 and 814.' On the other hand, some of the 
substitutions are not conservative, such as the exchange of cystine for serine at 
position 443. None of these differences are located in parts of the enzyme which 
have yet been identified as vital, although all are positioned in the highly conserved 
C-terminal domain of the enzyme. 
There are other differences between the two mouse clones. The clone 
obtained by Savini et al has a shorter 5' untranslated region consisting of 59 
nucleotides, compared to the 304 nucleotide 5' UTR of the clone presented in this 
thesis (figure 4.4). Within the 5' untranslated regions there are two nucleotide 
alterations at positions -39 and -40, where the sequence is GG in the published 
sequence, and AA in the sequence given here. The 3' untranslated region of the clone 
obtained by Savini et a! is 151 nucleotides long while that of the clone given in this 
thesis consists of 117 bases (figure 4.4). There are two minor differences here as 
well, with there being four Gs present 14 and 44 bases after the stop codon in my 
sequence, but only three Gs at the same positions in the published sequence. 
Additionally, when the sequence of the longer 3' UTR from the 2.7kb mouse cDNA 
clone (figure 4.6) is compared, there is a further difference. An A has been 
exchanged in the published sequence for a 0 which is present in the 2.7kb clone 14 
nucleotides down from the poly A signal. The clone obtained by Savini et al extends 
three bases further downstream than the 2.7kb clone but still lacks a poly A tail. 
Finally, Savim et al identified a recognition site for the restriction enzyme Smal 
within their clone. There is no recognition site for this enzyme within the clone 
given in this thesis. The absence of the site has been confirmed both by restriction 
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mapping and by sequencing. There are, then, several differences between the two 
mouse DNA ligase I cDNAs and, in every case where the amino acid sequence is 
affected, the published sequence differs from human DNA ligase I while the 
sequence presented here is the same as that of the human enzyme. However, in all 
important aspects, the clones appear to be identical. This is of interest since it 
confirms the absence of the two 'strong' casein kinase II phosphorylation sites 
identified in the human sequence. 
In conclusion, mouse DNA ligase I cDNA has been cloned and sequenced. 
The cDNA is incomplete since it lacks a number of bases from the 3' end, but 
encodes the entire enzyme. It is highly homologous to the human enzyme and, with 




EXPRESSION OF MOUSE DNA LIGASE I cDNA 
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Following the cloning of mouse DNA ligase I cDNA, attempts were made to 
express the cDNA in the cell line 46BR.1G1 for two reasons: (1) To demonstrate 
that the cDNA encodes a full-length active DNA ligase I enzyme by rescue of the 
DNA ligase I deficiency of 46BR1G1. (2) To improve upon the previous expression 
studies utilising the human DNA ligase I cDNA in the vector pBAHLneo (chapter 3) 
by modification of the mouse enzyme to make it detectable in the presence of the 
endogenous human enzyme and thus enable proper demonstration of expression of a 
wild-type enzyme within the cells. 
51 Jlntroduction of a Marker into Mouse DNA Ligaise 11 
The C-terminal domain of DNA ligase I is involved in catalysis (Tomkinson 
et a! 1990), therefore a marker peptide could interfere with ligation activity if placed 
within this region of the enzyme. The N-terminal domain is thought to be involved 
in regulation of DNA ligase I activity and in interaction with other cellular factors 
(Prigent et al 1992). However, it is less likely that a marker peptide would affect 
enzyme function if located in the regulatory domain of the enzyme rather than in the 
catalytic domain. Sequence encoding a hydrophilic marker peptide called 'FLAG' 
(Hopp et a! 1988), consisting of eight amino acids, was therefore placed at the 5' end 
of the mouse DNA ligase I cDNA coding region. This peptide has been successfully 
used by other workers to tag proteins without affecting biological activity (for 
example see Kunz et al 1992). 
A 64 base oligonucleotide (483W, figure 5.1) was designed for use in 
conjunction with a 20 base primer (482W) specific for a region of the mouse DNA 
ligase I cDNA immediately 3' of the Bamlil site (figure 5.2). The 64 base primer 
consists of a Not! site preceded by eight bases, which is the minimum distance from 
DNA ends required for efficient Not! cutting. This is combined with a concensus 
Kozak translation initiation sequence (CCGCCATGG, Kozak 1984), which is 
followed by the flag sequence (Asp-Tyr-Lys-Asp-Asp-Asp-Asp-Lys) specified by 
codons chosen according to mouse codon usage tables. Finally, there are the first 20 
bases from the mouse DNA ligase I cDNA ceding region. There are three ATG 
codons at the ( )end of the cDNA and homology with the human cDNA begins after 
the second ATG. Additionally, there is a Kozak signal immediately upstream of the 
second ATG. It has therefore been assumed that the second ATG in the mouse 
cDNA is the true translation start site. Consequently the 20 bases of cDNA coding 
region are the first 20 bases following the second ATG. 
The primers were used to amplify a 1kb section of mouse DNA ligase I 
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Figure 5.2: introduction of the FLAG sequence into mouse DNA ligase I cDNA by 
PCR. A. fragment of the mouse cDNA is represented, extending from the 5' end to 
downstream of'the , Bim}il site. The hatched box represents the 5' untranslated region 
of the cDNA. Binding sites for the two primers used are indicated. Primer 482W 
binds the non-coding strand, while primer 483W binds the coding strand. The 
resulting 1kb PCR product is shown, with the 5' untranslated region replaced with 
the FLAG sequence (Closed box). The modified cDNA 5' end was isolated from this 
fragment as a 0.3kb NotI/SstI fragment. PCR conditions were as follows: denaturing 
for 1 min at 94°C, annealing for 1 min at 58°C and synthesis for 1 min at 72°C. 
No 
—483W 	 BaniHI 
StI 	 —482W 
PCR 
Nc1 	 Bar?HI 
StI 
(figure 5.2). In this 1kb fragment all of the cDNA 5' sequence up to the second ATG 
has been lost, and replaced with a NotI site and 24 bases encoding the flag peptide. 
The PCR fragment was digested with NotI and BamHI and cloned into 
Noti/BaniHI-digested pBluescriptfl KS+ for propagation. The modified 5' end of the 
eDNA was isolated from this plasmid as a 0.3kb SstI fragment, using one SstI site 
from pBluescript and the other from within the PCR fragment. The 5' end of the 
3.2kb mouse DNA ligase I cDNA clone was removed as a 0.6kb SstI fragment, 
using one SstI site from pBluescript and the other from within the cDNA, and 
replaced with the modified 5' end. This produced a modified mouse DNA ligase I 
cDNA with the entire 303 bases of 5' untranslated region removed, including the first 
ATG, and replaced with a NotI site and the flag sequence. This plasmid was 
designated pfML. 
The entire modified 5' end of the cDNA was sequenced, which verified that 
the desired changes had been made, and that no mutations had been introduced 
during the PCR amplification (figure 5.3). 
5.2 Expression of FllagLigsise in E. coli 
The plasmid, pfML was introduced into E. coli strain BL21(DE3) (Studier 
and Moffatt 1986), which expresses 17 RNA polymerase from a chromosomal copy 
of the gene when induced. In pfML, the modified cDNA is under the control of the 
17 promoter of pBluescriptll KS+ and will therefore be expressed when the cells are 
induced to make 17 RNA polymerase. 
Cultures of BL21(DE3) cells transformed with pfML were induced to 
produce T7 RNA polymerase, and cell extracts electrophoresed through a 
polyacrylamide gel. Coomassie blue staining of the gel (figure 5.4a) revealed a 
ladder of protein bands in all tracks. However, at least three novel bands are visible 
in all tracks containing extracts from one of the cultures of cells transformed with 
pfML (clone 2). The largest of these novel bands is slightly larger than the 1 l5kDa 
marker, and the others are approximately 30kDa or less, with the smaller proteins 
possibly arising from degradation of the largest polypepiide. 
Human DNA ligase I is 125-130kDa in size as determined by SDS-PAGE 
(Teraoka and Tsukada 1982, Tomkinson et al 1990) and mouse DNA ligase I is 
likely to be of a similar size. Consequently the protein visible slightly above the 
1 l5kDa size marker could be mouse DNA ligase I with the marker peptide attached. 
The appearance of this band even when the cells were uninduced is probably due to 
the basal level of transcription of the 17 RNA polymerase gene as observed by other 
workers (Studier and Moffatt 1986). 
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Figure, 5.3: Sequence of the 0.3kb NoWSsU fragment containing the modified 5' end 
of the cDNA. The FLAG sequence was introduced as required and no base 
alterations were introduced into the cDNA sequence during amplification. The 
positions of the NotI site, Kozak sequence, flag and the start of the mouse DNA 
ligase I cDNA are indicated. 
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Figure 5.4: Expression of pfML in E. coil. a) Extracts, from untransformed 
BL21(DE3), BL21(DE3) transformed with pBluescriptll KS+ and BL21(DE3) 
transformed with pfML (2 separate clones) were prepared at 0, 1, 2 and 3 hours 
following induction and electrophoresed through a polyacrylamide gel. The gel was 
stained with Coomassie blue to visualise the protein bands. The positions of novel 
bands, faintly visible only in all clone 2 tracks, are marked with an arrow. Protein 
marker sizes are gived in kDa. b) An identical gel to that in figure 5.4a was 
electroblotted and probed with the anti-FLAG monoclonal antibody MI. The single 
band clearly visible in clone 2 tracks and also visible in clone 1 tracks corresponds to 
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An identical gel was electroblotted onto a nylon membrane and probed with 
an anti-FLAG monoclonal antibody (figure 5.4b). This revealed a single band in all 
clone 2 tracks at a position equivalent to the largest novel protein band observed on 
the Coomassie-stained gel. Additionally, a much fainter band was visible in all clone 
1 tracks at the same position. None of the presumed degradation products were 
visualised and therefore are either unrelated to the flag-DNA ligase I protein or have 
lost the flag sequence during breakdown. 
These experiments demonstrate that a single protein of approximately the 
same size as DNA ligase I and carrying the flag marker peptide is transcribed from 
pfML. Therefore the modified cDNA, when expressed, produces a protein which is 
apparently full-length and which is detectable using the anti-flag monoclonal 
antibody. This protein was not isolated and assayed for activity in order to show that 
the cDNA encodes an active protein, since expression of full-length DNA ligase I in 
E. colt produces an inactive enzyme which requires further post-translational 
modification before it can catalyse ligation reactions (Kodama et al 1991). 
5.3 Expression of TF'llag-Ligase in 461BR Under Control of the Phosphogilycerate 
Kinase Promoter 
A new vector was constructed to express the modified mouse DNA ligase I 
cDNA in 46BR. The vector was designed to eliminate the problems with faulty 
initiation or termination of transcription experienced with the expression vector 
pBAneo (chapter 3). 
The expression vector was constructed in pBluescriptll KS+ by Carolanne 
McEwan. First, the mouse phosphoglycerate kinase promoter was cloned into the 
plasniid as a 550bp EcoRI/PstJ fragment. The phosphoglycerate kinase promoter was 
chosen because it has been used successfully to express HPRT minigenes (Magin et 
al 1992). This was followed by a 2.4kb EcoRl fragment containing the bacterial 
neomycin resistance gene under control of the mouse metallothionein promoter to 
provide selection for transformants in G418. This is the same neor  gene as that used 
in pBAneo and it was cloned into the vector with the metallothionein promoter in 
both orientations. Finally, a 1.3kb fragment containing the last two exons and 3' 
untranslated region of the HPRT gene was cloned into the Sstll site of the vector by 
addition of SstII linkers. This fragment was included to provide transcription 
termination and polyadenylation signals, thereby eliminating the need for cloned 
sequences to provide their own polyadenylation signals and also promoting proper 
termination of transcription. This completed construction of the new expression 
vectors (figure 5.5) which were designated pDWM2O1 (neo' in the same orientation 
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Figure 5.5: Expression vectors pDWM201 and pDWM202. The mouse 
phosphoglycerate kinase promoter (shaded box) drives expression, with transcription 
termination sequences provided by the 3' end of the HPRT gene. This includes exons 
8 (hatched box) and 9 (closed box) as well as the eighth intron (open box). The 
neomycin phosphotransferase gene is driven by the mouse metallothionein promoter 
which is present in the same orientation as the phosphoglycerate kinase promoter in 
pDWM201 and in the opposite orientation in pDWM202. Key restriction sites are 
given. 
ScaI 
I 	1 . 1 	 I 
24kb 	 550bp 	 1.3kb 
as the phosphoglycerate kinase promoter) and pDWM202 (neor and the 
phosphoglycerate kinase promoter in opposite orientations). 
A cDNA encoding mouse HPRT (isolated from pHPT5 as a 1.3kb PstI 
fragment) was cloned into both vectors so that they could be tested for their ability to 
drive expression from the phosphoglycerate kinase promoter of cDNAs inserted in 
the appropriate orientation. These plasmids were designated pDWM203 (pDWM201 
+ HPRT) and pDWM204 (pDWM202 + HPRT). They were then introduced into 
HPRT-deficient RJK88 chinese hamster cells by calcium phosphate precipitation by 
Angela Pow. Equal quantities of each plasmid were introduced into equal numbers 
of cells. At the same time, pDWM1 11 (Magin et al 1992) was also transfected into 
RJK88 cells. This plasmid contains an HPRT mini-gene and cells transfected with it 
can express active HPRT enzyme. It was included in the experiment as a positive 
control for HPRT expression in the RJK88 fibroblasts. Transformed cells were 
selected for growth in the synthetic antibiotic G418. 
Total RNA was prepared from untransformed RJK88 cells, from RJK88 cells 
transformed with pDWM203 and pDWM204, as well as from the wild-type 
embryonic stem cell line E14. The RNA was size-fractionated, blotted and probed 
with HPRT cDNA (figure 5.6) This revealed a 1.5kb HPRT message, present only in ' 
RNA prepared from the wild-type cells or those transformed with the vectors 
expressing HPRT cDNA. No HPRT-specific message was detectable in RJK88 RNA 
in the absence of the expression vectors. Therefore the vector was successfully 
expressing HPRT cDNA. However an actin reprobing of the filter revealed that the 
RNA loadings were equal (data not shown) and therefore that HPRT was being 
expressed from the vectors at a level substantially lower than that in wild type cells. 
An additional 5.1kb band of unknown identity was visible in all the RNA taken from 
RJK88 cells. 
Cells expressing active HPRT can be selected by growth in HAT medium 
which contains hypoxanthine, aminopterin and thymidine. Aminopterin is a toxic 
base analogue which blocks de novo synthesis of purines and pyrimidines. However, 
cells can bypass the metabolic block using hypoxanthine and thymidine, if they 
utilise the purine salvage pathway. HPRT is one of the enzymes involved in this 
pathway, therefore cells can only grow in HAT medium if they are HPRT. RJK88 
fibroblasts are HPRT, so transformants expressing HPRT from an integrated 
plasmid can be selected. 
As an additional test for HPRT expression from the vectors, HPRT+  cells 
were selected in HAT medium by Angela Pow and the extent of HPRT expression 
determined by counting colonies (figure 5.7). RJK88 cells transformed with 
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Figure 5.6: Northern blot of RNA prepared from the HPRT-deficient cell line 
RJK88, RJK88 transformed with plasmids pDWM203 and pDWM204, and the wild-
type cell line E14. The blot was probed with HPRT cDNA. The positions of the 
ribosomal sub-units are indicated and their sizes given in kb. The position of the 
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Figure 5.7: Bar chart showing the extent of HPRT expression in RJK88 cells 
transformed with pDWM1 ii, pDWM203 and pDWM204, as measured by counting 



















pDWM1 11 pDWM203 pDWM204 
pDWM1 11 showed the highest level of HPRT expression, but cells transformed with 
both pDWM203 and pDWM204 were also expressing HPRT. There was no 
significant difference in HPRT expression between pDWM203 and pDWM 204. 
These plasmids differ only in the orientation of the neor  gene, which therefore 
apparently does not affect expression. 
The discrepancy between the higher levels of HPRT expression in the wild-
type cell line E14, and from pDWM1 11 and the much lower expression levels from 
vectors pDWM203 and 204 could be due to the new expression vectors not working) 
as efficiently, or because HPRT expression is enhanced by intron sequences present/ 
in the endogenous gene and in the minigene in pDWM1 11, but not in pDWM203f 
and 204. 
Mouse DNA ligase I cDNA and the cDNA with the flag marker were cloned 
into the Not! site of pDWM201, placing them under control of the phosphoglycerate 
kinase promoter. The new plasmids were designated pPGKMLne0 and 
pPGKIMLneo. The vectors were linearised with XhoI since the mouse DNA ligase I 
cDNA contains a Scal site, and introduced into the cell line 46BR.1G1 by 
electroporation. Following transformation, 0418-resistant colonies were grown as 
pools and assayed for sensitivity to 3-aminobenzamide. The hypersensitivity of 
46BR to 3-aminobenzamide is rescued 100% by wild-type human DNA ligase I 
cDNA (chapter 3, and repeated in parallel with these experiments - data not shown), 
but no correction was detectable by introduction of the mouse cDNA, with or 
without the marker (data not shown). This raised a number of possibilities. The 
mouse cDNA clone could be mutated and not encode a functional enzyme, or 
perhaps the mouse enzyme cannot complement the human defect. However, 
sequencing had so far indicated an extremely high degree of homology between 
mouse and human cDNAs with no obviously significant amino acid alterations 
between the two. Since both tagged and untagged mouse cDNAs had given a 
negative result, there was no evidence for the removal of the 5 untranslated region 
and addition of the marker having affected expression. A more likely explanation for 
the failure of the mouse eDNA to rescue the 3-arninobenzamide hypersensitivity is 
that the mouse enzyme was simply not being expressed at a high enough level. 
Using the anti-FLAG monoclonal antibody to probe protein extracts from cells 
transformed with the marked eDNA confirmed this. No tagged protein was 
detectable (data not shown). 
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5.4 Expression of FllagLigsise in 46B1 Under Conitroll of the Hunan B-Actin 
Promoter 
Given the failure of the expression vector pDWM201, the tagged and 
untagged mouse DNA ligase I cDNAs were cloned into the original expression 
vector pBAHLneo, under control of the human B-actin promoter. This meant that the 
mouse cDNA should be transcribed since the vector had already been used 
successfully in other experiments. However, this vector relies on cloned sequences to 
provide their own polyadenylation signal and the presence of this signal at the 3' end 
of the mouse DNA ligase I clone had not yet been confirmed by sequencing. Since 
cDNA synthesis commences from an oligo dT primer which hybridises to the poly A 
tail of messenger RNA, it was assumed that the cDNA clone would turn out to be 
complete right up to the poly A tail. 
No suitable sites could be identified for linearisation of the plasmids prior to 
introduction into mammalian cells. Consequently, the plasmids were introduced as 
closed circular molecules. This meant that there was no preference for the vectors to 
integrate into the genome with the neo' module, thehuman B-actin promoter and the 
cDNA maintained as one intact unit. Instead, the plasmid could break anywhere, 
including within one of these elements, with the possible result that either 
transformed cells would not be resistant to G418, or that they would be unable to 
transcribe the cDNA, or both. The plasmids were introduced into 46BR.1G1 by 
electroporation and G418-resistant colonies were grown up as clones or as pools. 
Initially, pools of transformed cells were assayed for sensitivity to 3-
aminobenzamide. Their pattern of survival was indistinguishable from that of 
untransformed 46BR.1G1 cells, although cells transfected with human DNA ligase I 
cDNA showed wild-type levels of survival (data not shown). No rescue of the 
hypersensitivity to 3-aminobenzamide was detectable with the cDNA tagged or 
untagged (data not shown). This could have been because only a very small 
proportion of the cells resistant to G418 were also expressing the mouse DNA ligase 
I cDNA since the plasmid was not linearised. Twelve G418-resistant colonies were 
tested for presence of the tagged mouse DNA ligase I cDNA by PCR. The primers 
originally used to introduce the FLAG sequence (482W, 483W), were used in the 
PCR assay. These primers produce a 1kb fragment from the 5' end of the mouse 
cDNA with the marker. This 1kb product was seen with eight out of the twelve 
colonies screened (figure 5.8). This was an unexpectedly high proportion, but still 
does not adequately demonstrate that these colonies all carry an intact cDNA under 
control of the human 13-actin promoter. However, at this stage it was discovered, by 
sequencing, that the mouse DNA ligase I cDNA clone used in these experiments is 
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Figure 5.8: Screening G418-resistant colonies transfected with pBAfMLneo for the 
presence of mouse DNA ligase I cDNA sequences by PCR, using primers 482W and 
483W. Denaturing was carried out at 94°C for 1mm, annealing at 580C for 1mm 
and DNA synthesis at 72°C for 1mm. STD: molecular weight markers, 23.1kb, 
9.4kb, 6.6kb, 4.4kb, 2.3kb, 2.0kb and 1.6-0.2kb at lOObp intervals, C: negative 
controls, Reactions carried out in the absence of DNA substrate or in the absence of 
primers, fML: reaction carried out using pfML as substrate, 1-12: reactions carried 
out on extracts prepared from colonies of cells transfected with pBAfMLneo. The 
position of the 1kb PCR product is indicated by an arrow. 
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not complete. It is truncated from the 3' end and lacks a polyadenylation signal and 
poly A tail. This fact could account for the failure of the mouse cDNA to rescue the 
3-aminobenzamide hypersensitivity of 46BR. 1G1, since any messenger RNAs 
transcribed from the integrated plasmid would probably be too unstable to be 
translated and produce mouse DNA ligase I protein in significant amounts (Jackson 
and Standardt 1990). This is not inconsistent with the demonstrated expression of the 
cDNA in E. coli since bacterial messenger RNAs do not require a poly A tail for 
stability. 
The absence of any mouse DNA ligase I enzyme within the cells was 
confirmed by preparing Western blots of protein extracts from each of the positive 
clones and probing with the anti-FLAG monoclonal antibody. No protein was 
detectable (data not shown). 
A further complication to these experiments was discovered with the 
publishing of the mouse DNA ligase I cDNA sequence (Savini et al 1994). 
Comparison of their sequence with the sequence obtained for the mouse DNA ligase 
I cDNA clone described in chapter 4 revealed a reading error. This had resulted in 
the first two codons following the initiator methionine being read as CGAGAA 
when in fact they should have been CAGAGA. At the amino acid level this 
translated to a change from glutamine and arginine, to arginine and glutamate. 
Introduction of the FLAG sequence onto the N-terminus of mouse DNA ligase I by 
PCR (figure 5.2) resulted in the incorporation of this sequencing error into the cDNA 
and therefore into the protein. However, since these two amino acid alterations are at 
the extreme N-terminus of the protein which has already been altered by addition of 
the eight amino acid FLAG sequence, it is unlikely that they would affect the 
function of the enzyme. 
Subsequent to these experiments, work carried out by Teraoka et al in 1993 
suggested that N-terminal modification of DNA ligase I can affect its activity. It had 
previously been shown that DNA ligase I expressed in E. coli as a fusion protein 
with 3-galactosidase at the N-terminus is inactive (Prigent et al 1992). However 
Teraoka et al found that active DNA ligase I could be expressed in E. coli when the 
only alteration present was a threonine residue inserted immediately 3' of the 
initiator methionine. Obviously, small changes at the N-terminus of this enzyme can 
affect its activity. However, these experiments were carried out in E. coli, and 
Prigent et al also showed that the inactive enzyme could be activated by casein 
kinase II. This kinase is present in all mammalian cells and would probably also 
phosphorylate the FLAG DNA ligase I. A further difficulty is that the N-terminus of 
DNA ligase I is blocked, presumably due to post-translational modification 
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(Tornkinson et al 1990). If the presence of FLAG affects this modification then it is 
possible that it could also affect enzyme activity. In view of the fact that no 
detectable FLAG DNA ligase I was produced in the mammalian cells, while 
unmodified DNA ligase I is readily detectable it seems unlikely that any of these 
factors led to the failure of the experiment. 
In retrospect it would have been preferable to have confirmed the presence of 
a polyadenylation signal within the cDNA prior to trying to express it from a vector 
which does not provide this signal. However the failure of the experiments using the 
expression vector pDWM20 1, which provided a signal, cannot be due to the lack of 
a poly A sequence in the cDNA. This vector also failed to produce detectable 
quantities of mouse DNA ligase I protein. It seems that the separate experiments 
with the two different expression vectors failed for different reasons. The first 
experiments, using the phosphoglycerate kinase vector failed because transcription 
from the plasmid was low (figure 5.6) and no detectable protein was produced. The 
second experiments probably failed because mouse DNA ligase I mRNAs without a 
poly A tail are probably too unstable to be translated (Jackson and Standardt 1990). 
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CHAPTER 6 
MOUSE DNA LIGASE I GENE STRUCTURE 
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Two mutations have been identified in the DNA ligase I gene of the human 
cell line 46BR (Barnes et al 1992b), both of which have a detrimental effect on DNA 
ligase I activity. Understanding of how these mutations give rise to all the 
abnormalities which were observed in the patient from whom the cell line was 
derived could potentially be gained from a mouse model for DNA ligase I 
deficiency. In order to create a mouse model, one of the 46BR mutations must first 
be introduced into the mouse DNA ligase I gene in embryonic stem cells by gene 
targeting. The first mutation, G1u566 to Lys, is at the active site of the enzyme, 
rendering it completely inactive, and could therefore be lethal in a homozygote. 
However the enzyme with the second mutation, Arg771 to Trp, retains residual 
activity and cells expressing only this mutant form are viable (Barnes et al 1992b). 
Consequently the Arg77 1 to Trp mutation was selected as the best candidate for 
gene targeting experiments. 
In order to target the mouse gene, some structural information was first 
required and this chapter describes investigation of the mouse DNA ligase I gene 
structure. This was done at a preliminary level to provide information enabling 
isolation of a mouse genomic fragment containing sequence equivalent to the site of 
the Arg771 to Trp mutation identified in 46BR. 
6.1 Southern Hybridisation Analysis 
Mouse DNA ligase I cDNA was used to investigate the structure of the 
mouse DNA ligase I gene by hybridisation to mouse genomic DNA. DNA was 
prepared from the embryonic stem cell line E14TG2a and cut with BamHI, EcoRI or 
Hindill. A Southern blot of this restricted DNA was probed with full-length mouse 
DNA ligase I cDNA which revealed a complex pattern of bands (figure 6.1, table 
6.1). Eight BamHI fragments of sizes 9.4kb, 7.2kb, 6.4kb, 3.9kb, 3.6kb, 1.9kb, 1.2kb 
and 1.1kb, five EcoRI fragments of sizes 13.5kb, 10.0kb, 5.9kb, 5.2kb and 4.5kb, 
and seven Hindlil fragments of sizes 10.7kb, 6.7kb, 4.2kb, 3.9kb, 2.1kb, 1.8kb and 
1.7kb. The bands are of different intensities, not because of partial digestion, but due 
to varying amounts of coding region in each fragment allowing differing amounts of 
cDNA probe to bind. Totalling the sizes of the bands in each digest suggests the 
mouse gene covers 3 1-39kb of DNA. 
For comparison, genomic DNA was prepared from the human cell line HeLa 
and also digested with BamHI, EcoRI and Hindlil. This DNA was blotted and 
probed with full-length human DNA ligase I cDNA (figure 6. 1), disclosing a 
different, but equally complex pattern of bands. Three BamHI fragments of sizes 
139 
Figure 6.1: Southern blot of mouse (E14TG2a) and human (HeLa) genomic DNA 
digested with BamHI, EcoRI and Hindlil and probed with mouse and human DNA 




BamHI EcoRl Hindlil 
	













Table 6.1: Genomic Fragments Hybridising to Mouse DNA Ligase I cDNA and cDNA 
Subfragments. 
Hybridising  
Fragments (kb)  
Probe BamHl EcoRI Hindifi 
mouse DNA ligase 9.4 13.5 10.7 
IcDNA 7.2 10.0 6.7 
6.4 5.9 4.2 
3.9 5.2 3.9 




0.6kb EcoRI/PstJ 7.2 5.9 10.7 
6.4 4.5 6.7 
0.5kb PstIfBamHI 7.2 10.0 10.7 
3.9 4.5 3.9 
0.35kb 3.6 10.0 10.7 
BamHIfPvull  3.9 
0.6kb Pvull/Sall 9.4 10.0 10.7 
3.6 5.2 
1.9  
0.35kb SaII/Pvull 9.4 13.5 10.7 
5.2 1.8 
0.4kb Pvufl/PstJ 9.4 13.5 2.1 
1.2 1.8 
1.7 
0.5kb PstI/EcoRI 3.9 13.5 4.2 
1.1 1.7 
10.7kb (probably an unresolved multiple band), 6.7kb and 3.7kb, seven EcoRI 
fragments of sizes 10.7kb, 7.5kb, 5.3kb, 4.4kb, 3.6kb, 3.3kb and 2.5kb (the same 
pattern as seen with 46BR genomic DNA, chapter 3, figure 3.2), and two HindIll 
fragments of about 40kb and 18.5kb in size. The size of the largest HindIll fragment 
is approximate since the largest size marker used was 23.13kb. Other workers have 
observed a different pattern of BamHI, EcoRI and Hindill fragments within the 
human DNA ligase I gene (Barnes et al 1992a, Noguiez et al 1992). They have 
found that the human gene consists of 28 exons spanned by four BamHI fragments, 
seven EcoRI fragments and five Hindlil fragments (figure 6.2). Apart from the 
different numbers of human gene fragments, very few of the fragments are related in 
size. For, example, figure 6.1 shows three BamHI fragments of 10.7kb, 6.7kb and 
3.7kb, while the published human gene structure has four BamHI fragments, all of 
which are more than 10kb in size. The discrepancies may have arisen because the 
human DNA came from different sources arid partly also because of inaccuracies in 
measuring fragment sizes from Southern blots. Overall, when the bands are added 
up, it seems from these results that the human gene occupies 31.8 to about 60kb of 
DNA, which is consistent with the accurately determined value of 53kb (Noguiez et 
al 1992). 
In order to determine how the mouse genomic fragments relate to the mouse 
cDNA it was necessary to work out how they are organised within the gene. To this 
end the mouse cDNA was cut into sub-fragments (figure 6.3) and each used in turn 
to probe the genomic DNA. The results from this analysis are summarised in table 
6.1. 
Initially, the 5' 0.6kb EcoRIIPstI fragment of the cDNA was used as a probe 
(figure 6.4a). It hybridised to the 7.2kb and 6.4kb BamHI fragments, to the 5.9kb 
and 4.5kb EcoRl fragments and to the 10.7kb and 6.7kb HindlIl fragments, which 
must therefore be at the 5' end of the gene. This shows that the 0.6kb of 5' cDNA 
sequence spans two genomic fragments. It follows that there must be an intron 
interrupting this segment of sequence since the cDNA itself does not contain any 
Bam}H, EcoRI or Hindifi sites in this region. 
Next, the DNA was probed with the 0.5kb PstIfBamHI fragment (figure 
6.4a), which bound to the 7.2kb and 3.9kb BamHI fragments, to the 10.0kb and 
4.5kb EcoRl fragments and to the 10.7kb and 3.9kb HindIll fragments. This allowed 
the first few fragments of the gene to be arranged in order. Both probes used so far 
bound to the 7.2kb BamHI fragment, but only the first probe bound to the 6.4kb 
BamHI fragment, therefore these fragments are ordered 5'-6.4kb-7.2kb-3.9kb-3'. 











Figure 6.3: Restriction map of mouse DNA ligase I cDNA. Each fragment shown 
was used as a probe. The EcoRI sites are not within the cDNA itself, but are present 
within the adaptors ligated onto the cDNA ends during cDNA synthesis. Drawn to 
scale. Sizes are given in kb. 
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Figure 6.4a: Mouse genomic DNA probed with 0.6kb EcoRI/PstI and 0.5kb 
PsU/BamHI fragments of mouse DNA ligase I cDNA. The Southern blot of mouse 
genomic DNA digested with BamHJ, EcoRI and HindIll (figure 6.1) was stripped of 
probe and reprobed with the 0.6kb EcoRI/PstI fragment. A similar Southern filter 
was probed with the 0.5kb PstI/BamHI fragment. Molecular weight marker sizes are 
given in kb. For reference, the mouse DNA ligase I cDNA restriction map (from 
figure 6.3) is reproduced. 
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5.9kb-4.5kb-10.Okb-3'. The HindIII fragments are ordered 5'-6.7kb-10.7kb-3.9kb-3' 
because the two probes overlapped on the 10.7kb fragment. 
The 0.35kb BamHJIPvuII cDNA fragment hybridised to the 3.6kb BamHI 
fragment, to the 10.0kb EcoRl fragment and to the 10.7kb and 3.9kb HindIll 
fragments (figure 6.4b). Therefore the fourth BamHI fragment is the 3.6kb fragment, 
while there was no new information on the order of the EcoRI fragments. The 
reappearance of the 10.7kb HindlIl band was somewhat confusing but re-
examination of the original pattern (figure 6.1) showed that this band is very intense 
and is possibly a doublet. This extended the order of the Hindlil fragments to 5'-
6.7kb- 10.7kb-3 .9kb- 10.7kb-3'. 
Next, the 0.6kb PvuIIlSalI fragment was used as a probe (figure 6.4b). It 
bound to the 9.4kb, 3.6kb and 1.9kb BamHI fragments, to the 10.0kb and 5.2kb 
EcolU fragments and to the 10.7kb HindIll fragment. The order of the BamHI bands 
became 5'-6.4kb-7.2kb-3.9kb-3.6kb-9.4/1.9kb-3' and the order of the EcoRI 
fragments became 5'-5.9kb-4.5kb-10.Okb-5.2kb-3'. This probing also confirmed that 
there are indeed two 10.7kb HindIll fragments. 
Then the Southern was probed with the 0.35kb SalJJPvuII cDNA fragment 
(figure 6.4c). It hybridised to the 9.4kb BamHI fragment, to the 13.5kb and 5.2kb 
EcoRI fragments and to the 10.7kb and 1.8kb HindHI fragments. Therefore the order 
of the BamHI fragments became 5' 6.7kb-7.2kb-3.9kb-3.6kb-1.9kb-9.4kb-3', the 
complete order of the EcoRI fragments is 5'-5.9kb-4.5kb-10.Okb-5.2kb-13.5kb-3', 
and the HindIll pattern was extended to 5'-6.7kb-10.7kb-3.9kb-10.7kb-1.8kb-3'. 
When the DNA was probed with the 0.4kb PvuIIIPstI fragment (figure 6.4c), 
it picked up the 9.4kb and 1.2kb BamHI fragments, the 13.5kb EcoRl fragment and 
the 2.1kb, 1.8kb and 1.7kb HindHI fragments. The BamHI band pattern became 5'-
6.4kb-7.2kb-3.9kb-3.6kb- 1 .9kb-9.4kb- 1 .2kb-3' and the Hindlil pattern was 
lengthened to 5'-6.7kb- 10.7kb-3.9kb-l0,7kb- 1 .8kb-2. lkb/1 .7kb-3'. 
Finally, the 3' 0.5kb PstIfEcoRI cDNA fragment was used (figure 6.4c), 
revealing BamHI 3.9kb and 1.1kb fragments, the EcoRl 13.5kb fragment and 
HindIll 4.2kb and 1.7kb fragments. This shows that there is apparently a second 
3.9kb BamHI fragment. Unexpectedly, this probe did not pick up the 1.2kb BarnHI 
fragment which hybridised to the 0.4kb PvuIIJPstI cDNA fragment; It is therefore 
probable that the PstI site is very close to the 3' end of the exon within the 1.2kb 
BamHI fragment or else very close to the 5' end of the exon contained within the 
downstream BamHI fragment. This would mean that there is not enough homology 
on one side of the PstI site for hybridisation to occur and the cDNA probes used 
would therefore not detect a common fragment. The final pattern of BamHI bands is 
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Figure 6.4b: Southern blot of mouse genomic DNA digested with BamBI, EcoRI 
and HindIll (figure 6.1) stripped and reprobed with 0.35kb Bani}il/Pvull and 0.6kb 
Pvull/Sall fragments of mouse DNA ligase I cDNA. Molecular weight marker sizes 
are given in kb. The 3.6kb BamHI fragment to which the 0.6kb Pvull/SalI probe 
hybridised is not visible in this figure, although it could be seen on the original 
autoradiogram. For reference, the mouse DNA ligase I cDNA restriction map (from 
figure 6.3) is reproduced. 
Figure 6.4c: Southern blot of mouse genomic DNA digested with BamHI, EcoRI and 
Hindifi (figure 6.1) stripped and reprobed with 0.35kb SalI/PvuII, 0.4kb Pvull/PstI 
and 0.5kb PstI/EcoRI fragments of mouse DNA ligase I cDNA. Molecular weight 
marker sizes are given in kb. The 9.4kb BamHI fragment to which the 0.4kb 
PvuH/PstI probe hybridised is barely visible in this figure, although it could be seen 
on the original autoradiogram. For reference, the mouse DNA ligase I cDNA 
restriction map (from figure 6.3) is reproduced. 
Eco RI 	Pstl 	BamHl Pvull 	Sail Pvuil 	PstI 	EcoRl 
5 11 	 I I 	I I 	I I 1 3 1 
I 	I 	I 	I 	I 	I 





BamHl EcoRi HindIll 
	









Eco RI 	PstI 	BamHI PvuII 	Sail PvulI 	PstI 	EcoRl 
5 I I I 	I I 	I I 13'  
I 	I 	I 	I 	I  
0.6 	0.5 	0.35 0.6 	0.35 
I
0.4 	0.5 
0.3 5kb SaII/PvuII 	0.4kb PvuIl/PstI 
BamHI EcoRl Hindlil 	BamHI EcoRl Hindlil 
	
23.130— 	 - -- - 
9.419— 	 . 
6.559— 	 A i' 
.-, 
4.371 - 
0.5kb  PstI/EcoRI 













5 '-6.4kb-7 . 2kb-3 .9kb-3 .6kb-i .9kb-9.4kb- 1 .2kb-3 .9kb/i. ikb-3'. The order of the 
3.9kb and 1.1kb fragments could not be resolved by these probings. The complete 
HindlEll fragment pattern is 5'-6.7kb- 1O.7kb-3.9kb- iO.7kb- i .8kb-2. 1kb-i .7kb-4.2kb-
3'. 
All three complete individual fragment patterns are shown in figure 6.5. In 
this figure, a convention of one exon per hybridising fragment has been used. Exons 
have been placed so that the BamHI, EcoRl and Hindifi sites lie within introns since, 
with the exception of one BamHI site, the cDNA itself contains no sites for these 
enzymes. Therefore any sites within the gene cannot be in the coding region and 
must lie in introns. The exons are not necessarily single since they may contain other 
introns which, lacking a recognition site for one of the three restriction enzymes 
used, would not have been detected. The PstI site at the 3' end has been placed 
within the 1.2kb BarnHI fragment, although it could equally be in the next fragment 
downstream. 
6.2 Mouse DNA Ligase I Gene Map 
A map of the mouse DNA ligase I gene was obtained by fitting together the 
three restriction patterns (figure 6.6). In this final map the gene has eleven exons. 
This is a minimum number for reasons already explained. Exact positions of some of 
the restriction sites with respect to the exons have yet to be determined, for example, 
the 3' end of the 9.4kb BamHI fragment could lie between the seventh and eighth 
exons, or between the eighth and ninth exons. 
Throughout this analysis there was no evidence for a mouse DNA ligase I 
pseudogene which would have been detectable as a single fragment hybridising to all 
(or most) of the probes used. Therefore all fragments identified are authentic 
segments of the gene. The sum of the BamHI fragments suggests that the gene is 
38.6kb in size, the sum of the EcoRI fragments suggests a size of 39.1kb and the 
sum of the HindHI fragments suggests a size of 41.8kb. These values are all in close 
agreement, which indicates that there are probably no large intron fragments missing 
from the gene map which is therefore probably complete. Overall then, the gene 
occupies 3 9-42kb of DNA. This figure has increased from the initial estimate of 31-
39kb due to the presence of doublet bands. 
When what is known of the mouse gene structure is compared with the 
human gene structure (Noguiez et al 1992, figure 6.6), it appears that the mouse 
gene is somewhat smaller than the human gene which occupies 53kb of DNA in 
contrast to 39-42kb. The human gene has 28 exons, while only eleven were 
identified in the mouse gene. However, the nature of the analysis meant that mouse 
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Figure 6.5: Order of mouse DNA ligase I genomic fragments. Individual patterns are 
shown for BamHI, EcoRI and HindIII digested DNA. No attempt has been made to 
reconcile numbers of exons, positions of restriction - sites from the cDNA etc. 
Fragments are drawn to scale. Hatched boxes indicate exons. 
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Figure 6.6: Mouse DNA ligase I gene map. The arrangement of BarnHI, EcoRl and 
HindIll restriction fragments within the gene is shown. Alternative positions for 
some restriction sites are given, based entirely on the Southern analysis results, 
without taking fragment sizes into account. Hatched boxes indicate exons. For 
comparison, the structure of the human DNA ligase I gene (from figure 6.2) is 
reproduced (not to the same scale). 
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introns were only detectable by the presence of a BamHI, EcoRI or Hind][11 site and 
it is probable that many introns went undiscovered because they lack one of these 
sites. Given the very high degree of sequence conservation between human and 
mouse DNA ligase I cDNAs, it is likely that the exon structures are identical, with 
both genes having 28 exons, and therefore size differences between the two genes 
must be due to varying intron dimensions. This has been observed in other genes. 
For example both the human and mouse HPRT genes have nine exons, while the 
introns vary in size, so that the human gene occupies 42kb of DNA (Kim et al 1986) 
and the mouse gene occupies 33kb (Melton et al 1984). 
By knowing which cDNA features lie in which of the cDNA fragments used 
to probe the gene structure, it is possible to determine where these features are 
located in the gene. For example, the ATP binding site and site equivalent to the first 
46BR mutation (G1u566 to Lys) are positioned immediately 3' of the Sall site in the 
cDNA and therefore lie within the 9.4kb BamHI, 5.2kb EcoRl and 10.7kb HindlIl 
genomic fragments. 
At the time this analysis was carried out no sequence information was 
available for the region of mouse DNA ligase I cDNA around the site of the second 
46BR mutation (Arg771 to Trp). However a number of the restriction sites within 
the mouse cDNA are apparently conserved between mouse and human cDNAs 
(figure 6.7). In particular, there is a Pvull site 0.9kb from the 3' end of both mouse 
and human cDNAs. The site of the Arg77 1 to Trp mutation lies downstream from 
this PvuII site in the human DNA ligase I sequence. If this PvuII site corresponds to 
the mouse Pvull site at the same position then the site of the Arg77 1 to Trp mutation 
is contained within the 13.5kb mouse EcoRI genomic fragment. It was subsequently 
confirmed by sequencing that the PyuII site is conserved between human and mouse 
DNA ligase I cDNAs, and therefore that the 13.5kb EcoRl genomic fragment is 
indeed the fragment of interest. 
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Figure 6.7: Comparison of restriction sites between human and mouse DNA ligase I 
cDNAs. Both cDNAs are drawn to scale. Sizes are given in kb. The Pvufl site 0.9kb 
from the 3' o end of both human and muse cDNAs is shown in bold type. 
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CHAPTER 7 
CLONING OF A GENOMIC FRAGMENT CONTAINING THE 
ARGININE TO TRYPTOPHAN MUTATION SITE 
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Sequence corresponding to the site of the Arg77 1 to Trp mutation identified 
in the human cell line 46BR should be present within a 13.5kb EcoRl fragment of 
the mouse gene. This chapter concerns cloning of this 13.5kb genomic fragment and 
identification of an arginine codon equivalent to human Arg77 1. 
7.1 Cloning of Mouse DNA Ligase I Genomic Fragments 
There are five mouse DNA ligase I EcoRI genomic fragments, of sizes 
13.5kb, 10.0kb, 5.9kb, 5.2kb and 4.5kb. For construction of a library, the two largest 
fragments are suitable for cloning into a bacteriophage 2 replacement vector which 
accepts inserts in the size range 7-20kb. However the smaller fragments are more 
likely to be clonable in an insertion vector. The range in fragment sizes consequently 
prevents the entire gene being cloned from a single EcoRI library. Since the 13.5kb 
fragment was the one of interest, a genomic library of mouse EcoRl fragments was 
therefore constructed in the replacement vector X EMBL4 (Frischauf et al 1983). 
This library was expected to allow cloning of the two largest DNA ligase fragments, 
with the possibility of also obtaining some of the smaller fragments as multiple 
inserts with other fragments. 
The library was screened using full-length mouse DNA ligase I cDNA as a 
probe. The full-length cDNA was used in order to be able to detect any of the DNA 
ligase I genomic fragments which might be present. Ligase signals were detected at a 
frequency of 1/100,000 and seven clones giving a positive signal were plaque 
purified. Of these seven, five contained a 13.5kb fragment and two contained a 
10.0kb fragment (figure 7.1a). Five of the clones also carried a second fragment, 
ranging in size from about 1.5kb to 4kb. None of the clones appeared to have any of 
the three smaller EcoRI DNA ligase I genomic fragments as inserts. 
The identity of the clones was confirmed by probing Southern blots of the 
genomic clones with probes specific for the 13.5kb and 10.0kb ligase genomic 
fragments. A 0.4kb PvuIL'PstI fragment from the 3' end of the mouse DNA ligase I 
cDNA is specific for the 13.5kb fragment (chapter 6, figure 6.4c) and hybridised to 
this fragment in five of the clones (figure 7. lb). When a 0.35kb BamHIIPvull cDNA 
fragment specific for the 10.0kb genomic fragment (chapter 6, figure 6.4b) was used 
as a probe it hybridised to a 10.0kb fragment in the remaining two clones (figure 
7. ic). No. additional ligase-specific fragments were detectable by probing with the 
full-length mouse DNA ligase I cDNA (figure 7. id). The 13.5kb fragment was sub-
cloned into the EcoRI site of pUC8 and, since this fragment was the one of interest, 
nothing further has yet been done with the 10.0kb fragment. 
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Figure 7.1: DNA ligase I genomic clones, a) Inserts cut out of ) EMBL4 cloning 
vector with EcoRI and elecirophoresed through a 0.8% agarose gel. Positions of the 
19.9kb and 8.8kb ? arms, and 10.0kb and 13.5kb inserts are indicated. Tracks 3 and 
4 show the 10.0kb fragment. All other tracks show the 13.5kb fragment. Multiple 
inserts are visible in tracks 2, 3, 4, 5 and 6. Equivalent fragments in different lanes 
have not migrated evenly, possibly due to unequal loading of the gel. b) Southern 
blot of the DNA gel probed with the 0.4kb Pvull/PstI fragment of mouse DNA 
ligase I cDNA specific for the 13.5kb genomic fragment. This fragment is visible in 
tracks 1, 2, 5, 6 and 7. A second band visible in track 6 above the 13.5kb band is 
probably due to incomplete cutting. c) Southern blot of the DNA gel stripped and 
reprobed with the 0.35kb Bam}ll/Pvull fragment of mouse DNA ligase I cDNA 
specific for the 10.0kb genomic fragment. This fragment is visible in tracks 3 and 4. 
Again, the two extra larger bands are probably due to incomplete cutting. d) 
Southern blot of the DNA gel stripped and reprobed with full-length mouse DNA 
ligase I cDNA. Extra bands are probably due to partial digestion. STD: molecular 
weight markers 23.1kb, 9.4kb, 6.6kb, 4.4kb, 2.3kb, 2.0kb, 1.4kb, 1.1kb, 0.9kb. 
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7.2 Restriction Mapping and Intron/Exon Structure of the 13.5kb EcoRl 
Genomic Fragment 
More detailed information was required on the structure of the 13.5kb 
genomic clone before targeting of the mouse DNA ligase I gene could commence. 
Initially, several restriction enzymes with rare recognition sites were tested for 
cutting the 13.5kb genomic fragment and, and in addition to those sites already 
identified, sites were found for the enzymes BstEII, EcoRV, KpnI and SstI (figure 
7.2). 
The Southern blotting analysis carried out previously (chapter 6) had shown 
that the 13.5kb fragment contains the last five of the exons which were detectable in 
the mouse DNA ligase I gene (chapter 6, figure 6.6). For the purposes of this 
analysis, these exons are numbered from 7 to 11, although there are almost certainly 
many more than eleven exons present within the gene (chapter 6). Three of these 
exons still remained to be positioned unambiguously within the fragment with 
respect to restriction sites. Figure 7.3 shows that exon 8 has three possible positions, 
exon ten has two, and exon eleven has four possible locations. To identify the exact 
locations of these exons, the 13.5kb genomic clone was cut with each enzyme for 
which a recognition site has been identified (except BstEII and EcoRV, because 
these sites are located very close to an SstI site), singly, and also in double digests. 
The resulting fragments were probed with a 1.25kb Sall/EcoRl (3') fragment of 
mouse DNA ligase I cDNA which hybridises to exons 7 to 11 of the mouse DNA 
ligase I gene. (figure 7.4). The reasoning behind this experiment was that only those 
restriction fragments containing exons would hybridise to the probe. Figure 7.3 
shows that there are three possible locations for exon number 8. It could lie within a 
0.6kb HindIIIJSstI fragment, in a 0.8kb SstJJBamHI fragment or within a 0.7kb 
BamHIIHindIII fragment. These possibilities were resolved by digestion with 
BamHI and HindIll which produced 9 fragments (figure 7.4a). Two of these 
fragments are of interest, a 1.3kb HindIIIIBamHI fragment which contains the first 
two possible locations for exon 8, and the 0.7kb BamHIIHindllI fragment which is 
the third possible location for exon 8. The 1.3kb band did not hybridise to the probe, 
while the 0.7kb fragment did hybridise (figure 7.4b). Exon number 8 therefore lies 
within the 0.7kb BamHJJHindIll fragment (Figure 7.5). There are two KpnI sites 
within the 13.5kb fragment, producing KpnI fragments of 14.7kb and 1.4kb from the 
whole plasmid (13.5kb fragment in pUC8). Figure 7.3 shows that exon 10 could be 
located in two positions, either within the 1.4kb KpnI fragment or upstream of it. 
When the KpnI fragments were blotted and probed with the mouse DNA ligase I 
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Figure 72: Map of the 13.5kb EcoRl genomic fragment of mouse DNA ligase I 
showing restriction sites. For reference, the sizes of all BamHI and HindilI 
restriction fragments are given. The sizes of some of these fragments are slightly 
different to those given in chapter 6 because cloning of the 13.5kb EcoRl genomic 
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Figure 7.3: Map of the 13.5kb EcoRl genomic fragment of mouse DNA ligase I 
showing restriction sites. This map gives information about the clone prior to any 
Southern blotting analysis to precisely locate exons. Exons for which the position 
with respect to restriction sites is known are filled in, others are hatched and the 
alternative positions given. For reference, the sizes of all BamBI and HindIII 
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Figure 7.4: Mapping positions of the exons within the 13.5kb genomic fragment. a) 
The whole plasmid (13.5kb EcoRl fragment cloned into the EcoRI site of pUC8) 
was cut with BamHI, Hindill, KpnI, SstI, BamHIfHindIII, Bamih/KpnI, 
Bani}1J/SstI, HindIllIKpnI, HindIll/SstI and Kpnh/SstI and electrophoresed through a 
0.8% agarose gel. b) Southern blot of the DNA gel probed with a 1.25kb Sall/EcoRl 
(3') fragment of mouse DNA ligase I cDNA. Sizes are given in kb.The bands in the 
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Figure 7.5: Final map of the 13.5kb EcoRl genomic fragment of mouse DNA ligase 
I. This fragment is shown cloned into pUC8 (not to scale) and the positions of 
BamHI and Hindifi sites within the polylinker are indicated. Restriction fragment 
sizes are given for reference to figure 7.4. Hatched boxes indicate exons. Sub-
fragments used for subsequent PCR analysis are indicated by 1, 2, 3 and 4. The 
position of an arginine residue equivalent to the site of the Arg77 1 to Tip mutation is 
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cDNA, only the 14.7kb fragment hybridised to the probe (figure 7.4b). The 1.4kb 
KpnI fragment therefore does not contain any exons and exon 10 must consequently 
be located in the position upstream of this fragment (figure 7.5). Similarly, there are 
four possible positions for exon 11 (figure 7.3). However two of these locations can 
be eliminated because they lie within the 1.4kb KpnI fragment which has already 
been shown not to contain any exons. The remaining two possibilities are (1) within 
a 1.0kb SstI fragment which overlaps the 1.4kb KpnI fragment, and therefore to the 
3' side of the KpnI site contained therein, and (2) within a 2.4kb SstI/HindIII 
fragment. Digestion of the plasmid with SstI and Hindill produced 9 fragments 
(figure 7.4a), including the 1.0kb and 2.4kb fragments of interest. Only the 1.0kb 
fragment hybridised to the probe, while the 2.4kb fragment did not. This therefore 
positions exon 11 within the 1.0kb SstI fragment and, since it must lie 3' of the KpnI 
site, the exon is contained in the 0.6kb KpnJJSstI fragment. The locations of these 
three exons were confirmed by all the other digests. There were however two 
problems with this analysis. First, the HindllhJKpnI digest was only a partial and was 
therefore not used. Secondly, hybridisation of exon number 7 was difficult to detect 
in many cases. This exon is present in a 1.6kb fragment from the 5' end of the 13.5kb 
EcoRI genomic fragment (figure 7.3). Throughout the analysis in chapter 6 this 
fragment hybridised very faintly, but always visibly to mouse DNA ligase I cDNA 
probes. However, during this analysis, hybridisation of the 1.6kb Hindifi fragment 
was never detected. Also, in other digests which produced a fragment containing 
only this exon and no others, the fragment containing exon 7 only hybridised to the 
probe very faintly. For example a BamHI digest produced a 6.9kb fragment 
containing exon number 7, which bound to the probe much less than the other 
hybridising fragments (figure 7.4b). That this fragment hybridises at all indicates 
that it must contain an exon, and a BamHIIHindIII double digest which cuts this 
fragment down to 3.9kb Hindu, 1.6kb HindIll and 1.3kb HindllhJBarnHI fragments 
demonstrates that it is not either of the fragments flanking the 1.6kb HindIll 
fragment that carries the exon, since these do not hybridise either (figure 7.4b). 
BamHI/KpnI, BamHIJSstI, KpnIJSstI and SstI digests produce the same result. 
Therefore the results from chapter 6 indicate that exon 7 must be located within the 
1.6kb fragment, while the results presented in this chapter are consistent with this 
location, but do not actually confirm it. 
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7.3 Identification of the Arginine to Tryptophan Mutation Site in the 13.5kb 
Mouse EcoRI Genomic Fragment 
Having obtained further structural information for the 3' end of the gene, the 
next step was to locate the actual site within the mouse gene equivalent to Arg77 1 in 
human DNA ligase I. Since no relevant mouse DNA ligase I sequence was available, 
twenty base primers (887Y and 888Y) were designed from the human cDNA 
sequence (Barnes et al 1990, Noguiez et al 1992) specific for each end of the 153bp 
human exon 23 which carries the Arg77 1 to Trp mutation. PCR was performed using 
these primers on the 13.5kb genomic fragment itself, as well as upon four sub-
fragments from the region containing the eighth, ninth and tenth mouse exons 
(fragments 1, 2, 3 and 4, figure 7.5). A PCR product of about 150 bp was seen in the 
presence of the whole 13.5kb genomic fragment as well as sub-fragments 2 and 3 
(figure 7.6). The only exon common to these two fragments is the eighth exon, 
which therefore contains sequence equivalent to human exon number 23. There must 
be a very high degree of homology between mouse and human sequences in this 
region, as shown by the fact that the human-specific primers hybridised to the mouse 
DNA, and produced an amplified DNA product which co-migrates on a gel with the 
PCR product from human exon 23 (data not shown). 
The same primers were used to sequence the mouse DNA corresponding to 
human exon 23 (figure 7.7). The sequence obtained was identical to that obtained by 
sequencing of the mouse DNA ligase I cDNA in this region. Of 153 bases there are 
17 changes between mouse and human resulting in only two alterations at the amino 
acid level. Both alterations are conservative, a change from alanine to serine and 
from aspartate to glutamate. The other nucleotide changes are almost all silent third 
base alterations, therefore this region of DNA ligase I is extremely highly conserved 
and is probably crucial for proper enzyme function. It is therefore unsurprising that 
the Arg77 1 to Trp mutation identified here in 46BR adversely affects human DNA 
ligase I activity. There is an arginine codon in the mouse sequence in exactly the 
same position as that at which the mutation occured in 46BR and it is highly 
probable that an equivalent alteration in the mouse gene would have the same 
detrimental effect. 
Sequencing also indicated that, for this exon at least, the intron/exon 
boundaries are identical to those in the human gene (Noguiez et al 1992), with the 
flanking nucleotides also being homologous. This supports the theory that the mouse 
and human DNA ligase I genes both have the same exon structure, with 28 exons in 
each. The sequenced exon conforms to the GT-AG splicing concensus (Padgett et al 
1986) with a GT splice donor dinucleotide and an AG acceptor. 
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Figure 7.6: PCR analysis of the 13.5kb EcoRl genomic fragment of mouse DNA 
ligase I. DNA fragments plus primers were denatured for lmin at 94°C, annealed for 
30s at 690C and synthesis was carried out at 72 0C for 30s. Control reactions were 
carried out with no DNA or with no primers. C: control, ML: PCR on mouse DNA 
ligase I cDNA, 13.5: PCR on the 13.5kb EcoRl genomic fragment of mouse DNA 
ligase I, 1, 2, 3 and 4: PCR on genomic sub-fragments (see figure 7.3). The exon 23-
specific product is indicated by an arrow. Sizes are in kb. 








Figure 7.7: Nucleotide and amino acid sequence of human exon 23 and the 
equivalent mouse exon. Human Arg771 is circled. Base and amino acid alterations 
are underlined. Flanking bases from the introns are given in lower case. 
L K K D Y L D G V G DT L D L V V 
human: CCagCTGAAGAAGGACFACCTGATGGCGTGGGTGACACCCTGGACCCJTTG 
mouse: CCagCTGAAGAAGACTACCTGACGIGTGGGTGACACTCTGGACC -1- GTyJTG 
L K K D Y L D G V 0 DT L D L V V 
I GA Y 	G 	0 K®A G 	YG.G F 
human: ATCGGCGCCTACCTGGGCC0GGQGAAGCGGGCCGCCGTACJj17 
mouse: 
I GA Y 	G 	G K R A G 	Y 	G F 
LL A S Y D ED SE EL Q A IC K 
human: CTGCTGGCCTCCTACGACGAGGACAGTGAGGAGCTGCAGGCCATATGCAAGCtg 
mouse: CTGUGGCTCCTACGAIGAGGAAGTGMGAGCUCAGGCjATATGCAGgtcctg 
LL A A Y D E E SE EL Q A IC K 
CHAPTER 8 
GENE TARGETING AT THE MOUSE DNA LIGASE I LOCUS 
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A deleterious mutation is present on each allele of the DNA ligase I gene in 
the patient from whom the cell line called 46BR was derived, and these cells are 
therefore deficient in DNA ligase I. This deficiency has given rise to a number of 
abnormalities, both clinical and cytological, some of which overlap with the 
symptoms of Blooms syndrome, also shown to involve DNA ligase I deficiency. A 
mouse model for BS could prove invaluable in studying the disease, however no 
mutation has yet been identified in cell lines established from these patients. It is 
therefore not yet possible to carry out gene targeting experiments to generate a 
model of classical BS. 46BR may represent a variant form of Blooms syndrome, but 
whether this is true, or not, awaits identification of the underlying defect in BS. If 
this is the case, introduction of one of the mutations identified in 46BR. into the 
mouse DNA ligase I gene could yield a model for a form of Blooms syndrome. 
However, even if the defects in the cell line 46BR are unrelated to Blooms syndrome 
and represent a unique case, it is of interest to generate a mouse model for DNA 
ligase I deficiency. 
A 13.5kb EcoRl fragment of the mouse DNA ligase I gene containing an 
arginine codon equivalent to human Arg77 1 has been cloned and the site of this 
codon within the fragment has been identified. In the human cell line 46BR this 
codon has mutated on one allele of the gene, and now specifies tryptophan, an amino 
acid alteration which significantly reduces the activity of the enzyme. This EcoRI 
fragment is to be used to introduce an arginine to tryptophan mutation in the 
equivalent position to that in 46BR by gene targeting. This is to be done in two steps. 
First a null mutation will be introduced, knocking out one allele of the gene 
completely, by removal of several exons, followed by a second targeting step in 
which the exons will be restored, but specifying an Arg to Trp mutation. 
It is necessary to carry out this targeting in two steps, rather than one, 
because it would be impossible to screen large numbers of cells efficiently for a 
single base alteration. Screening for the loss of several exons and then for their 
replacement along with the mutation, is much simpler. 
Following my work on the structure of the mouse DNA ligase I gene, it was 
originally proposed that I would carry out the first targeting step. However this 
proved not to be possible, due to lack of time. This work was instead carried out by 
others in the laboratory and I would therefore like to thank Carolanne McEwan for 
construction of the vector and PCR, Anne-Marie Ketchen for cell culture work and 
Jim Selfridge for PCR, Southern analysis, embryo injection and mouse work. Since I 
did not actually do the gene targeting work myself, this chapter is intended to be an 
overview rather than a detailed description of the experiments. 
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8.1: Targeting Vector Construction 
A targeting vector was to be constructed which would remove several exons, 
including the exon carrying sequence equivalent to the human Arg77 1 to Trp 
mutation, from the 3' end of one allele of the DNA ligase I gene in mouse embryonic 
stem cells, thus creating a null mutation. Since targeting events are extremely rare, a 
method of enrichment for this happening was also required. This was to be provided 
by positive-negative selection (Mansour et al 1988) based on the method used by 
Stacey et a! in 1994. The cells in which the gene was to be targeted are male and 
HPRT-deficient, therefore a targeting vector which introduces a functional copy of 
the HPRT gene will allow cells containing the plasmid to be selected by means of 
HPRT activity. Cells which have integrated the plasmid will express functional 
HPRT and will consequently be able to grow in HAT medium, while non-expressing 
cells will die (positive selection). However, the plasmid DNA will not always 
integrate by homologous recombination, but will also integrate randomly to generate 
non-targeted HAT-resistant cells. A method of selection against random integrants is 
therefore also necessary (negative selection). Random integration generally occurs 
via DNA ends in which case the whole plasmid is inserted. Therefore if a plasmid is 
designed so that when linearised it will have a negatively selectable marker at one 
end, it should be possible to select against random integrants. In this case the marker 
to be used was the viral thymidine kinase gene. Cells expressing this gene can be 
selected against using gancyclovir which is a nucleoside analogue specific for the 
viral enzyme. 
With this in mind, the targeting vector was designed so that homologous 
recombination between two regions of homology with the mouse DNA ligase I gene 
would remove the four 3' exons and replace them with a functional HPRT minigene. 
A viral thymidine kinase gene was placed adjacent to one region of homology, 
providing selection against random integration of the plasmid. 
Targeting vector construction was as follows (figure 8.1). First, the 13.5kb 
EcoRI mouse DNA ligase I genomic fragment cloned in pUC8 was digested with 
SstI and religated. This removed two SstI fragments which carry the last four exons 
of the gene. Following SstI digestion, all but one of the BamHI sites contained 
within the 13.5kb genomic fragment had been removed. This left one BamHI site in 
the 3' untranslated region, and one in the pUC8 polylinker. The vector was next 
digested with BamHI and religated, which removed all but 1.8kb of the 3' flanking 
region. Therefore the 13.5kb genomic fragment had been modified by removal of the 
last four exons and of the 3' end. This left 3.3kb from the 5' end of the fragment, 
containing the single remaining exon, and 1.8kb of the 3' flanking region. 
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Figure 8.1: Targeting vector construction. The starting material was the 13.5kb 
EcoR! genomic fragment (open box) cloned in pUC8. This fragment contains the 
last five exons (hatched boxes) of the mouse gene. First, the plasmid was digested 
with the enzyme SstI and religated. This removed a region of DNA containing the 
last four exons. Next, the plasmid was digested with BamHI and religated, thus 
removing the Tend of the genomic fragment. A 2.7kb fragment containing an HPRT 
minigene under control of a phosphoglycerate kinase promoter (shaded boxes) was 
then cloned into the now unique SstI site. This was followed by the cloning of a 
2.8kb fragment containing a thymidine kinase gene driven by a phosphoglycerate 
kinase promoter (filled-in box) into the now unique BamHI site. It was cloned in as a 
BamHI/Bdll fusion at the upstream end of the fragment to preserve a unique Bamlil 
site at the downstream end. The resulting vector contains two regions of homology 
with the mouse DNA ligase I gene, of 3.3kb and 1.8kb. These are interrupted by the 
HPRT minigene, and a thymidine kinase gene lies 3' of the 1.8kb region of 
homology. This vector is called MLTV (mouse ligase targeting vector). Key 
restriction sites are shown. R marks the site of the codon equivalent to that 
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An HPRT minigene, with HPRT controlled by the mouse phosphoglycerate 
kinase promoter (Magin et a! 1992) was cloned into the SstI site of the modified 
genomic fragment, in place of the missing four exons. A viral thymidine kinase 
gene, also driven by the mouse phosphoglycerate kinase promoter, was cloned into 
the BamHI site by a BamIllfBclI fusion at the 5' end of the fragment and as a simple 
BamHI ligation at the 3' end, thus preserving a unique BamHI site at the 3' end of 
this marker for linearisation purposes. 
The final targeting vector, constructed in pUC8, consists of two blocks of 
homology with the endogenous mouse DNA ligase I gene, of 3.3kb and 1.8kb, 
interrupted by an active HPRT minigene, and with a viral thymidine kinase gene 
placed adjacent to the 1.8kb block of homology (figure 8.1). There are two unique 
linearisation sites within the vector, an EcoRI site at the 5' end of the 3.3kb block of 
homology, and a BamHI site at the 3' end of the thymidine kinase gene. This vector 
was designated MLTV (mouse ligase targeting vector). 
8.2: Targeting the Mouse DNA Ligase I Gene 
Figure 8.2 shows the predicted alteration of the mouse DNA ligase I gene 
following targeting with MLTV. Recombination occurs between the two regions of 
homology flanking the HPRT minigene, and a region of the endogenous DNA ligase 
I gene containing the last four exons is replaced with HPRT. In correctly targeted 
cells, no other part of the vector should be inserted into the genome and therefore the 
thymidine kinase gene is lost along with other vector sequences. The targeted gene 
consequently lacks four exons from the 3' end, but retains 3' flanking sequences. 
MLTV was linearised by EcolU digestion and introduced into mouse 
embryonic stem cells by electroporation. Transfected cells were enriched for 
targeting events by growth in HAT medium supplemented with gancyclovir. Cells 
surviving this selection were then screened for targeting of the DNA ligase I gene by 
PCR. Screening for targeted alleles of the gene was achieved using one primer 
specific for the 3' end of the HPRT minigene, and one specific for the 3' flanking 
region of the gene, 1.8kb from the predicted site of HPRT insertion (figure 8.3). 
These primers should therefore give a PCR product of 1.8kb in size. The second 
primer is specific for sequence outwith that included in the targeting vector - its 
sequence is present within the BamHI fragment deleted from the vector during its 
construction. Consequently, only correctly targeted cells can give rise to this PCR 
product since one primer is specific for vector-derived sequences, and the other is 
specific for endogenous DNA ligase I sequences. 115 clones resistant to HAT and 
Figure 8.2: Targeting the mouse DNA ligase I gene in HPRT embryonic stem cells. 
The linearised vector, MLTV, is shown lying adjacent to the homologous region of 
the mouse DNA ligase I gene. A section of the gene containing exons 8 to 11 is 
depicted as looping out since it has no homology with MLTV. Homologous 
recombination should occur between the two regions of homology, around exon 7 
and in the 3' flanking region. The result of this recombination event is shown. Exons 
8 to 11 have been lost from the gene and replaced with the HPRT minigene (shaded 
boxes). No other part of MLTV has integrated into the gene, therefore the thymidine 
kinase gene (closed box) has been lost. The resulting cells will be HPRT+ due to 
integration of the HPRT minigene and will therefore be able to grow in HAT 
medium. They will also be resistant to gancyclovir since the thymidine kinase gene 
is not present. 
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Figure 831i Screening for targexingevents at the mouse DNA ligase I locus. A map 
of the I3.5kj)E'coRI., genomic fragment used in targeting vector construction is 
shown. hesi.zsândpositions of EcoRI, BamHI and Hind]EII restriction sites 
detectable by hybridisation to mouse DNA li:gase I cDNA are indicated. Arrows 
pointing .upstran indicate that the 10.7kb 11indll and 9.4kb BarnHI fragments 
overlap, with the 1.5kb EcoRI fragment and the next EcoRl fragment upstream. The 
structure of part the modified gene, following targeting, is shown below. This 
section 'of thdgne is all that is. left of the 13.5kb fragment (see figure 8.2 for 
detaits). The remaining hybridising fragments . are indicated below the diagram. 
Above, the two arrows mark the positions at which the PCR primers used for 
screening will bind. One is specific for the 3' end of the HPRT minigene, while the 
other is specific for the 3' flanking region of the gene, within a BamHI/HindIll 
fragment. The 1.8kb PCR product, spanning the junction between HPRT and the 
continuing gene, is indicated. Open boxes: mouse DNA ligase I gene, hatched boxes: 
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gancyclovir were screened by this method and three gave rise to the 1.8kb PCR 
product (figure 8.4). These positives were named numbers 12, 53 and 106. 
The three positive clones were further analysed by Southern blotting. Figure 
8.3 shows the BamHI and Hindlil fragments which are contained within the 13.5kb 
EcoRI genomic clone, as well as those fragments which overlap with it. Also shown 
are the fragments which are predicted to be present following a targeting event. It 
can be seen from this figure that mouse DNA ligase I cDNA should hybridise to the 
13.5kb EcoRl fragment; 10.7kb, 1.8kb, 2.1kb, 1.7kb and 4.2kb HindlIl fragments 
and 9.4kb, 1.2kb, 1.1kb and 3.9kb BarnHI fragments from the untargeted gene. 
However, in the targeted gene, exchange of a 4.9kb internal fragment for the 2.7kb 
HPRT minigene should alter these fragment patterns. It would therefore be predicted 
that the 13.5kb EcoRl fragment would be reduced to a 11.3kb fragment, while the 
2.1kb, 1.7kb and 4.2kb HindIll fragments would disappear. Similarly, the 1.2kb, 
1.1kb and 3.9kb BamHI fragments would be lost and the 9.4kb fragment would be 
extended to a 13.1kb fragment. 
However this analysis is complicated by the fact that there are two copies of 
the gene since DNA ligase I is autosomal. Therefore all of the fragments from the 
wild-type gene will be seen in addition to those derived from the targeted gene. A 
Southern blot should consequently show a wild-type pattern of bands, but with 
additional 11.3kb EcoRli and 13.1kb BamHI fragments. The other alterations should 
be detectable as differences in band intensities. For example, in targeted cells the 
intensities of the 2.1kb, 1.7kb and 4.2kb HindHI bands should be half that of those in 
untargeted cells. 
Figure 8.5 shows the results of probing a Southern blot of genomic DNA 
prepared from each of the three clones with a 2.2kb BamHJJEcoRI fragment of 
mouse DNA ligase I cDNA (the 3' two thirds of the cDNA). Table 8.1 summarises 
the predicted and actual results from this experiment. When the DNA was digested 
with EcoRI only three bands were detectable from clones 53 and 106 as well as 
control wild-type DNA. These are 13.3kb, 10.0kb and 5.2kb in size, with the two 
smaller bands arising from parts of the gene not affected by the targeting, but 
detectable with the probe used (see chapter 6). No extra 11.3kb fragment arising 
from the targeted gene was visible. However, in the DNA from the targeted cells, the 
intensity of the 13.5kb EcoRl fragment was reduced compared to that in the DNA 
from the non-targeted cells. It therefore appears that the 13.5kb fragment was lost 
following targeting, as predicted, and it is likely that the expected 11.3kb fragment is 
present after all, probably as an unresolved band due to comigration with the 10.0kb 
fragment (since if it comigrated with the 13.5kb fragment there would be no 
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Figure 8.4: Screening for targeting events using PCR. A sample of the clones able to 
grow in HAT medium supplemented with gancyclovir is shown (numbers 50-60). 
Genomic DNA prepared from each clone was used for PCR with the primers 
described in figure 8.3. The 1.8kb product indicated by an arrow in the clone 53 
track is specific for a targeting event. Its absence in all the other clones indicates that 
they have not been correctly targeted. HM-1: genomic DNA was prepared from the 
wild type embryonic stem cell line in which the targeting experiments were carried 
out. STD: Molecular weight markers of sizes 23.1kb, 9.4kb, 6.6kb, 4.4kb, 2.3kb, 
2.0kb and 1.6kb down to 0.7kb at lOObp intervals. 
* 
STD 50 51 	52 53 54 55 	56 57 	58 59 60 HM-1 
Figure 8.5: Screening for targeting events by Southern blotting. Genomic DNA was 
prepared from each of the targeted clones identified by PCR (clones 12,53 and 106). 
DNA was then digested with either EcoRI, BamHI or Hindu, electrophoresed 
through an agarose gel, blotted and probed with mouse DNA ligase I cDNA. HM-1: 
genomic DNA was prepared from the wild type embryonic stem cell line in which 
the targeting experiments were carried out. 
EcoRl 	 BamHI 	 Hindill 
I 	 II 	 ii 








1.0kb— 	 - 
0.8kb- 
- 
Table 8.1: Genomic fragments arising from the mouse DNA Ligase I gene following 
targeting. Fragment sizes in brackets are those fragments arising from parts of the 
gene outwith the 13.5kb EcoRl fragment used in the targeting experiments. 
Fragments marked with an asterisk are those which were present at a reduced 
intensity in the DNA from targeted cells compared to non-targeted cells. 
Fragments Predicted from Fragments Predicted from Fragments 
Wild-Type Gene Targeted Gene Detected 
EcoRl 13.5kb 11.3kb 13.5kb* 
(10.0kb) (10.0kb) (10.0kb) 
(5.2kb) (5.2kb) (5.2kb) 
BamHI 9.4kb 13.1kb 13.1kb 
3.9kb (3.6kb) 9.4kb* 





HindHl 10.7kb 10.7kb 10.7kb 
4.2kb (3.9kb) 4.2kb* 




reduction in intensity). The same pattern is visible in the clone 12 track, but there is 
an additional unidentified larger fragment present. 
When the genomic DNA was digested with BamHI, seven fragments 
hybridised to the probe from clones 53 and 106. These are 13.1kb, 9.4kb, 3.9kb, 
3.6kb, 1.9kb, 1.2kb and 1.1 kb in size, with the 3.6kb and 1.9kb bands arising from 
other parts of the gene not involved in the targeting (see chapter 6). The 13.1kb 
fragment is the product expected to arise from the correctly targeted gene and is not 
present in the DNA from non-targeted cells. the other predictions are also borne out, 
since the 9.4kb, 3.9kb, 1.2kb and 1.1kb bands are all present at a reduced intensity, 
as would be expected if they were lost following targeting. The same pattern of 
bands is present in the clone 12 track, except that the predicted 13.1kb fragment is 
absent and has been replaced with an unidentified larger fragment. 
Digestion with Hind][11 produced the six bands expected to be seen, of sizes 
10.7kb, 4.2kb, 3.9kb, 2.1kb, 1.8kb and 1.7kb, with the 3.9kb fragment arising from a 
part of the gene upstream from the site of targeting. The correctly targeted gene was 
expected to be detectable only by a reduction of certain band intensities, since no 
new fragments should be generated which could hybridise to the probe used. 
Unequal loadings between the non-targeted and targeted DNA meant that 
comparisons were difficult to make. However, by comparing the 10.7kb and 1.8kb 
bands it can be seen that there is very much less wild-type DNA present on the blot 
than DNA from clones 12 and 53, yet the intensities of the 4.2kb, 2.1kb and 1.7kb 
bands are very similar in all three tracks. The 10.7kb and 1.8kb bands should be 
unaffected by targeting, but the 4.2kb, 2.1kb and 1.7kb bands were predicted to be 
lost following targeting. For these three bands to be present at the same intensity in 
wild-type and targeted DNA indicates that there must have been a reduction in their 
intensity in the clone 12 and 53 tracks which contain more DNA overall than the 
wild-type tracks. Therefore both clones 12 and 53 are shown by HindIll digestion to 
have been correctly targeted. 
On the basis of the results obtained, together with the PCR analysis, clones 
53 and 106 are correctly targeted, while the situation with clone 12 is uncertain. It 
has probably been targeted with a tandem plasmid integration. Clones 53 and 106 
were therefore used for further work. 
8.3: Mouse Models for DNA Ligase I Deficiency 
The gene targeting experiments were carried out in mouse embryonic stem 
cells so that mice carrying the altered gene could then be generated. ES cells are 
pluripotent, with the result that, if they are injected into embryos they can contribute 
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to all the tissues of the resulting animal, which is then called a chimaera. If they have 
also contributed to the germ line, the animal will be able to pass on the genes from 
the injected cells to its offspring. This means that it is possible, by breeding, to 
generate animals which are homozygous for a gene which was targeted at only one 
allele in the original embryonic stem cells. 
Mouse embryos were injected with the targeted clones 53 and 106. 
Chimaeras were generated from both clones, although the best chimaera was judged 
to have arisen from clone 53. This chimaera was bred to produce mice heterozygous 
for the DNA ligase I null mutation. These mice are apparently phenotypically 
normal, indicating that the single active allele of DNA ligase I is sufficient for the 
requirements of the cell. These mice are •now being mated in attempts to produce 
mice homozygous for the mutation. Such mice would be completely lacking in DNA 
ligase I activity and it is uncertain whether or not they would be viable. To date 10 
homozygous wild-type mice and 12 heterozygotes have been obtained from these 
crosses. No homozygous mutants have been observed, so they are apparently unable 
to survive even as far as birth. The findings so far therefore suggest that mice 
homozygous for the DNA ligase I null mutation are not viable. This is not 
unexpected, since DNA ligase I is thought to have a crucial role in both replication 
and repair of DNA. 
Work is currently underway to perform the second stage of the targeting. The 
deleted exons will be reintroduced into the gene, carrying the mutation specifying an 





46BR is a human cell line carrying a damaging mutation on each allele of the 
DNA ligase I gene and it is therefore defective in the activity of this enzyme (Barnes 
et al 1992b, Prigent et al 1994). It has the same aberrant phenotype as its 
transformed derivative, called 46BR.1G1 (Lehmann et al 1988). 46BR.1G1 is 
sensitive to ethylmethane suiphonate and 3-aminobenzamide, and this sensitivity is 
rescued by transfection with wild-type human DNA ligase I sequences. A direct link 
therefore exists between the DNA ligase I deficiency and the abnormal cellular 
phenotype of 46BR. Cell lines derived from Blooms syndrome patients are also 
defective in DNA ligase I activity (Willis and Lindahi 1987, Chan et al 1987, Willis 
et al 1987) and it is interesting that 46BR also displays other abnormalities seen in 
BS cell lines, including sensitivity to certain DNA damaging agents (Teo et al 1982, 
1983a, Hook et al 1984, Arlett and Harcourt 1978). Blooms syndrome cell lines and 
46BR also exhibit some significant differences. Most notable of these dissimilarities 
is the fact that 46BR displays only a slightly elevated rate of sister chromatid 
exchanges (Teo et al 1983a). On the other hand, all BS fibroblast cell lines studied to 
date have a significantly elevated sister chromatid exchange level (Chaganti et al 
1974), a property which is used in Blooms syndrome diagnosis. Additionally, the 
individual from whom the cell line 46BR was originally derived suffered from many 
of the symptoms of Blooms syndrome (Webster et al 1992, German and Passarge 
1989). Like Blooms syndrome patients, she was sensitive to sunlight, severely 
immunodeficient and her growth was retarded. Her death at 19 years of age followed 
a series of lung infections, which BS patients also typically suffer from, and she had 
been diagnosed as having a malignant lymphoma although this was not confirmed. 
This is also characteristic of Blooms syndrome since development of cancer while 
still young is one of its most notable clinical features. 
Such clinical similarities and the discovery that both 46BR and BS cell lines 
have abnormal DNA ligase I activity has led to the suggestion that 46BR may 
represent a form of Blooms syndrome. This is despite the fact that as yet, all BS cell 
lines studied appear to represent a single complementation group (Weksberg et al 
1988), which 46BR is not a member of. The disease site in BS cells is apparently 
located on chromosome 15 (McDaniel and Schultz 1992), while the DNA ligase I 
gene is present on chromosome 19 (Barnes et al 1990, Barnes et al 1992a). 46BR 
does not simply denote another Blooms syndrome complementation group, however, 
since the cells display many properties not shared with BS cells. It may therefore 
represent a variant form of the disease. 
In diseases such as xeroderma pigmentosum, a specific enzyme pathway is 
involved, in this case the excision repair pathway, (Cleaver 1968, Cleaver 1990 and 
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references therein) and the many complementation groups identified arise from the 
many gene products participating in that pathway. However, there is a variant form 
of XP, displaying typical clinical features but different cytological properties to the 
other seven XP complementation groups. It is thought that the incision steps of 
excision repair are defective in XP groups A to G, while in the variant form, it is 
post-replication repair that is affected. In this disease therefore, there are seven 
complementation groups displaying the same characteristics because they are 
defective at the same step of excision repair, and a variant form, showing slightly 
different cytological features because a different repair pathway is affected, but the 
same clinical features because the overall effect on repair is the same. A variant form 
of ataxia telangiectasia has also been identified (Jaspers et al 1988), but the 
circumstances in this case are less well understood. The situation in Blooms 
syndrome appears to be more complex since DNA ligase I is only one of a number 
of enzyme abnormalities that have been identified and which apparently all arise 
from a single defect. In this case it seems that it is not a single enzymic pathway that 
is affected, but rather that there is a single defect affecting many functions. Further, 
DNA ligase I, itself, is not an enzyme involved in a single specific pathway, but 
instead appears to take part in many cellular processes. It seems likely that the 
overlap between BS and 46BR may have occured simply because of a wide-ranging 
defect in BS cells which affects DNA ligase I among several other enzymes. 
Clarification of this point awaits identification of the defective locus in Blooms 
syndrome cells. 46BR could be regarded as a variant form of Blooms syndrome 
since, as with XP variant, it displays many typical clinical symptoms of the disease, 
together with different cellular features from classical disease cell lines. Further, the 
same enzyme is affected in both 46BR and BS cell lines. This classification probably 
also depends to some extent on the definition of a variant disease form. 
A mouse model for Blooms syndrome would be extremely useful in the study 
of the disease, and possibly in the evaluation of potential therapies. However, since 
the primary defect in this disease remains unknown it is not yet feasible to create 
such a model. If 46BR is regarded as a variant form of Blooms syndrome then a 
mouse carrying the 46BR mutation would be a model for a type of BS. 
Unfortunately, even if this is the case, the model would not be particularly useful for 
purposes of studying BS since the underlying defect is different and, as far as is 
known, 46BR is a unique case. It could, nevertheless, still be invaluable in the study 
of DNA ligase I, its function during mammalian growth and development, and the 
consequences of its deficiency. 
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Mammalian DNA ligase I is very highly conserved. Mouse and human 
enzymes are 84% homologous at the amino acid level and there are very few 
sequence differences within the C-terminal domains. More variation occurs in the N-
terminal domains, with two regions of nonhomology in particular. The C-terminal 
domain is involved in catalysis (Tornkinson et al 1990, Kodama et al 199 1) and the 
N-terminal domain is thought to be involved in regulation (Prigent et al 1992). 
Given that DNA ligase I apparently has such a vital role within the cell, it is not 
surprising that the structure of the catalytic domain should be so highly conserved. If 
the role of the N-terminus is purely regulatory, and if this occurs via interaction with 
other proteins, then some sequence divergence would be expected. DNA ligase I is 
known to interact with a number of proteins. Heat-resistant and heat-labile 
stimulatory factors have been identified, as well as a heat-labile inhibitor (Kenne and 
Ljunquist 1988, Fairman et al 1992, Yang et al 1992, Yang et al 1993). It seems 
probable that these proteins interact with regions of the N-terminal domain and it is 
interesting to speculate that the two stretches of nonhomolgy in this domain may be 
binding sites for one or more of them. If the regulatory factors have not been as well 
conserved as DNA ligase I during evolution, their recognition sequences may also 
have diverged with the result that regions of nonhomology would arise within an 
otherwise highly conserved enzyme. As well as these unidentified protein factors, 
mammalian DNA ligase I can be phosphorylated by casein kinase II and this 
phosphorylation is a requirement for enzyme activation (Prigent et al 1992). Casein 
kinase II is known to interact with the N-terminal domain of DNA ligase I since the 
C-terminal domain is active independently of phosphorylation. Casein kinase II is a 
ubiquitous enzyme and therefore its recognition sites would be expected to be 
conserved. Indeed, a number of concensus casein kinase II phosphorylation sites are 
present throughout the sequences of both mouse and human enzymes. The human 
enzyme also contains two particularly strong concensus sequences and it has been 
suggested that one of these is the site of phosphorylation (Prigent et al 1992). 
However, the mouse amino acid sequence lacks both of these sites indicating that 
phosphorylation occurs elsewhere. Apart from these differences there are apparently 
no other major changes between mouse and human DNA ligase I and the sites of the 
two mutations identified in the DNA ligase I sequence of 46BR are identical in the 
mouse enzyme. 
Although the mouse and human enzymes are very similar, there has been a 
lot of divergence in their gene structures. The human gene is significantly larger, 
occupying 53kb of DNA (Noguiez et al 1992), while the mouse gene occupies only 
39-42kb. The restriction fragment patterns of both genes are completely different, 
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but this is unsurprising since most of the sites investigated lie within introns and 
would therefore not be expected to be conserved. Superficially, the exon structures 
of the two genes are also unrelated, with the human gene consisting of 28 exons 
(Prigent et al 1992), while throughout this thesis the mouse gene has been referred to 
as having only 11. However, as was explained in the relevant chapter (chapter 6), 
this is a minimum number due to the nature of the analysis, and there is no evidence 
to suggest that the mouse gene does not also consist of 28 exons. It is noteworthy 
that the only exon which was looked at in detail (human exon 23) was found to have 
an exact parallel in the mouse gene. The equivalent mouse exon consists of an 
identical number of nucleotides with very few alterations. The splice sites are 
identical and even the first few bases of flanking intron sequence are conserved. It 
seems likely from this finding that the other exons are similarly conserved, and that 
the mouse gene is also made up of 28 exons. 
The identity between human and mouse DNA ligase I sequences means that 
it is possible to introduce the same mutations into the mouse enzyme as are present 
in the human enzyme in 46BR by gene targeting, and thus go on to create a mouse 
model for the DNA ligase I deficiency of 46BR. The mutations in 46BR both arose 
as a result of a single base change (Barnes et al 1992b) which means that the 
targeting will introduce an extremely subtle alteration into the gene. Unfortunately, 
the DNA ligase I gene is not directly selectable and therefore some other method of 
screening for targeting events is necessary. Single base changes can sometimes be 
detected as the introduction or loss of a restriction enzyme recognition site. However 
this still requires the preparation, digestion, electrophoresis, blotting and probing of 
genomic DNA from every clone to be tested for targeting events. Such a method of 
screening is therefore prohibitively tedious for large numbers of clones. A better 
method, involving two targeting events has been devised for targeting the mouse 
DNA ligase I gene in male HPRT-deficient embryonic stem cells. The first step is to 
create a null mutation by replacement of the last few exons of the mouse DNA ligase 
I gene with an HPRT minigene which can be selected for. Next, the gene is to be 
targeted again, to replace the HPRT minigene with the missing exons, containing the 
equivalent of the Arg77 1 to Trp mutation of 46BR. The second targeting event can 
be selected for by loss of HPRT activity. 
The mutation to be introduced into the mouse DNA ligase I gene specifies an 
alteration of an arginine residue (Arg768 in mouse) to tryptophan. The equivalent 
mutation in the human gene reduces the activity of the enzyme by an unknown 
mechanism (Barnes et al 1992b, Prigent et al 1994). It retains the ability to form a 
covalent enzyme-adenylate intermediate, indeed most is present in the adenylated 
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form in vivo (Prigent et al 1994). The mutation must therefore affect a step in the 
reaction mechanism that follows adenylation. Subsequent to adenylation, the AMP 
moiety is transferred to a 3' phosphoryl group in a nicked DNA strand, which is then 
sealed accompanied by release of AMP (Lehman 1974). Transfer of AMP to DNA 
by human DNA ligase I carrying the Arg771 to Trp mutation is also apparently 
normal since accumulation of the DNA-AMP reaction intermediate can be measured 
(Prigent et al 1994). Therefore it must be the final step of ligation that is abnormal. 
How the mutation could have this effect is unclear. It is possible that the mutation 
itself directly affects ligation activity. Alternatively, inability to catalyse 
phosphodiester bond formation may be related to the altered aggregation properties 
of the mutant enzyme which seems to bind tightly to another similarly sized protein. 
(Lehmann et al 1988). 
Replacement of the last few exons of the mouse DNA ligase I gene with an 
HPRT minigene has already been carried out, and the targeted cells used to generate 
a chimaera. No animals homozygous for the DNA ligase I null mutation have been 
bred from this chimaera, although homozygous wild-type and heterozygous animals 
have been obtained. The numbers of progeny which have been born suggest that 
some homozygous mutants should have been obtained if they are viable. It therefore 
appears that development is severely compromised in animals lacking DNA ligase I 
activity. Investigations are currently underway into how long DNA ligase I 
homozygous mutant embryos are able to survive before development is terminated. 
A demonstration that DNA ligase I is essential for viability is not unexpected 
for several reasons. Consider the DNA ligase 1-deficient cell line 46BR and its 
transformed derivative 46BR. 1 G 1. During the transformation of 46BR one of the 
DNA ligase I mutations was lost and 46B R. 1 G 1 consequently retains only the allele 
of the gene carrying the Arg771 to Trp mutation (Barnes et al 1992b). This leaves 
the enzyme with a reduced, but measurable amount of ligation activity and the cell 
line is therefore not totally DNA ligase I-deficient, maintaining about 1/20 of normal 
activity (Prigent et al 1994). The other mutation, G1u566 to Lys, renders the enzyme 
inactive by modifying the active site. That this mutation, which inactivates DNA 
ligase I, was the one to be lost during transformation suggested originally that it 
could be lethal in a homozygote. This is the reason why the Arg771 to Trp mutation 
was selected for gene targeting experiments. 
A further reason for supposing that a homozygous DNA ligase I null 
mutation might be lethal is implied by the growth of 46BR. As a consequence of the 
reduced DNA ligase I activity, 46BR cells are extremely sickly in culture, growing 
at best, at only 1/4 the rate at which healthy wild-type cells grow. They are also 
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much smaller and grow in clumps, instead of spreading out as wild-type cells would. 
The cells are obviously struggling to grow, yet they retain some DNA ligase I 
activity. Similarly, the patient from whom 46BR was established was severely 
developmentally retarded, although she did have one copy of the DNA ligase I gene 
specifying an enzyme with residual activity. If the partial removal of DNA ligase I 
activity is so detrimental, then its complete absence would be expected to have very 
serious repercussions for the cell. 
DNA ligase I is apparently involved in two vital aspects of cellular 
metabolism. The sensitivity of 46BR to a wide range of DNA damaging agents 
demonstrates that DNA repair is faulty in these cells, and therefore DNA ligase I 
must be required for DNA repair to take place (Teo et al 1982, 1983a). The 
induction of DNA ligase I messenger RNA in response to ultraviolet irradiation also 
suggests involvement in DNA repair (Montecucco et al 1992). However, DNA 
ligase I is also induced in response to cell proliferation, implying a role in DNA 
replication (Chan and Becker 1985, Söderhäll 1976). This is confirmed by the 
presence of DNA ligase I within DNA replication complexes which have been 
isolated from mammalian cells (Malkas et al 1990, Wu et al 1994), and also by the 
observation that joining of replication intermediates is delayed in 46BR cells 
(Henderson et al 1985). Such an enzyme, which is required for the processes of 
DNA repair and replication, would be expected to be essential to the cell, and 
therefore to the whole animal. 
How does a deficiency of DNA ligase I activity make embryos inviable? 
Homozygous DNA ligase I null mutants would be expected to be defective in both 
DNA repair and DNA replication. In the '46BR' patient (Webster et al 1992), 
aberrant DNA repair was manifest in her sensitivity to sunlight and suspected cancer 
at death, but was not actually the cause of her death. She lived to the age of 19, and 
died of other causes before accumulation of DNA damage could be fatal. Although 
she was probably not as deficient in DNA repair as a homozygous DNA ligase I null 
mutant might be, it is likely that the null mutant would survive for some time before 
the build-up of damaged DNA became overwhelming. With regard to this, it is 
interesting to note that mice have been generated which are homozygous for a null 
mutation in the ER CC-1 gene, which is involved in the incision step of the excision 
repair pathway (McWhir et al 1993). ERCC-1 homozygous mutants were found to 
survive pregnancy to term, but then died before weaning, due to liver failure, arising 
from oxidative stress. Likewise, DNA ligase I mutants would probably also survive 
pregnancy if they were purely defective in DNA repair. It seems more likely then, 
that the homozygous DNA ligase I mutants are not viable due to defective DNA 
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replication. When cells are growing and dividing DNA ligase I levels increase, 
presumably because the enzyme is required for ligation of DNA replication 
intermediates. An absence of ligation would interfere with DNA replication, which 
would, in turn, affect the division of cells during embryo development. It therefore 
seems reasonable to assume that homozygous DNA ligase I null mutants are inviable 
because a block on DNA replication creates a block on cell division; which then 
halts embryo development. 
Given the sequence conservation between mouse and human DNA ligase I 
enzymes it is reasonable to assume that, once it has been correctly targeted, the 
activity of the mouse enzyme would be affected in the same way as that of the 
human enzyme by introduction of one of the mutations identified in 46BR. It is 
however by no means certain that this would have the same overall effect on the 
mouse carrying the mutation. A number of mouse models for human diseases have 
been generated, and the results have not always been as expected. 
Consider the human disease Lesch-Nyhan syndrome (Lesch and Nyhan 
1964). The symptoms of this disease include delayed mental retardation and 
compulsive self-mutilation, which arise as a result of HPRT deficiency (Seegmiller 
et al 1967). Two independent mouse models for Lesch-Nyhan syndrome were 
generated in 1987 using HPRT-deficient embryonic stem cells (Hooper et al 1987, 
Kuehn et al 1987). However the typical Lesch-Nyhan symptoms were not present 
spontaneously in either case. It was subsequently shown that mice rely more on the 
enzyme APRT than on HPRT for their purine salvage pathway, whereas the situation 
is reversed in humans. Therefore loss of HPRT activity does not have such serious 
consequences in mice as in humans. However, when APRT activity was blocked in 
HPRT-deficient mice, they started to exhibit self-injurious behaviour much like that 
observed in Lesch-Nyhan syndrome patients (Wu and Melton 1993). Two models 
for cystic fibrosis have been generated independently, and it is interesting that the 
phenotypes of both differed significantly. Snouwaert et al (1992) obtained mice 
which were very seriously affected and died soon after birth, while the symptoms of 
the mice generated by Dorin et al (1992) were milder. However in both cases the 
mice suffered from disorders associated with cystic fibrosis and therefore apparently 
represent valid models for the disease. A further human disease for which a mouse 
model has been generated is Gauchers disease, of which there are two forms, with 
either mild or very severe symptoms (Tybulewicz et al 1992). The mutant mice 
exhibited extreme features of the disease, dying within 24 hours of birth, and thus 
are similar to the severe form of Gauchers disease. A recent interesting example is 
the generation of mice deficient in the enzyme urate oxidase (Wu et al 1994). 
Humans naturally lack this enzyme which converts the end product of purine 
metabolism, uric acid, to more soluble allantoin. As a result they are predisposed to 
hyperuricemia, leading to gouty arthritis and renal stones. Other mammals have 
retained the enzyme, which protects them from developing hyperuricemia, and they 
cannot therefore be used to study this disorder. Inactivation of urate oxidase in mice 
was shown to confer obligate hyperuricemia and its associated disorders, rather than 
just a predisposition to the disease, thus demonstrating that the murine enzyme is 
indispensable. These examples show that, while mice can be genetically engineered 
to carry mutations specifying human diseases, they will not necessarily develop the 
same form of the disease. 
In the light of the above examples, the possibility that mice carrying the 
arginine to tryptophan DNA ligase I mutation may not exactly reflect the 46BR 
phenotype should be considered. Murine cells may rely on their different DNA 
ligases to a different extent than human cells, as was found to be the case with 
HPRT. With regard to this, the patterns of induction of DNA ligase I are identical 
between human and mouse cells, suggesting that its requirement by the cells is the 
same (Söderhäll 1976, Chan and Becker 1985). 
It is conceivable that DNA ligase II or III could compensate for a lack of 
DNA ligase I activity, thus diminishing the effects of the mutation, but there is no 
evidence to support this to date. If the multiple forms of DNA ligase act in a similar 
manner to the multiple forms of DNA polymerases within mammalian cells then this 
could happen. There are five different DNA polymerases designated a, B, 1, 8 and 
(Wang 1991, and references therein). Each has a specific function: Polymerase a 
carries out lagging strand synthesis during DNA replication; Polymerase B is thought 
to carry out short patch DNA repair synthesis; Polymerase 'Y synthesises 
mitochondrial DNA; Polymerase 8 carries out leading strand synthesis during DNA 
replication, and polymerase E may be involved in DNA replication and ultraviolet 
induced repair synthesis. Thus it would appear that each enzyme is adapted for a 
specific purpose and that they should not be interchangeable. However, in vitro at 
least, polymerase B can take over the role of polymerase a and carry out both leading 
and lagging strand synthesis. The specific cellular functions of mammalian DNA 
ligases have not yet been as extensively studied. DNA ligase I is thought to be 
involved in repair and replication of DNA, while all that is known about DNA ligase 
II is that it does not appear to take part in DNA replication (Soderhäll and Lindahl 
1975, SOderhäll 1976, Chan and Becker 1985). DNA ligase ifi also apparently plays 
no part in DNA replication (Elder and Rossignol 1990), but may be involved in 
DNA repair and recombination (Jessberger et al 1993). As with mammalian DNA 
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polymerases it seems probable that each ligase has its own specific function, 
although the analogy may end there. It seems unlikely that either DNA ligase II or 
ifi could take over the function of DNA ligase I because neither seems to function 
during DNA replication. Both DNA polymerases a and B, on the other hand are 
thought to carry out single specific tasks which are closely related. The 
demonstration that mouse embryos lacking any DNA ligase I activity cannot survive 
even until birth also tends to suggest that the other ligases cannot substitute for DNA 
ligase I. 
Conclusion 
The aim of this project was to investigate the structure of the mouse DNA 
ligase I gene with a view to introducing a deleterious mutation by gene targeting. 
The purpose of this was to create a mouse model for DNA ligase I deficiency. So far, 
the gene targeting work has proceeded satisfactorily, with the knock-out of one allele 
of the DNA ligase I gene in mouse embryonic stem cells. These have been injected 
into recipient blastocysts, and the mutated gene transmitted successfully by the 
resulting chimaera. No animals have been obtained which are homozygous for the 
DNA ligase I mutation and it seems probable that such a genotype is lethal. The 
subsequent stage of gene targeting is underway, to restore the mutated DNA ligase I 
gene, but with a point mutation that affects DNA ligation activity. As with the DNA 
ligase I null mutation, mouse embryonic stem cells carrying the point mutation will 
be used to generate chimaeras which will be bred in the hope of obtaining animals 
homozygous for the mutation. These animals should suffer from the same DNA 
ligase I deficiency as the '46BR' patient and it will be of great interest to study its 
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Summary 
Ligation of DNA after replication and repair is a prerequisite for the preservation of DNA and 
chromosome structure and function. Biochemical studies with Bloom's syndrome cells have revealed an 
abnormal DNA ligase I activity. However, genetic analysis has not revealed any differences in transcript 
levels or in the cDNA sequences of DNA ligase I between Bloom's syndrome and normal cells. Another 
human cell line, 46BR, derived from an immunodeficient patient, also has an abnormal DNA ligase I. 
This cell line has recently been demonstrated to harbour two different missense mutations, one at each 
allele of DNA ligase I. These mutations resulted in a decreased ability of partially purified cell extracts 
to form an enzyme—adenylate reaction intermediate. We show that 46BR hypersensitivity to an alkylating 
agent, ethyl methanesulphonate, and to the polyADP-ribose polymerase inhibitor 3-aminobenzamide, is 
rescued by transfection of wild-type DNA ligase I sequences. This provides additional genetic evidence 
that the defect in 46BR is at the DNA ligase I locus. 
DNA repair is a central process in the mainte-
nance of life, and its deficiency results in several 
human diseases (Friedberg, 1985). Most studies 
with cells derived from patients with DNA-repair 
deficiency and with those derived from in vitro 
mutagenesis programmes have yielded mutants 
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deficient in the early stages of DNA excision 
repair. Nucleotide excision repair involves the 
recognition of damage, with subsequent incision 
to each side leaving a gapped duplex which is 
filled by a DNA polymerase activity utilizing the 
complementary strand as a template. A defect in 
the incision step results in a disorder termed 
xerodenna pigmentosum that is characterized by 
the development of skin cancers and neurological 
lesions (Friedberg, 1985, and refs. therein). How-
ever, some mutants have been identified that 
have lesions in other steps of DNA repair and 
these will prove informative in elucidating aspects 
of repair and chromosome dynamics. For exam- 
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pie, Cockayne's syndrome cells have normal lev-
els of general excision repair capacity, but are 
defective in preferential excision repair of active 
genes (Venema et al., 1990). 
Recently Bloom's syndrome (BS) cells were 
demonstrated to have aberrant DNA ligase I 
activity (Chan et al., 1987, 1988; Willis and Lin-
dahl, 1987; Willis et al., 1987). BS is an autosomal 
recessive disorder characterized by both pre- and 
post-natal growth retardation, sun-sensitive tel-
angiectatic facial lesions and a high incidence of 
cancer (German, 1974). DNA ligase I alterations 
have also been reported for cell types other than 
BS cells (Rusquet, 1988). The most extensively 
studied of these cell lines, 46BR, was derived 
from an immunodeficient patient also suffering 
from growth retardation and sunlight sensitivity. 
A lesion in DNA ligase I for 46BR was initially 
suggested by the persistence of strand breaks 
after treatment of cells with the alkylating agent 
dimethyl sulphate (DMS), although unscheduled 
DNA synthesis (a measure of DNA synthesis 
during excision repair) was normal (Teo et al., 
1983a). Hence the initial stages of repair are 
normal, but ligation seems to be affected. 
The cellular phenotypes of 46BR and cells 
derived from BS patients show some overlap, but 
also some significant differences. For example, 
while both cell types are sensitive to ethyl-
methane-sulphonate (EMS), 46BR cells are hy-
persensitive to 3-aminobenzamidè (3AB), but BS 
cells are only sensitive to 3AB at high doses (Teo 
et al., 1983b and refs. therein; Lehmann et al., 
1988). In addition, the most remarkable feature 
of BS cells is the 10-20-fold increased sponta-
neous sister-chromatid exchange frequency which 
is not apparent in 46BR cells. Isolation of human 
DNA ligase I cDNA clones has made it possible 
to demonstrate that the DNA ligase I gene is 
present and transcribed normally in BS cells 
(Petriniet al., 1991; Barnes et al., 1992a), and 
DNA ligase I cDNAs derived from these' cells 
have a normal nucleotide sequence and are able 
to complement Saccharomyces cerevisiae DNA 
ligase cdc 9 mutants. Furthermore, the DNA 
ligase I gene is present on chromosome 19 (Barnes 
et al., 1992b), yet the high sister-chromatid ex-
change phenotype of BS cells is complemented by 
human chromosome 15 (McDaniel and Schultz,  
1992). However, missense mutations have been 
identified in both ligase I genes in 46BR cells 
(Barnes et al., 1992a). The mutation at one allele 
changes the charged amino acid Glu566 to Lys. 
This residue is found in a highly conserved seg-
ment of DNA ligase I known to bind ATP, and 
subsequently form a DNA ligase 1—adenylate re-
action intermediate. Furthermore, it has been 
demonstrated (Kodama et al., 1991) that this 
mutation results in loss of complementing activity 
of an Escherichia co/i hg mutant and a greatly 
impaired ability to form a ligase—AMP intermedi-
ate. The 'mutation at the second allele (Arg771 to 
Trp) is also in a conserved residue. It has been 
demonstrated (Barnes et al., 1992a) that this is 
the only allele expressed in a transformed 46BR 
cell line, and that in vitro assays of partially 
purified 4613R : 'cell extracts show a decreased 
ability to bind ATP. These in vitro results provide 
a strong basis to conclude that the mutations may 
be responsible for the phenotype of 46BR cells. 
These observations may be interpreted in a 
number of ways., In BS the DNA ligase I gene is 
not mutated, bUt either post-translational modifi-
cation or some other factor mediating DNA hg-
ase I activity is abnormal. Alternatively, BS cells 
may have a more general defect resulting in a 
broad spectrum of proteins behaving aberrantly, 
whereas 46BR possesses mutations at the DNA 
ligase I loci and hence exhibits a phenotype truly 
reflective of a ligase mutant, as opposed to BS 
cells where only a subset of the total phenotype is 
the result of aberrant ligase action. 
Before establishing an animal model for dis-
eases associated with DNA ligase I deficiency, we 
report genetic complementation of the EMS and 
3AB hypersensitivity of 46BR cells by introducing 
a vector expressing 'human ligase I cDNA. These 
results extend the work of Barnes et al. (1992a) 
by providing additional evidence that the alter-
ations at the 46BR DNA higase I' loci are causal 
to the phenotype, in contrast to the situation in 
BS cells. 
Materials and methods 
Cell lines and culture 	 ' 
The pSV3gpt transformed fibroblast cell line 




neo 	 human B-ac(in promoter UTR IVS I human DNA ligase I cDNA 
EcoRI 	 Ea,RI 	 Sal VXhol Ea, RI Scm RI XhoVSa!I 
78bp 832bp 1.5kb 
2.4kb 	 - 	4.3kb 	 3.2kb 
ig. 1. Expression vector p/3AHLneo. The human ligase I 
DNA (open box) was put under the control of the human 
1-actin promoter (heavy shading). The 5' untranslated region 
UTR, closed box) and first intron (IVS 1, light shading) of 
1-actin are also present upstream of the ligase cDNA. The 
acterial neomycin phosphotransferase gene was driven by the 
nouse metallothionein promoter (neo, open box). The arrows 
Ilustrate the directionof transcription. Key restriction sites 
re also illustrated to highlight the 3.2-kb Xho I fragment 
ised in hybridization experiments. EcoRI sites which gener- 
te the diagnostic 1.5-kb ligase cDNA fragment are also 
marked. 
nann et al., 1988), as was the SV40 transformed 
ontrol cell line MRC5V1 (Huschtscha and Hoili-
lay, 1983). Cells were maintained in Glasgow 
nodified Eagle's medium (GMEM), supple-
nented with 10% foetal calf serum, 50 U/mi 
)enicillin, 50 j.tg/ml streptomycin sulphate, 1 mM 
odium pyruvate, 2 MM L-glutamine and 1 x 
ion-essential amino acids. Media for propagating 
ransfectants was additionally supplemented with 
00 p.g/ml G418 (Geneticin, Gibco). 
'lasmids and DNA preparations 
Plasmid pAHLneo is illustrated in Fig. 1. It 
vas constructed by cloning the EcoRI/HindIII 
ragment from pLK444 (Gunning et al., 1987) 
nto Bluescript (Strategene). This fragment con-
ained the 3-kb human /3-actin promotor Se-
luence, a 78-bp 5'-untranslated region and a 
32-bp intron which included an enhancer Se-
luence. Into the EcoRI site of this plasmid, up-
tream of the f3-actin gene fragment, was cloned 
2.4-kb EcoRI fragment containing the bacterial 
teomycin phosphotransferase gene regulated by 
he mouse metallothionein-I gene promoter 
Selfridge et al., 1992). This plasmid was desig-
tated p/3Aneo. Human DNA ligase I cDNA was 
loned into p/3Aneo, downstream of the f3-actin 
ene fragment, by isolation of a 3.2-kb .1(vnl  
fragment from pHL (Barnes et al., 1990), attach-
ment of XhoI linkers and ligation into the Sail 
site of p/3Aneo. This recombinant plasmid was 
designated p/3AHLneo. All plasmids were propa-
gated in E. coli TG1 cells. Plasmid DNA was 
isolated and purified using Qiagen columns ac-
cording to the manufacturer's instructions. Plas-
mids were linearized by incubation with the re-
striction enzyme Sca I, which has a recognition 
sequence in the ampicillinR  gene Of the Blue-
script vector, prior to transfection. Genomic DNA 
was isolated according to the method of Pellicer 
et al. (1978). 
Southern hybridization 
10 Ag of restricted DNA was size fractionated 
on a 0.8% agarose gel and blotted onto Gene-
Screen Plus (DuPont) according to a modification 
(Reed and Mann, 1985) of the Southern (1975) 
procedure. Prehybridization and hybridization 
was in a solution of 6 x SSC, 1% SDS, 10% 
dextran sulphate and 100 /Lg/ml sonicated her-
ring sperm DNA at 65°C. Filters were hybridized 
with random primed 32 P-labelled ligase I cDNA 
probes (Feinberg and Vogelstein, 1984). The 
washing procedure was that recommended for 
GeneScreen Plus membranes. 
Northern blot analysis 
Total cellular RNA was prepared as described 
(MacDonald et al., 1987; Stroman et al., 1977). 20 
j.tg of total RNA was size fractionated in a 1.4% 
agarose - 0.66 M formaldehyde gel and blotted 
onto GeneScreen Plus Membrane using 10 x SSC. 
Prehybridization, hybridization and washing pro-
cedures were carried out as for Southern blot 
analysis, but at 60°C. 
Assay to measure EMS sensitivity 
Cells were plated into 30-mm dishes (5 x iO 
cells for MRC5V1 and 2.5 X 10 5 cells for 46BR 
and transfectants), incubated overnight and then 
exposed to EMS in complete medium (dose range 
0-15 mM) for 2 h. Each dose point was done in. 
duplicate. The cells were rinsed twice with warm 
PBS and incubated in complete medium for a 
further 5 days. Surviving cell number was deter-
mined utilizing a [ 3 H]hypoxanthine incorporation 
assay (Cleaver, 1989). Essentially cells were 
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washed twice in serum-free GMEM and incu-
bated in serum-free GMEM with 0.5 Xi/ml 
[ 3 H]hypoxantjne for 4-5 h. Cells were washed 
twice with PBS and lysed with 1% SDS. The 
lysate was collected and high molecular weight 
nucleic acids precipitated by addition of 0.8 vol. 
20% TCA. The precipitate was collected onto 
Whatman GF/C filters and the incorporation 
measured by scintillation counting. 
Assay to measure 3AB sensitivity 
Cells were plated into 60-mm dishes (200 cells 
for MRC5V1 and 1000 cells for 46BR and trans-
fectants) in complete medium containing differ-
ent concentrations (0-8 mM) of 3AB. Each dose 
point was done in duplicate. Dishes were fixed 
and stained after 10-15 days and surviving 
colonies were counted. The % survival in 3AB for 
each cell line was calculated as (mean plating 
efficiency in 3AB/mean plating efficiency in con-
trol medium) x 100. 
Electroporation of cells 
5 x 105  cells were incubated with 30 jig of the 
appropriate linearized plasmid in 0.8 ml GMEM. 
The plasmid was electroporated into the cells 
using a Biorad electroporation apparatus (500 
AF, 350 V). Cells were left for 10 min and then 
plated into 60-mm dishes. G418 selection (500 
j.g/ml) was applied 2 days after electroporation 
and colonies were either picked when visible, or 
grown as pools. 
Results 
Construction and transfection of a vector express-
ing the human DNA ligase I cDNA 
Fig. 1 illustrates the expression vector pfl 
AHLneo, designed to express the human DNA 
ligase I cDNA under the control of the human 
f3-actin promoter. An intron is also included since 
some reports suggest that splicing of a transcript 
can increase its expression (Palmiter et al., 1991). 
This intron also contains an enhancer element 
(Gunning et al., 1987). Plasmid p/3Aneo is identi-
cal except that it lacks the ligase I cDNA se-
quences. This plasmid was used as a negative 
control in all experiments. In our hands transfect-
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Fig. 2. Southern blot analysis of 46BR and 46BR transfec 
tants. 46BRpAHLneo denotes 46BR cells transfected wit 
the expression vector pf3AHLneo. 46BRpf3Aneo denote 
46BR cells transfected with the control vector p/3Aneo. Cell 
were propagated either as pools of transfectants or as sing) 
clonal isolates (numbered). The arrow 'a', highlights the 1.5-k 
fragment diagnostic for the presence of vector-derived huma 
ligase I cDNA. 
ble utilizing CaPO4-coprecipitatjon, but electrc 
poration was successful. 20-30 G418 resistan 
colonies were generated from an initial numbe 
of 5 X 10 cells electroporated. These were eithe 
allowed to grow together as pools or primar 
colonies were picked and clonal transfectani 
were established. Cells transfected with p/3AHL 
neo were selected for G418 resistance only, i.t 
for the expression of the neo gene. There was n 
selection for DNA ligase I expression, althoug 
this should, in most cases, have cotransfecte 
with the neo sequences. 
Detection of ligase I transfectants 
Fig. 2 illustrates a Southern blot analysis c 
genomic DNA digested with EcoRI and probe 
with human ligase cDNA (the 3.2-kb XhoI fral 
ment illustrated in Fig. 1). DNA was derive 
from 46BR or 46BR transfectants. Although 
detailed analysis has not been completed, most 
these hybridising fragments represent parts of th 
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ndogenous DNA ligase I gene. Integration and 
retention of vector derived ligase sequences in 
lones can be seen as novel DNA fragments 
ippearing in cell lines transfected with 
DfAHLneo. A novel 1.5-kb band is seen in 5 out 
)f 6 of the 46BRpAHLneo clones examined 
md in the pool of 46BRp/3AHLneo transfec-
ants. The exception, clone 4 must contain neo 
;equences (since it is G418 resistant) but has lost 
:he ligase sequences on integration. This 1.5-kb 
and is derived from an internal fragment of 
igase cDNA (see Fig. 1). The sizes of some other 
'iovel bands visible in the transfectants are deter-
nined by the nearest cellular EcoRI recognition 
;equence to the site of integration. These ligase 
DNA sequences are not apparent in transfec-
:ants harbouri th'control plasmid p/3Aneo. 
rhere is also a difference in the number of copies 
)f cDNA sequences integrated in the cell lines, as 
letermined by the intensity of the novel cDNA-
lerived 1.5-kb band, compared to the signals due 
:o the endogenous ligase I gene. For example, 
nones 2 and 6 contain a greater number of in-
;erts than clone 3. 
xpression of ligase cDNA sequences 
Fig. 3 illustrates a Northern blot analysis of 
otal RNA derived from 46BR and transfectant 
-ells, probed with human ligase cDNA. A tran-
,cript of 3.2 kb (Barnes et al., 1990) is apparent in 
ill cell lines with no obvious structural alteration 
evealed for 46BR compared to MRC5V1 tran-
cripts. A slightly larger transcript, with, an addi-
ional 78 bp (derived from the f3-actin 5' untrans-
ated region; see Fig. 1) was expected from the 
)/3AHLneo vector. This should have been re-
'ealed as a broader more intense ligase I signal in 
.NA derived from pf3AHLneo transfected cells. 
4o such transcripts were detected in cell lines 
ransfected with pAHLneo, however other tran-
cripts were revealed in the size range 6-9 kb. 
Ihese are not seen in 46BR RNA, in the pool of 
6BRpf3.Aneo transfectants, nor in 'the transfec-
ant 46BRpf3AHLneo clone 4 which has lost the 
igase sequences. Thus, these are due to the tran-
cription of the vector-derived ligase sequences, 
)ut initiation is probably occurring upstream of 
he /3-actin promoter. From size considerations 
tnd the similarity of the novel large transcripts 
Pool 
< p3AHLneo 
'- C= CO- I 
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Fig. 3. Northern analysis of MRC5VI, 46BR and 46BR trans- 
fectants. Nomenclature is the same as in Fig. 2. The arrow 'a' 
highlights the 3.2-kb endogenous ligase I transcript. Region 
'b' illustrates vector-derived ligase transcripts (6-9 kb) appar- 
ent in cells transfected with and having integrated p/3AHLneo. 
The asterisk indicates the position of the 28S ribosomal RNA 
subunit. 
between independent clones, this initiation is 
probably occurring within plasmid sequences, 
possibly from the metallothionein promoter which 
controls neo expression (see Fig. 1). There is a 
correlation between the extent of ligase transcrip-
tion from p/3AHLneo and the number of integra-
tions of this plasmid in a cell line. This is revealed 
on comparison of 46BRp/3AHLneo clone 2 with 
other clones. Clone 2 has more insertions of the 
ligase sequence (see Fig. 2) than the other clones. 
This is paralleled by an increase in the amount of 
the vector-derived ligase transcripts apparent in 
clone 2 compared with other clones (Fig. 3). This 
increase is not due to unequal loading as visual-
ized by ethidium bromide staining of the gel ('data 
not shown), comparing clones 1, 2, 5 and 6. 
Correction of EMS hypersensitivity in 46BR 
Fig. 4 illustrates the survival of MRC5V1,. 
46BR and 46BR transfectants exposed to EMS., 
46BR and its derivatives transfected with p/3Aneo 
exhibit hypersensitivity to EMS, whereas 
MRC5V1 reveals a pattern of survival typical of 
11 
normal cells (Teo et al., 1983b). 46BR derivatives 
transfected with p/3AHLneo show a sensitivity 
intermediate between MRC5V1 and 4613R. The 
three p/3AHLneo transfectants assayed (clones 1, 
2, 6) were rescued to the same extent and there 
was no correlation with the copy number of inte-
grated ligase sequences. The extent of correction 
can be calculated by dose modification at con-
stant survival (Cleaver, 1990). That is by express-
ing the ratio of the differences in EMS concen-
tration between 46BR and the correctants and 
between 46BR and MRC5V1 where 50% of cells 
survive [(b—a)/(c—a), in Fig. 4]. 46BR has been 
corrected by approximately 60% on transfection 
of p/3AHLneo sequences. MRC5V1 transfected 
with p/3AHLneo showed no difference in survival 




U 	 5 	 10 	 15 
mM EMS 
Fig. 4. Cell survival following EMS treatment of MRC5V1, 
46BR and 46BR transfectants. Cell survival was measured by 
[ 3 H]hypoxanthine incorporation into cellular nucleic acid. Key: 
+, MRC5V1; x, 46BR; 0, 46BRp/3Aneo clone 1; •, 
46BRp/3Aneo clone 2; 0, 46BRpI3AHLneo clone 1; , 
46BRp/3AHLneo clone 2; A, 46BRp/3AHLneo clone 6. a, b, 
and c are points used to calculate the extent of rescue of the 
EMS hypersensitivity phenotype. For each point standard 
errors of the mean were less than 7% of the survival value 
plotted. 
0 	2 	4 	6 	8 
mM 3AB 
Fig. 5. Survival in 3AB of MRC5V1, 46BR and 46BR tram 
fectants. Cell survival was measured by a colony-formin 
assay. Key: +, MRC5V1; x, 46BR; 0, 46BRp/3Aneo clone: 
, 46BRpf3AHLneo clone 2. Each point is the mean froi 
two separate determinations. 
Correction of 3AB hypersensitivity in 46BR 
Survival of MRC5V1, 46BR and 46BR tram 
fectants exposed to 3AB is illustrated in Fig. 
46BR and a derivative transfected with p/3Ane 
(clone 1) are hypersensitive to 3AB, while th 
survival of MRC5V1 is typical of normal cell 
(Lehmann et al., 1988). The 46BR derivativ 
transfected with pI3AHLneo (clone 2) shows 
pattern of survival similar to that of MRC5V: 
indicating complete correction of the hypersens 
tivity to 3AB phenotype of 46BR by the introdu( 
tion of functional ligase I sequences. 
Discussion 
The expression vector utilized in this study h 
been problematic due to the failureS of corre 
initiation from the 13-actin promoter. No nov 
transcripts were visualized at the expected si 
(78 bp greater than the 3.2-kb endogenous liga 
I transcript) in pI3AHLneo transfectants. A 







and vector ligase transcripts by mapping the initi-
ation sites using primer extension analysis, or 
PCR strategies were unsuccessful. Primer exten-
sion products were halted by secondary structure 
in the 5' untranslated region of the ligase I 
mRNA. PCR strategies utilizing amplimers based 
on sequences in the ligase coding region and the 
untranslated region of f3-actin contributed by the 
vector were unsuccessful due to cross-hybridiza-
tion of the necessarily GC-rich -actin amplimer. 
The GC-richness of the 78pb 13-actin UTR also 
made it unsuitable as a probe for Northern blot 
analysis. Nevertheless expression from this vector 
of high molecular weight transcripts was revealed 
by probing pf3AHLneo transfectants with ligase I 
eDNA. More significantly, there is a strong corre-
lation between the presence of introduced wild-
type ligase I sequences, the presence of novel 
ligase transcripts and the rescue of the EMS and 
3AB hypersensitivity phenotypes. Correction of 
the EMS hypersensitivity was only partial (60%), 
while correction of 3AB hypersensitivity was com-
plete. This discrepancy could arise because sensi-
tivity to EMS is a much less direct measure of 
ligase function than survival in 3AB, which in-
hibits an enzyme (poly ADP-ribose polymerase) 
required with ligase for efficient ligation. 
It is apparent that both 46BR and BS have a 
biochemical abnormality of DNA ligase I. How-
ever, there are clear differences between the phe-
notypes of 46BR and BS cells. No changes were 
found in the nucleotide sequence of BS ligase I 
eDNA which was shown to be functional by res-
cuing S. cerevisiae cdc9 ligase mutants (Petrini et 
al., 1991). j'hissuggests that, in vivo, DNA ligase 
I acts in a complex with (an)other protein(s). It is 
tempting to speculate that in the case of 46BR, 
the mutation (Arg771 to Trp) in the DNA ligase I 
gene has resulted in an inappropriate interaction 
of this protein in the complex. Note that this 
mutation still retains some ligase activity, and 
may have an effect on protein/protein interac 
tions that ligase I takes part in. A consequence of 
this is that rescue of the mutant phenotype is 
possible by transfection of wild-type ligase I se-
quences whereas this would not be possible for 
BS cells. In BS cells, another protein in this 
complex could have undergone a change which 
affects its interactions with DNA ligase I. This  
could result in ligase I being incorrectly modified 
and interacting aberrantly in the complex. Fur-
thermore the protein altered in BS cells may 
modulate or modify other proteins and hence 
give rise to additional phenotypes such as in-
creased spontaneous sister chromatid exchange. 
In conclusion, this paper presents genetic evi-
dence that the mutant phenotype in a mam-
malian cell line with altered DNA ligase I activity 
can be rescued on transfection and expression of 
wild-type DNA ligase I cDNA. These results also 
suggest that the phenotypes that overlap between 
BS cells and 46BR are due to a shared ligase 
aberration, although this may be due to muta-
tions in different proteins. With reference to our 
aim to produce animal models for ligase defi-
ciency it should be possible to generate these by 
homologous recombination in embryonic stem 
cells to create single nucleotide alterations to the 
mouse DNA ligase I gene. Cells from the result-
ing animals could then be checked for concor -
dance with the 46BR phenotype. 
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